

University of Dundee

**Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling**

Platt, Lucy; Sweeney, Sedona; Ward, Zoe; Guinness, Lorna; Hickman, Matthew; Hope, Vivian

*Published in:*  
Public Health Research

*DOI:*  
[10.3310/phr05050](https://doi.org/10.3310/phr05050)

*Publication date:*  
2017

*Licence:*  
UK Government Non-Commercial Licence

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Platt, L., Sweeney, S., Ward, Z., Guinness, L., Hickman, M., Hope, V., Hutchinson, S. J., Maher, L., Iversen, J., Craine, N., Taylor, A., Munro, A., Parry, J., Smith, J., & Vickerman, P. (2017). Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. *Public Health Research*, 5(5). <https://doi.org/10.3310/phr05050>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling

*Lucy Platt, Sedona Sweeney, Zoe Ward, Lorna Guinness, Matthew Hickman, Vivian Hope, Sharon Hutchinson, Lisa Maher, Jenny Iversen, Noel Craine, Avril Taylor, Alison Munro, John Parry, Josie Smith and Peter Vickerman*



***National Institute for  
Health Research***



# Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling

Lucy Platt,<sup>1\*</sup> Sedona Sweeney,<sup>1</sup> Zoe Ward,<sup>2</sup>  
Lorna Guinness,<sup>1</sup> Matthew Hickman,<sup>2</sup> Vivian Hope,<sup>3</sup>  
Sharon Hutchinson,<sup>4</sup> Lisa Maher,<sup>5</sup> Jenny Iversen,<sup>5</sup>  
Noel Craine,<sup>6</sup> Avril Taylor,<sup>7</sup> Alison Munro,<sup>8</sup>  
John Parry,<sup>3</sup> Josie Smith<sup>6</sup> and Peter Vickerman<sup>2</sup>

<sup>1</sup>Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

<sup>2</sup>School of Social and Community Medicine, University of Bristol, Bristol, UK

<sup>3</sup>Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK

<sup>4</sup>School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK

<sup>5</sup>Viral Hepatitis Epidemiology and Prevention Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia

<sup>6</sup>Health Protection Division, Public Health Wales, Cardiff, UK

<sup>7</sup>School of Media Society and Culture, University of the West of Scotland, Paisley, UK

<sup>8</sup>School of Social Science, University of the West of Scotland, Paisley, UK

\*Corresponding author

**Declared competing interests of authors:** Lorna Guinness reports grants from the London School of Hygiene and Tropical Medicine during the conduct of the study. Matthew Hickman is a member of the Public Health Research Funding Board. Sharon Hutchinson reports grants from the National Institute for Health Research during the conduct of the study and personal fees from AbbVie Inc. and Gilead Sciences, Inc., outside the submitted work. Avril Taylor reports grants from NHS National Services Scotland during the conduct of the study. Alison Munro reports personal fees from Janssen UK outside the submitted work. John Parry reports grants from the London School of Hygiene and Tropical Medicine during the conduct of the study.

Published September 2017

DOI: 10.3310/phr05050



This report should be referenced as follows:

Platt L, Sweeney S, Ward Z, Guinness L, Hickman M, Hope V, *et al.* Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. *Public Health Res* 2017;**5**(5).



# Public Health Research

ISSN 2050-4381 (Print)

ISSN 2050-439X (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full PHR archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/phr](http://www.journalslibrary.nihr.ac.uk/phr). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Public Health Research* journal

Reports are published in *Public Health Research* (PHR) if (1) they have resulted from work for the PHR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Public Health Research* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## PHR programme

The Public Health Research (PHR) programme, part of the National Institute for Health Research (NIHR), evaluates public health interventions, providing new knowledge on the benefits, costs, acceptability and wider impacts of non-NHS interventions intended to improve the health of the public and reduce inequalities in health. The scope of the programme is multi-disciplinary and broad, covering a range of interventions that improve public health. The Public Health Research programme also complements the NIHR Health Technology Assessment programme which has a growing portfolio evaluating NHS public health interventions.

For more information about the PHR programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/phr>

## This report

The research reported in this issue of the journal was funded by the PHR programme as project number 12/3070/13. The contractual start date was in October 2013. The final report began editorial review in May 2016 and was accepted for publication in December 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PHR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the PHR programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PHR programme or the Department of Health.

**© Queen's Printer and Controller of HMSO 2017. This work was produced by Platt *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.**

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).



## Public Health Research Editor-in-Chief

**Professor Martin White** Director of Research and Programme Leader, UKCRC Centre for Diet and Activity Research (CEDAR), MRC Epidemiology Unit, Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge; Visiting Professor, Newcastle University; and Director, NIHR Public Health Research Programme

## NIHR Journals Library Editor-in-Chief

**Professor Tom Walley** Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

## NIHR Journals Library Editors

**Professor Ken Stein** Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key** Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Director of the NIHR Dissemination Centre, University of Southampton, UK

**Ms Tara Lamont** Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie** Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell** Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:  
[www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling

Lucy Platt,<sup>1\*</sup> Sedona Sweeney,<sup>1</sup> Zoe Ward,<sup>2</sup> Lorna Guinness,<sup>1</sup> Matthew Hickman,<sup>2</sup> Vivian Hope,<sup>3</sup> Sharon Hutchinson,<sup>4</sup> Lisa Maher,<sup>5</sup> Jenny Iversen,<sup>5</sup> Noel Craine,<sup>6</sup> Avril Taylor,<sup>7</sup> Alison Munro,<sup>8</sup> John Parry,<sup>3</sup> Josie Smith<sup>6</sup> and Peter Vickerman<sup>2</sup>

<sup>1</sup>Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

<sup>2</sup>School of Social and Community Medicine, University of Bristol, Bristol, UK

<sup>3</sup>Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK

<sup>4</sup>School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK

<sup>5</sup>Viral Hepatitis Epidemiology and Prevention Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia

<sup>6</sup>Health Protection Division, Public Health Wales, Cardiff, UK

<sup>7</sup>School of Media Society and Culture, University of the West of Scotland, Paisley, UK

<sup>8</sup>School of Social Science, University of the West of Scotland, Paisley, UK

\*Corresponding author [lucy.platt@lshtm.ac.uk](mailto:lucy.platt@lshtm.ac.uk)

**Background:** There is limited evidence of the impact of needle and syringe programmes (NSPs) and opioid substitution therapy (OST) on hepatitis C virus (HCV) incidence among people who inject drugs (PWID), nor have there been any economic evaluations.

**Objective(s):** To measure (1) the impact of NSP and OST, (2) changes in the extent of provision of both interventions, and (3) costs and cost-effectiveness of NSPs on HCV infection transmission.

**Design:** We conducted (1) a systematic review; (2) an analysis of existing data sets, including collating costs of NSPs; and (3) a dynamic deterministic model to estimate the impact of differing OST/NSP intervention coverage levels for reducing HCV infection prevalence, incidence and disease burden, and incremental cost-effectiveness ratios to measure the cost-effectiveness of current NSP provision versus no provision.

**Setting:** Cost-effectiveness analysis and impact modelling in three UK sites. The pooled analysis drew on data from the UK and Australia. The review was international.

**Participants:** PWID.

**Interventions:** NSP coverage (proportion of injections covered by clean needles) and OST.

**Outcome:** New cases of HCV infection.

**Results:** The review suggested that OST reduced the risk of HCV infection acquisition by 50% [rate ratio (RR) 0.50, 95% confidence interval (CI) 0.40 to 0.63]. Weaker evidence was found in areas of high ( $\geq 100\%$ ) NSP coverage (RR 0.77, 95% CI 0.38 to 1.54) internationally. There was moderate evidence for combined high coverage of NSPs and OST (RR 0.29, 95% CI 0.13 to 0.65). The pooled analysis showed that combined high coverage of NSPs and OST reduced the risk of HCV infection acquisition by 29–71% compared with those on minimal harm reduction (no OST,  $\leq 100\%$  NSP coverage). NSPs are likely to be cost-effective and are cost-saving in some settings. The impact modelling suggest that removing OST (current coverage 81%) and NSPs (coverage 54%) in one site would increase HCV infection incidence by 329% [95% credible interval (CrI) 110% to 953%] in 2031 and at least double (132% increase; 95% CrI 51% to 306%) the number of new infections over 15 years. Increasing NSP coverage to 80% has the largest impact in the site with the lowest current NSP coverage (35%), resulting in a 27% (95% CrI 7% to 43%) decrease in new infections and 41% (95% CrI 11% to 72%) decrease in incidence by 2031 compared with 2016. Addressing homelessness and reducing the harm associated with the injection of crack cocaine could avert approximately 60% of HCV infections over the next 15 years.

**Limitations:** Findings are limited by the misclassification of NSP coverage and the simplified intervention definition that fails to capture the integrated services that address other social and health needs as part of this.

**Conclusions:** There is moderate evidence of the effectiveness of OST and NSPs, especially in combination, on HCV infection acquisition risk. Policies to ensure that NSPs can be accessed alongside OST are needed. NSPs are cost-saving in some sites and cost-effective in others. NSPs and OST are likely to prevent considerable rates of HCV infection in the UK. Increasing NSP coverage will have most impact in settings with low coverage. Scaling up other interventions such as HCV infection treatment are needed to decrease epidemics to low levels in higher prevalence settings.

**Future work:** To understand the mechanisms through which NSPs and OST achieve their effect and the optimum contexts to support implementation.

**Funding:** The National Institute for Health Research Public Health Research programme.

# Contents

<b>List of tables</b>	<b>xiii</b>
<b>List of figures</b>	<b>xv</b>
<b>Glossary</b>	<b>xvii</b>
<b>List of abbreviations</b>	<b>xix</b>
<b>Plain English summary</b>	<b>xxi</b>
<b>Scientific summary</b>	<b>xxiii</b>
<b>Chapter 1 Introduction</b>	<b>1</b>
Rationale for current study	2
Research objectives	2
Research design	3
<b>Chapter 2 Systematic review of the effectiveness of needle and syringe programmes and opioid substitution therapy in preventing hepatitis C transmission among people who inject drugs</b>	<b>5</b>
Objectives	5
Research questions	5
Methods	5
<i>Selection criteria</i>	6
<i>Data collection and analysis</i>	7
<i>Grading of evidence</i>	7
Results	8
<i>Study selection</i>	8
<i>Excluded studies</i>	8
<i>Description of studies</i>	8
<i>Effects of interventions</i>	10
<i>Publication bias</i>	22
Discussion	22
<i>Overall completeness and applicability of evidence</i>	24
<i>Quality of the evidence</i>	24
<i>Potential biases in the review process</i>	24
<i>Changes from original protocol</i>	27
<b>Chapter 3 The impact of needle and syringe provision on hepatitis C transmission among people who inject drugs in the UK and Australia: an analysis of pooled data sets</b>	<b>29</b>
Methods	29
<i>Outcomes</i>	29
<i>Interventions</i>	29
<i>Statistical analyses</i>	32
<i>Meta-analysis</i>	32
<i>Pooled analysis of the effects of opioid substitution therapy and needle and syringe programmes on new hepatitis C infection</i>	32

<i>Secondary outcomes</i>	33
<i>Pooled effects and systematic review findings</i>	34
Findings	34
<i>Meta-analysis to test for study heterogeneity in the effect of opioid substitution therapy and needle and syringe programmes on the risk of hepatitis C acquisition</i>	34
<i>Pooled analysis of the effect of opioid substitution therapy and needle and syringe programmes on new hepatitis C infection</i>	35
<i>Pooled analysis of the effect of opioid substitution therapy and needles/syringe programmes on injecting risk behaviours</i>	35
<i>Pooling estimates with systematic review findings</i>	37
Conclusion	37
<i>Limitations</i>	38
<i>Concluding remarks</i>	39
<b>Chapter 4 Costing of needle and syringe programmes</b>	<b>41</b>
Introduction	41
Methods	41
<i>Needle and syringe programme costing</i>	41
Results	45
<i>Needle and syringe programme outputs</i>	45
<i>Needle and syringe programme costs</i>	46
Conclusions	50
<i>Limitations</i>	50
<b>Chapter 5 Impact modelling</b>	<b>53</b>
Introduction	53
Methods	53
<i>Model description</i>	53
<i>Model parameterisation</i>	56
<i>Model calibration and uncertainty</i>	56
<i>Impact analysis</i>	62
<i>Sensitivity analysis</i>	62
Results	63
<i>Baseline epidemic projections and model validation</i>	63
<i>Impact of existing interventions</i>	66
<i>The impact of current high-risk behaviours</i>	66
<i>Impact of scaling up needle and syringe programmes</i>	67
<i>Sensitivity analysis</i>	68
Conclusions	68
<i>Strengths and limitations</i>	70
<i>Other evidence and implications</i>	70
Summary	71
<b>Chapter 6 Cost-effectiveness analysis</b>	<b>73</b>
Methods	73
<i>Model calibration</i>	73
<i>Cost data</i>	73
<i>Effectiveness</i>	74
Results	74
<i>Model outputs</i>	74
<i>Cost-effectiveness</i>	75
<i>Sensitivity analysis</i>	77
Conclusions	80

<b>Chapter 7 Conclusions and recommendations</b>	<b>83</b>
Opioid substitution therapy and needle and syringe programme efficacy estimates	83
Costs of needle and syringe programme provision through different modalities	84
Cost-effectiveness of needle and syringe programme provision	84
Impact modelling of needle and syringes programmes and opioid substitution therapy	84
Limitations	85
Patient and public involvement	86
Implications for service and local decision-makers	86
Research priorities	86
<b>Acknowledgements</b>	<b>89</b>
<b>References</b>	<b>91</b>
<b>Appendix 1</b> Supplementary material for <i>Chapter 2</i>	<b>101</b>
<b>Appendix 2</b> Supplementary material for <i>Chapter 3</i>	<b>103</b>
<b>Appendix 3</b> Supplementary material for <i>Chapter 4</i>	<b>109</b>
<b>Appendix 4</b> Supplementary material for <i>Chapter 5</i>	<b>111</b>
<b>Appendix 5</b> Supplementary material for <i>Chapter 6</i>	<b>117</b>



# List of tables

<b>TABLE 1</b> Characteristics of included studies	<b>11</b>
<b>TABLE 2</b> Risk-of-bias assessment for included studies	<b>15</b>
<b>TABLE 3</b> Summary of findings for primary analyses	<b>24</b>
<b>TABLE 4</b> Summary of demographic, injecting risk behaviour, intervention coverage and outcome measures by study site	<b>30</b>
<b>TABLE 5</b> Definition of combined harm reduction intervention	<b>32</b>
<b>TABLE 6</b> Association between intervention coverage defined as (a) combination harm reduction interventions and (b) NSP coverage and OST alone and new HCV infection cases	<b>36</b>
<b>TABLE 7</b> Total and unit costs by site	<b>46</b>
<b>TABLE 8</b> Total costs and needles by city	<b>48</b>
<b>TABLE 9</b> Total investment per opioid user, by city	<b>48</b>
<b>TABLE 10</b> Model parameters	<b>57</b>
<b>TABLE 11</b> Baseline scenario characteristics for each setting	<b>66</b>
<b>TABLE 12</b> Total deaths and infections averted through NSPs, by city	<b>74</b>
<b>TABLE 13</b> Total health-related costs over 50 years (GBP millions), by city	<b>75</b>
<b>TABLE 14</b> Cost-effectiveness results: average total costs, QALYs and ICERs for baseline NSPs compared with no NSPs over a 50-year time horizon	<b>76</b>
<b>TABLE 15</b> Cost-effectiveness results: average total costs, QALYs and ICERs for baseline NSPs compared with no NSPs over a 100-year time horizon	<b>76</b>
<b>TABLE 16</b> Univariable metaregression analysis for adjusted studies measuring impact of current OST use on HCV infection incidence	<b>101</b>
<b>TABLE 17</b> Univariable metaregression analysis for studies measuring impact of high NSP coverage on HCV infection incidence	<b>101</b>
<b>TABLE 18</b> Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and injecting with a used needle/syringe	<b>103</b>
<b>TABLE 19</b> Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and reuse of the same needle/syringe for injecting	<b>104</b>



<b>TABLE 20</b> Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and frequency of injecting	<b>104</b>
<b>TABLE 21</b> Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and use of shared spoons and filters	<b>105</b>
<b>TABLE 22</b> Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and injecting-site infection	<b>106</b>
<b>TABLE 23</b> Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and HCV infection testing	<b>106</b>
<b>TABLE 24</b> Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and HIV testing	<b>107</b>
<b>TABLE 25</b> Parameters for costing uncertainty analysis	<b>109</b>
<b>TABLE 26</b> Outputs: fixed sites	<b>109</b>
<b>TABLE 27</b> Outputs: pharmacies in cost study	<b>110</b>
<b>TABLE 28</b> Outputs: other needle distribution modes	<b>110</b>
<b>TABLE 29</b> Summary of data collated for each setting for model calibration	<b>115</b>
<b>TABLE 30</b> Cost associated with NSP for cost-effectiveness model	<b>117</b>
<b>TABLE 31</b> Cost associated with different stages of disease progression for cost-effectiveness model	<b>117</b>
<b>TABLE 32</b> Quality-of-life values used in cost-effectiveness analysis	<b>118</b>

# List of figures

<b>FIGURE 1</b> Flow chart of included studies	<b>9</b>
<b>FIGURE 2</b> Impact of current use of OST vs. non-OST use on HCV infection incidence from adjusted analyses	<b>17</b>
<b>FIGURE 3</b> Impact of current use of OST vs. no OST on HCV infection incidence findings from unadjusted analyses	<b>18</b>
<b>FIGURE 4</b> Impact of other modes of OST on HCV infection risk acquisition	<b>19</b>
<b>FIGURE 5</b> Impact of high NSP coverage vs. low or no NSP coverage on HCV infection risk acquisition from unadjusted analysis	<b>20</b>
<b>FIGURE 6</b> Impact of low NSP coverage on HCV infection risk acquisition	<b>21</b>
<b>FIGURE 7</b> Combined OST and high-coverage NSPs	<b>22</b>
<b>FIGURE 8</b> Funnel plot with pseudo-95% confidence limits assessing publication bias in 12 studies of current OST exposure	<b>23</b>
<b>FIGURE 9</b> Funnel plot with pseudo-95% confidence limits assessing publication bias in 15 studies of high NSP exposure	<b>23</b>
<b>FIGURE 10</b> Flow chart summarising the combined HCV antibody and RNA test results among PWID in the UK and Australia	<b>33</b>
<b>FIGURE 11</b> Meta-analysis summarising study-level estimates of the effect of high NSP coverage (> 100%) on HCV infection incidence	<b>34</b>
<b>FIGURE 12</b> Meta-analysis summarising study-level estimates of the effect of current OST use on HCV infection incidence	<b>35</b>
<b>FIGURE 13</b> Meta-analysis combining pooled analyses with systematic review findings to measure the impact of high NSP coverage (> 100%) on HCV infection incidence	<b>38</b>
<b>FIGURE 14</b> Meta-analysis combining pooled analyses with systematic review findings to measure impact of current OST exposure on HCV infection incidence	<b>38</b>
<b>FIGURE 15</b> Cost drivers as a proportion of total costs	<b>47</b>
<b>FIGURE 16</b> Needle and syringe programme costing uncertainty analysis	<b>49</b>
<b>FIGURE 17</b> Schematic of injecting duration and infection components of model	<b>54</b>
<b>FIGURE 18</b> Graphs showing model fitting of the baseline scenarios in each setting	<b>60</b>
<b>FIGURE 19</b> Impact of each intervention scenario on HCV infection prevalence and incidence in each setting	<b>63</b>

<b>FIGURE 20</b> Impact of removing NSP, OST, NSP and OST or treatment of PWID on the number of new infections from 2016 to 2031 for each setting	<b>67</b>
<b>FIGURE 21</b> Impact of removing transmission risk associated with high-risk behaviour on decreasing the number of new infections from 2016 to 2031 for each setting	<b>67</b>
<b>FIGURE 22</b> Impact of increasing NSPs in each setting on the number of new infections from 2016 to 2031	<b>68</b>
<b>FIGURE 23</b> Sensitivity analysis results: percentage contribution of the uncertainty in different model parameters to the overall variation in the relative increase in number of infections when NSP is removed (only those aspects with > 3% contribution in any of the settings are shown)	<b>69</b>
<b>FIGURE 24</b> Incremental cost-effectiveness: Bristol	<b>77</b>
<b>FIGURE 25</b> Incremental cost-effectiveness: Dundee	<b>77</b>
<b>FIGURE 26</b> Incremental cost-effectiveness: Walsall	<b>77</b>
<b>FIGURE 27</b> Cost-effectiveness sensitivity analysis: Bristol	<b>78</b>
<b>FIGURE 28</b> Cost-effectiveness sensitivity analysis: Dundee	<b>78</b>
<b>FIGURE 29</b> Cost-effectiveness sensitivity analysis: Walsall	<b>79</b>

# Glossary

**Australian Needle Syringe Programme Survey** An annual survey of people who inject drugs conducted by the University of New South Wales.

**Needle Exchange Surveillance Initiative** An annual survey of people who inject drugs conducted by Public Health Scotland.

**Unlinked Anonymous Monitoring Programme** An annual survey of people who inject drugs conducted by Public Health England.



# List of abbreviations

ACROBAT-NRSI	A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions	NESI	Needle Exchange Surveillance Initiative
ANSPS	Australian Needle Syringe Programme Survey	NICE	National Institute for Health and Care Excellence
AOR	adjusted odds ratio	NSP	needle and syringe programme
BDP	Bristol Drugs Project	OR	odds ratio
CI	confidence interval	OST	opioid substitution therapy
CrI	credible interval	PWID	people who inject drugs
DAA	direct acting antiviral	QALY	quality-adjusted life-year
DBS	dried blood spot	RCT	randomised controlled trial
GBP	UK pounds sterling	RDS	respondent-driven sampling
GRADE	Grading of Recommendation, Assessment, Development and Evaluation	RNA	ribonucleic acid
HCC	hepatocellular carcinoma	RR	rate ratio
HCV	hepatitis C virus	SVR	sustained virological response
HIV	human immunodeficiency virus	UAMP	Unlinked Anonymous Monitoring Programme
ICER	incremental cost-effectiveness ratio	WHO	World Health Organization
IPED	image and performance enhancing drug	WTP	willingness to pay



## Plain English summary

**A**lmost half of people who inject drugs (PWID) have the hepatitis C virus (HCV), so preventing transmission is crucial to reduce inequalities in health. The provision of clean injecting equipment through needle and syringe programmes (NSPs) and opioid substitution therapy (OST) are the primary interventions by which to reduce HCV infection among PWID in the UK. We undertook a study to assess how effective both interventions are in preventing new cases of HCV infection and to examine the cost-effectiveness (i.e. value for money) of NSPs. To estimate effectiveness, we conducted a review of international evidence and analysed existing data that measure service use and HCV infection. We collected data on the costs of running NSPs. We applied findings to mathematical models to estimate the effect on the spread of HCV infection if we withdrew or increased the interventions, and assessed how cost-effective they are. Use of OST reduces the chances of being infected with HCV infection by 37–60%, having a clean needle or syringe for each injection reduces the chance of infection by 20–76%, and OST and having a clean needle or syringe in combination reduces the chance of infection by 35–87%. We found NSPs to be cost-effective and money saving in many settings: maintaining services could save up to £5.4M in HCV infection treatment costs, as well as improving quality of life. Findings from the mathematical modelling predict that removing either or both NSPs and OST would result in an increase in HCV infections over the next 15 years. Increasing participation in NSPs in line with OST could reduce new HCV infections by half.





# Scientific summary

## Background

Although there is good evidence that needle and syringe programmes (NSPs) and opioid substitution therapy (OST) in combination reduce injecting risk behaviours and some evidence to show the impact on the incidence of human immunodeficiency virus (HIV), there is little evidence of their impact on hepatitis C virus (HCV) incidence among people who inject drugs (PWID). There had been no economic evaluations of NSPs undertaken in Western Europe, and few studies have considered the costs saved as a result of care and treatment being averted. In addition, previous existing studies relied on weak measures of NSP effectiveness. The aim of this project was to provide evidence on the probable impact of existing coverage levels of NSPs and changes in the extent of provision in preventing HCV infection incidence, and to assess the costs and cost-effectiveness of current NSPs provision and increasing coverage on HCV infection transmission among PWID.

## Objectives

The project answered the following research questions (RQs):

1. What is the impact of different coverage levels of NSP provision on the incidence of HCV infection among PWID?
2. What is the contribution of other risk factors to HCV infection incidence and the overall transmission of HCV infection among PWID?
3. What is the international evidence on the impact of NSPs with and without OST on the incidence of HCV infection among PWID?
4. What are the costs associated with existing NSP provision in three UK settings?
5. What is the impact and cost-effectiveness of existing provision of NSPs, compared with no provision, on HCV infection and HIV transmission and disease burden among PWID in three UK settings?
6. What are the possible strategies by which to increase the coverage of NSP provision in three UK settings, and the probable impact and cost-effectiveness of these strategies?

## Methods

Three linked data collection activities and the following analyses were undertaken:

1. Systematic review (RQ3).  
We conducted a Cochrane-registered systematic review of published studies and unpublished analyses that report on the effect of NSP exposure and/or OST on HCV infection incidence (Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, *et al.* Effectiveness of needle/syringe programmes and opioid substitution therapy in preventing HCV infection transmission among people who inject drugs. *Cochrane Database Syst Rev* 2016;**1**:CD012021). Risk of bias for published non-randomised studies was assessed using the ACROBAT-NRSI tool (A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions), developed by the Methods Groups of Cochrane. Risk of bias was not assessed for the unpublished studies included in the review. We conducted a meta-analysis to estimate the unadjusted effects of NSP exposure and/or OST on HCV infection incidence. Meta-analysis was conducted using random-effects models, pooling univariable and multivariable models separately. We examined heterogeneity with the *I*<sup>2</sup>-statistic and explored reasons for heterogeneity using univariable random-effects metaregression.

## 2. Analysis of pooled data (RQ1 and RQ2).

We collated six data sets previously used in a pooled analysis, for which the methods have been published previously. We added an additional three data sets, namely a community survey of PWID in Bristol ( $n = 336$ ), Public Health England's Unlinked Anonymous Monitoring Programme (UAMP) survey from England and Wales ( $n = 3408$ ) and the Australian Needle Syringe Programme Survey ( $n = 2391$ ), and we replaced one of the studies with updated data from Public Health Scotland's Needle Exchange Surveillance Initiative ( $n = 6988$ ), adding in an additional 6041 individuals. All sources contained comparable indicators on intervention use and new cases of HCV infection, except for UAMP, from which 1567 antibody-negative dried-blood spots were tested. A total of 14,734 observations were included, of which 7173 were anti-HCV negative and 185 were recent infections. The pooled data sets were analysed using logistic regression to model the odds of recent infection by NSP and OST exposure, adjusting for key confounders (injecting duration, sex, crack cocaine use and experience of prison) and assessing the joint effects of NSPs and OST. We combined the findings of the pooled analysis with the results of the systematic review in a meta-analysis.

An internationally standardised measure of an individual's NSP coverage was used, which was defined as the percentage of injections for which a new needle had been obtained (calculated as the average number of new needles obtained divided by the average number of injections). Binary measures of NSPs and OST were combined to form a measure of harm reduction coverage with four categories: (1) full harm reduction (on OST and  $\geq 100\%$  NSP coverage), (2) partial harm reduction (on OST and  $\leq 100\%$  NSP coverage), (3) partial harm reduction (no OST,  $\geq 100\%$  NSP coverage) and (4) minimal harm reduction (no OST,  $< 100\%$  NSP coverage).

## 3. Economic evaluation (costing analysis and cost-effectiveness analysis; RQ4 and RQ5).

We collected cost data from three cities in the UK for the financial year 2013–14. Sites were selected through a combination of convenience sampling based on the availability of impact data for the cost-effectiveness analysis, existing relationships with service managers and the feasibility of conducting a costing study. We collected cost data for three fixed sites, six pharmacies and three 'other' modalities (a mobile outreach service, a drop-in centre and an out-of-hours pharmacy). For pharmacies, only a subsample was costed in detail owing to the existence of multiple pharmacy NSPs in each setting. Data were collected through staff interviews, the review of service statistics and financial reports. We estimated the total and unit economic costs for distributing clean needles to PWID. Our approach to costing was incremental to existing services and was particularly focused on needle and syringe exchange. We followed standard methods for costing in an economic evaluation of a health intervention; we include all costs regardless of the payer and estimated a 'shadow cost', whereby the price does not accurately represent the value of resources. We estimated the cost-effectiveness of current NSP provision compared with no provision. Findings were fed back to collaborators and NSP staff to discuss plausibility as well as strategies to increase intervention coverage. For all analyses, health benefits [quality-adjusted life-years (QALYs)] and costs (health-care provider perspective) were attached to each HCV disease stage and we used recently published utility weights for injectors. Economic model results are presented as incremental cost-effectiveness ratios (ICERs) and probabilistic uncertainty analyses were used to estimate the uncertainty around the ICER, as well as the probability that the intervention is cost-effective at different willingness-to-pay (WTP) thresholds.

## 4. Modelling impact (RQ4–6).

An existing dynamic deterministic model of HCV infection transmission and OST/NSP intervention coverage among PWID was adapted. Intervention efficacy estimates were taken from the pooled analysis. The model fits were used to estimate the impact of historical and current NSP coverage levels for reducing HCV infection prevalence and disease burden in that setting, as well as the future impact of increasing or decreasing NSP coverage levels. The model estimated the contribution of different behavioural risk factors (e.g. homelessness and crack cocaine use) for increasing HCV infection transmission in these settings. All analyses focused on three settings (Bristol, Dundee and Walsall), which were selected based on varying levels of HCV infection prevalence and the availability of detailed behavioural data.

Patient and public involvement included an advisory group consisting of members of the National Needle Exchange Forum (a virtual network), Addaction (London, UK) and the Hepatitis C Trust (London, UK), who were consulted on all aspects of the study design and emerging findings. Preliminary findings of the pooled analysis and the costing analysis were also presented at the annual meeting of the National Needle Exchange Forum (a virtual network), attended by NSP employees and service users.

## Results

### Systematic review

In the systematic review we identified 28 studies (21 published, 7 unpublished) from 5670 records from North America ( $n = 13$ ), the UK ( $n = 5$ ), Europe ( $n = 4$ ), Australia ( $n = 5$ ) and China ( $n = 1$ ), comprising 1736 HCV incident infections and 6513.04 person-years of follow-up. Overall HCV incidence ranged between 0.09 and 42 cases per 100 person-years across the studies. Only two studies were judged to be at moderate overall risk of bias, 12 were judged as being at serious risk of bias and seven were judged as being at critical risk of bias; seven unpublished data sets were not assessed. Findings suggest that current OST (from 12 studies across all regions) reduces the risk of HCV infection acquisition by 50% [rate ratio (RR) 0.50, 95% confidence interval (CI) 0.40 to 0.63;  $I^2 = 0\%$ ;  $p = 0.89$ ]. This effect was maintained in sensitivity analyses excluding unpublished data sets or papers judged to be at critical risk of bias. We found no evidence of differential impact by the proportion of female participants in the sample, region of study, main drug used, history of homelessness or experience of prison. Weaker evidence was found for high NSP coverage derived from seven studies from North America and Europe only (RR 0.77, 95% CI 0.38 to 1.54) with high heterogeneity ( $I^2 = 78.8\%$ ;  $p < 0.001$ ). This effect remained consistent in sensitivity analyses. After removing studies from North America, high NSP coverage in Europe was associated with a 56% reduction in HCV infection acquisition risk (RR 0.44, 95% CI 0.24 to 0.80) with less heterogeneity ( $I^2 = 12.3\%$ ;  $p = 0.337$ ). There was moderate evidence for the impact of combined high coverage of NSPs and OST from four studies, resulting in a 71% reduction in the risk of HCV infection acquisition (RR 0.29, 95% CI 0.13 to 0.65).

### Pooled analysis

Findings from the pooled analysis suggested that in unadjusted analysis, PWID currently using OST had a 65% reduced odds of HCV infection [odds ratio (OR) 0.35, 95% CI 0.26 to 0.48]. High coverage with needles/syringes ( $\geq 100\%$ ) was not significantly associated with reduced odds of HCV infection (OR 0.83, 95% CI 0.60 to 1.16). Adjusting for the confounding effects of sex, experience of prison or injecting crack cocaine did not alter the intervention effects. When examining the effects of combined harm reduction interventions, the risk of new HCV infection was more than halved (54%) among those on full harm reduction, defined as receiving OST and  $\geq 100\%$  NSP coverage [adjusted odds ratio (AOR) 0.44, 95% CI -0.27 to 0.71], compared with those on minimal harm reduction (no OST,  $\leq 100\%$  NSP coverage). There were reduced odds of HCV infection acquisition among those on partial harm reduction [i.e. those exposed to high NSP coverage but not on OST (AOR 0.59, 95% CI 0.36 to 0.96)] and a higher effect for those on OST but with low NSP coverage (AOR 0.59, 95% CI 0.36 to 0.96). Full harm reduction compared with minimal exposure reduced the risk of injecting with a used needle/syringe by 50% (AOR 0.48, 95% CI 0.38 to 0.62), reduced reuse of the same needle/syringe for injecting by 40% (AOR 0.59, 95% CI 0.40 to 0.88) and reduced the frequency of injecting (AOR -41.2, 95% CI -45.5 to -38.0). There was weaker evidence for an association with injecting site infections or shared use of filters and spoons for drug preparation. Full harm reduction was associated with twice the odds of testing for both HCV infection and HIV (AOR 1.9, 95% CI 1.56 to 2.23 and AOR 1.9, 95% CI 1.6 to 2.20, respectively). Combining estimates of NSP effectiveness from the systematic review with two data sets not already represented in the review indicated that high NSP coverage reduced the risk of HCV infection acquisition by 39% (RR 0.61, 95% CI 0.43 to 0.87) with moderate heterogeneity ( $I^2 = 30\%$ ;  $p = 0.189$ ).

### Costing analysis and cost-effectiveness

We observed a degree of variation in costs across the three different commissioning areas evaluated, and variation in costs and outputs was observed across fixed sites and pharmacies. The primary cost driver in

most settings was the cost of supplies; this accounted for an average of 60% of total costs across sites (range 23–80%). This was followed in most cases by administrative and overhead costs, which accounted for 6–45% of total costs. There was some considerable uncertainty in our estimates owing to the fact that cost and output data on NSP distribution are not routinely collected within the UK. The unit cost per opioid needle distributed varied from £0.21 to £1.65, and the unit cost per opioid client (annually) varied from £19.01 to £124.13. Some fixed sites handled a larger number of image and performance enhancing drug users, resulting in a greater cost per opioid client; however, there was no clear distinction in the unit cost per opioid needle between modes of distribution.

Overall, we found that needle and syringe exchange services are highly likely to be cost-effective at almost any WTP threshold and are, in fact, cost-saving in some settings, despite some uncertainty in total outputs. In Dundee the large majority of iterations from the model were cost-saving, and in both Bristol and Walsall, the large majority of iterations were considerably below a WTP threshold of £13,000 per QALY gained. The difference in cost-effectiveness between cities is partly driven by the population size of PWID and the HCV infection prevalence in each study setting. Walsall had the smallest city-wide population of PWID, so a reduction in infections and deaths had less of an overall impact on cost-effectiveness. These cost-effectiveness estimates do not reflect the substantial gains from averting other health problems associated with injecting drug use, including HIV and other infections. Previous research has indicated that NSPs are highly effective in averting HIV infection; incorporating these health gains would substantially improve cost-effectiveness.

### Impact modelling

Findings from the impact modelling suggest that removing OST (current coverage 81%) and NSPs (coverage 56%) in Bristol would increase HCV infection incidence by 329% [95% credible interval (CrI) 110% to 953%] by 2031 and at least double (132% increase, 95% CrI 51% to 306%) the number of new infections over the next 15 years. In Dundee, which has the second highest NSP coverage (49%) of the three settings, removing NSP would result in a 61% increase (95% CrI 12% to 219%) in new infections, whereas removing OST (coverage 70%) alone would result in a 129% (95% CrI 43% to 543%) increase. Increasing NSP coverage to 80% has the largest impact in Walsall, which has the lowest current NSP coverage (28%), resulting in a 27% decrease (95% CrI 7% to 43%) in new infections and a 41% decrease (95% CrI 11% to 72%) in incidence by 2031 compared with 2016. Increasing NSP coverage to 80% results in an approximately 4% absolute drop in prevalence over 15 years in all settings owing to the slow turnover of the population of PWID. Findings show that experience of homelessness and crack cocaine injection increase transmission risk and, if these factors are removed, this could avert approximately 60% of HCV infections over the next 15 years.

## Conclusions

There is evidence from both the systematic review and the pooled analysis that current use of OST compared with no intervention reduces the risk of HCV infection acquisition. The intervention effect from the systematic review is strong but the evidence is considered to be of low quality because it is derived from observational studies with serious risk of bias. This is in part attributable to the ACROBAT-NRSI risk-of-bias assessment tool that we used, which compares study designs to randomised controlled trials as a gold standard rather than assessing studies on their own merit. Findings from the review show weak and low-quality evidence that NSP exposure reduces the risk of HCV infection acquisition, but with regional variation and with a strong effect observed in Europe, as well as less heterogeneity across the studies. Findings from both the review and pooled analysis suggest that the impact of combined high coverage of NSPs and OST was greater. Findings show difficulties in measuring NSP coverage, most probably as a result of misclassification of intervention coverage. Policies to ensure that NSPs can be accessed widely alongside the provision of OST are needed, and obstacles preventing the concurrent use of both NSPs and OST could be removed to maximise the reduction in HCV infection transmission. NSPs are cost-saving interventions in some sites and cost-effective in others. Despite variations in coverage, NSPs and OST are probably

preventing considerable HCV infections in the UK. Increasing NSP coverage will have the most impact in settings with low coverage. Scaling up other interventions, such as HCV infection treatment, are needed to decrease epidemics to low levels in higher-prevalence settings. Further research is needed to improve our understanding of the mechanisms through which NSPs and OST achieve their effect, and of the optimum contexts to support their implementation.

## Funding

Funding for this study was provided by the Public Health Research programme of the National Institute for Health Research.



# Chapter 1 Introduction

Evidence shows that injecting with used needles or syringes and sharing injecting equipment is the main risk factor for infection with the hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among people who inject drugs (PWID).<sup>1,2</sup> The current primary interventions for reducing HIV/HCV infection transmission among PWID are opioid substitution therapy (OST) and needle and syringe programmes (NSPs).<sup>3</sup> In 2005, there were an estimated 1700 NSPs in England, 70% of which were provided by community pharmacies, with the rest offered by specialist community-based services and outreach/mobile services and in custody suites.<sup>4</sup> NSPs in England are funded through Drug Action Teams and Local Strategic Partnerships, which are multiagency bodies involving local government, the police and health services.

Needle and syringe programmes are often a first point of contact with health services for PWID. They provide support to minimise drug and sexual risk-related harms, including the provision of clean needles/syringes and condoms in order to prevent blood-borne virus transmission, bacterial infections and other adverse health outcomes. By maximising the amount of clean injecting equipment in circulation, it is possible to minimise the time that contaminated equipment remains in use and the proportion of unsafe injections.<sup>5,6</sup> NSPs operate through a range of modalities including via fixed sites, outreach, peer PWID networks, vending machines and pharmacies. Engaging in behaviours that are socially stigmatised and illegal, PWID often have high rates of unemployment, homelessness and incarceration. NSPs also provide access to longer-term support by referring clients to medical, drug treatment or social support services.

Drug treatment for opioid addiction and dependence also encompasses a range of strategies to manage injecting drug use and to reduce associated harms, including medication-assisted treatment such as OST, medication-assisted treatment combined with psychosocial approaches and residential rehabilitation. The most commonly prescribed forms of OST are opioid agonist treatments, namely methadone maintenance therapy and partial agonist buprenorphine maintenance treatment, or the increasingly popular naloxone and buprenorphine (Subuxone®, Indivior Inc., Richmond, VA, USA). OST is prescribed to dependent users to diminish the use and effects of illicitly acquired opioids. It is usually taken orally and therefore reduces the frequency of injection and unsafe injecting practices.<sup>7</sup> As a treatment for opioid dependence, OST has been shown to increase health and social functioning, decrease crime and reduce the frequency of injection and unsafe injecting practices.<sup>8,9</sup> Evidence suggests that OST is most effective when it is continuous and provided at adequate doses.<sup>10,11</sup> In the UK, OST is prescribed by medically qualified clinicians or nurses and dispensed in both primary care or community settings (sometimes co-located at NSPs).

Both NSPs and OST are complex interventions that not only seek to reduce immediate harms caused by unsafe injecting practices, such as reducing HIV, HCV or bacterial infections, but also aim to address more complex social problems experienced by PWID by providing integrated care and referrals to other agencies including housing, social welfare, legal advocacy and sexual and mental health services. This report takes a more focused definition of how the interventions reduce the risk of infection with HCV infection and does not take into account the indirect routes or causal pathways through which the interventions might work by addressing the underlying social issues that might lead to injecting risk behaviours.

Although there is good evidence that NSPs and OST in combination reduce injecting risk behaviours and some evidence to show the impact on HIV incidence, there is little evidence of their impact on HCV infection incidence among PWID.<sup>3,12–15</sup> In 2012 and 2014, two reviews were published that estimated a moderate effect of NSPs on reducing HIV transmission by 48% [95% confidence interval (CI) 3% to 72%] and strong evidence for OST reducing HIV transmission by 54% (95% CI 33% to 68%).<sup>16,17</sup> Similar evidence is lacking for the effect of NSPs or OST on HCV infection. Previous reviews<sup>7,15,18</sup> have synthesised evidence for use of NSPs but have focused primarily on HIV as the main outcome and, as a consequence, have failed to include all the available evidence on HCV infection.<sup>3</sup> More recently, evidence on a range of risk-reduction interventions on HCV infection seroconversion, including behavioural interventions, NSP and OST, were reviewed.<sup>19</sup> This study measured the effect of NSP use, defined inconsistently as any attendance



at a NSP or attendance at one point in time, and showed an increased risk of seroconversion. Limitations of this review included substantial heterogeneity across studies, a lack of clarity on the measure of NSP use and a focus on evidence from North America, which limits the generalisability of findings to other settings, including the UK. Our review on the effect of OST use on HIV transmission detected many more studies than earlier Cochrane reviews.<sup>17</sup> We also expect that not all evidence on the effect of NSP on HCV infection transmission has been identified, so extending previous reviews would strengthen the evidence base as well as provide a more refined measure of coverage of NSP that accounts for frequency and the degree to which NSPs meet individuals' requirement for needles/syringes.

A recent analysis of pooled data presented a clearer definition of NSP use, defining coverage in terms of the proportion of injections with a sterile syringe. This analysis suggested that high coverage of NSPs ('100% NSP', i.e. obtaining  $\geq 1$  sterile syringes per injection) or OST can each reduce HCV infection risk by 50%; and NSPs and OST in combination can reduce HCV infection risk by 80%.<sup>20</sup> However, owing to a small number of incident HCV infection cases ( $n = 40$ ), the efficacy estimate for 100% coverage of NSPs was weak (95% CI 0.22 to 1.12) and there was insufficient power to evaluate whether or not a dose–response relationship exists. This project will provide a more robust understanding of the likely impact of existing coverage levels of NSPs and changes in the extent of provision.

There have been no attempts to estimate the cost-effectiveness of NSP provision in England, although NSPs and OST are the current primary interventions for reducing HIV/HCV transmission among PWID in the UK.<sup>3</sup> In addition, although a recent National Institute for Health and Care Excellence (NICE) evaluation considered the cost-effectiveness of NSPs, they were unable to estimate the incremental cost-effectiveness of increasing coverage because of 'a paucity of evidence underpinning effectiveness'.<sup>21</sup> Internationally, of the economic evaluations of NSPs, none has been undertaken in Western Europe, few have considered the costs saved as a result of care and treatment averted, and all studies have relied on weak measures of NSP effectiveness, such as using either changes in self-reported syringe sharing or ecological data relating NSP exposure to HCV infection prevalence or incidence in the population, which are unreliable and subject to substantial bias (Guinness L, Martin N, Harker M, Greco G, Vickerman P, 2012, unpublished). There is an urgent need to fill this evidence gap by producing the first Western European evidence for the cost-effectiveness of NSPs and an economic evaluation to use empirical data on NSP effectiveness in reducing HCV infection transmission at the individual level.

## Rationale for current study

Evidence for the effect of NSP use on HIV and HCV infection incidence is inconsistent.<sup>22,23</sup> Studies have lacked sufficient evidence on the frequency of use of the intervention, the quantity of needles/syringes distributed<sup>24</sup> or insufficient sample sizes to accurately measure the effect.<sup>3</sup> Economic evaluations of NSPs have not focused on Western European data, and existing studies have relied on weak measures of NSP effectiveness. Further evidence is essential in order to accurately estimate what level and combination of intervention is needed to substantially reduce HCV infection in PWID and the costs associated with increasing coverage to the optimal level.

## Research objectives

The aim of this project was to assess the impact and different coverage levels of needle and syringe provision with and without OST on the incidence of HCV infection among PWID as well as the costs and cost-effectiveness of NSPs.

There were six linked objectives.

- Objective 1: use pooled data sets and a deterministic model to measure the impact of different NSP coverage levels in the presence and absence of OST on the incidence of HCV infection among PWID in the UK.
- Objective 2: estimate the contribution of risk factors (e.g. homelessness and crack cocaine use) to HCV infection incidence and the overall transmission of HCV infection among PWID.
- Objective 3: conduct a systematic review of international evidence on the impact of NSPs with and without OST on the incidence of HCV infection among PWID.
- Objective 4: estimate the costs associated with existing NSP provision in three UK settings.
- Objective 5: estimate the impact and cost-effectiveness of existing provision of NSPs, compared with no provision, on HCV and HIV transmission and disease burden among PWID in three UK settings.
- Objective 6: determine possible strategies to increase the coverage of NSP provision in three UK settings, and the probable impact and cost-effectiveness of these strategies.

## Research design

The aims and objectives listed above were achieved through the implementation of five linked data collection activities and analyses. The findings from each study are summarised in the individual chapters below. *Chapter 2* details the systematic review, *Chapter 3* provides an analysis of pooled data sets, *Chapter 4* outlines the costing analysis, *Chapter 5* details the impact modelling and *Chapter 6* outlines the cost-effectiveness analysis.



# Chapter 2 Systematic review of the effectiveness of needle and syringe programmes and opioid substitution therapy in preventing hepatitis C transmission among people who inject drugs

## Objectives

Our primary objective was to assess the impact of NSPs and OST together and alone on the incidence of HCV infection among PWID. Our secondary objective involved exploring the effect of sample characteristics (e.g. experience of prison, homelessness, use of stimulant injection) on the transmission of HCV infection among PWID.

## Research questions

The specific research questions to be answered through the review were:

1. How effective is OST in reducing HCV infection incidence among PWID?
2. How effective are NSPs with and without the use of OST for reducing HCV infection incidence among PWID?
3. How does the effect of NSP and OST vary according to the duration of treatment (i.e. weekly vs. monthly attendance for NSPs)?
4. How does the effect of NSPs vary according to the type of service (fixed vs. mobile site; high vs. low coverage)?
5. How does the effect of OST vary according to the dosage of OST, the type of substitution used and adherence to treatment?

International evidence supports the use of combination interventions to prevent and treat HIV among PWID with the provision of NSPs, OST and HIV antiretroviral treatment as the key interventions.<sup>25</sup> There is good evidence that NSPs and OST reduce injecting risk behaviours and increasing evidence to show an impact on HIV incidence.<sup>16,17</sup> However, evidence of their impact on HCV infection incidence among PWID, in combination or alone, is limited.<sup>3,8,12–15,20</sup>

## Methods

The full methods used in the review are published in Platt *et al.*<sup>26,27</sup> This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. Here, we summarise the methods in brief as well as some of the key findings of the review. We conducted two primary searches of the literature based on key search terms identified by the review of reviews and the recent review of the effect of OST and NSPs on the risk of HIV and HCV infection among PWID.<sup>3,17</sup> The purpose of the two searches was to (1) identify studies that directly measured the impact of NSPs/OST on HCV infection incidence and (2) identify longitudinal studies that measured HCV infection incidence and report the impact of NSPs/OST as part of an adjusted analysis.

We searched MEDLINE (1946 to November 2015), PsycINFO (1806 to November 2015), EMBASE (1980 to November 2015), Global Health (1910 to November 2015), Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, NHS Economic Evaluation Database, Health Technology Assessment database, The Cochrane Library, the Cochrane Drug and Alcohol Register and Web of Science for observational and experimental studies measuring exposure to NSPs and/or OST (compared with no intervention) among PWID and HCV infection incidence. All searches were conducted in November 2015. When no measure was reported in observational studies, authors of studies were contacted and asked to provide unpublished data. We also searched publications of key international agencies as well as conference abstracts. Reference lists of all included articles were reviewed for eligible papers. A copy of the search strategy is published in Platt *et al.*<sup>26</sup>

### Selection criteria

We included all observational (prospective and retrospective cohorts, cross-sectional surveys and case-control studies) and experimental studies [randomised controlled trials (RCTs)] that measured exposure to either intervention versus no intervention or a reduced exposure, and that reported HCV infection incidence as an outcome.

We included cross-sectional surveys if they included a serological measure of recent infection [e.g. through positive ribonucleic acid (RNA) results on antibody-negative samples]. We excluded cross-sectional studies (including serial cross-sectional studies) reporting HCV infection prevalence only. We excluded studies relying on self-reported data for the outcome.

### Participants

We focused on studies of PWID (opioids and/or stimulants). Studies that include participants undergoing opportunistic HCV infection testing (outside the study setting) were excluded, as were those relating to PWID in the prison setting, because addiction services and treatment provision in this setting differ significantly from community and health-care settings.

### Outcome

Our outcome of interest was incidence of HCV infection in PWID as measured via repeat testing such as the detection of HCV RNA-positive status among HCV antibody-negative results or antibody avidity. Studies were also included if they reported a minimum of two HCV seroconversions (HCV antibody negative to HCV antibody positive) among the study participants from tests conducted at different time points.

Methods used in this systematic review in relation to the search strategies and approaches to data synthesis follow methods applied in a similar review to assess the impact of OST on HIV incidence.<sup>17</sup>

### Intervention

Exposure to NSPs was defined as the proportion of injections that are covered by a clean needle/syringe or attendance at a NSP. When it was not possible to estimate the proportion of injections covered by a clean needle/syringe, we defined exposure accounting for frequency of injection and the degree to which the NSP meets the individual's requirement for needles/syringes.

Exposure to OST was defined as current or recent continuous or interrupted treatment (past 6 months or for the duration of HCV infection observation period), or any past treatment with methadone or buprenorphine.

Interventions were defined as current OST (within past 6 months) or lifetime use of OST, and high NSP coverage (regular attendance at a NSP or all injections covered by a new needle or syringe) or low NSP coverage (irregular attendance at a NSP or < 100% of injections covered by a new needle or syringe).

### Control intervention

- No OST.
- Low coverage NSP or no NSP.

## Types of comparisons

- OST versus no OST.
- High NSP coverage with no OST versus low coverage NSP.
- Low NSP coverage with no OST versus no NSP.
- Combined high/low NSP coverage with OST versus no OST and low/no coverage NSP.

## Data collection and analysis

Two reviewers screened all title and abstracts, and disagreements were resolved following discussion. Full texts were screened by two people to assess eligibility. Data were extracted independently by two people and then checked for consistency. Full-text papers in languages other than English were translated by individuals fluent in those languages.

Meta-analysis was conducted using random-effects models, pooling univariable and multivariable models separately. We examined heterogeneity with the  $I^2$ -statistic and explored reasons for heterogeneity using univariable random-effects metaregression. We examined heterogeneity with the  $I^2$  and  $\tau^2$  statistics, and explored reasons for heterogeneity using univariable random-effects metaregression to evaluate the impact of the following covariates on intervention effect: geographical region of study; recruitment setting (community based or treatment); percentage of female participants; main drug injected; type of NSP; frequency of injecting; dose, duration and adherence to NSP/OST (i.e. continuous or interrupted treatment); and study design. There was insufficient information to assess the impact of adherence to NSPs/OST (i.e. continuous or interrupted treatment). We used Stata® version 14.0 (StataCorp LP, College Station, TX, USA) in all analyses and transferred the data into RevMan software version 5.3 (Cochrane, The Nordic Cochrane Centre, Copenhagen, Denmark).

## Grading of evidence

Risk of bias for all studies was assessed using the ACROBAT-NRSI tool (A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions), which is in development by the Methods Groups of Cochrane.<sup>28</sup> We assessed the overall quality of the evidence for the primary outcome using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. The GRADE Working Group developed a system for grading the quality of evidence,<sup>29–32</sup> which takes into account issues related not only to internal validity but also to external validity, such as the directness of results. In particular, they provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined and the sum of available data on the main outcomes.

The GRADE system uses the following criteria for assigning grades of evidence:

- High – we are very confident that the true effect lies close to that of the estimate of the effect.
- Moderate – we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- Low – our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
- Very low – we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.

Grading is decreased for the following reasons:

- serious (–1) or very serious (–2) study limitation for risk of bias
- serious (–1) or very serious (–2) inconsistency between study results
- some (–1) or major (–2) uncertainty about directness (the correspondence between the population, the intervention or the outcomes measured in the studies actually found and those under consideration in our systematic review)
- serious (–1) or very serious (–2) imprecision of the pooled estimate (–1)
- publication bias strongly suspected (–1).

Grading is increased for the following reasons:

- Strong evidence of association – significant relative risk of  $> 2$  ( $< 0.5$ ) based on consistent evidence from two or more observational studies, with no plausible confounders (+1). Very strong evidence of association – significant relative risk of  $> 5$  ( $< 0.2$ ) based on direct evidence with no major threats to validity (+2).
- Evidence of a dose–response gradient (+1).
- All plausible confounders would have reduced the effect (+1).

## Results

Text in this section is reproduced from Platt *et al.*<sup>26</sup> and Platt *et al.*<sup>28</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

### Study selection

Figure 1 shows the number of studies identified, reviewed and selected and the reasons for exclusion for both searches.

We identified 21 papers that directly included measures of the impact of exposure to either OST or NSPs on HCV infection transmission. In addition, we identified 11 eligible prospective studies that measured HCV infection incidence and contacted authors of these articles. Of these, unpublished data were obtained from seven cohort studies in Montreal, Canada;<sup>33</sup> Baltimore, USA;<sup>34</sup> San Francisco, USA;<sup>35</sup> London, UK;<sup>36</sup> and Sydney and Melbourne, Australia.<sup>37,38</sup> The full text of 141 papers was reviewed. A total of 19 papers were included, and 120 papers were excluded for the following reasons: no HCV infection incidence data ( $n = 55$ ); no measure of intervention exposure ( $n = 34$ ); contain no primary data ( $n = 20$ ); the sample was not PWID ( $n = 1$ ); all the sample were recruited from the intervention ( $n = 9$ ); and the article could not be obtained in its original language (Japanese) ( $n = 1$ ).

In total, we included 21 published studies<sup>14,39–58</sup> and seven unpublished studies<sup>33–37,59,60</sup> comprising 1827 HCV incident infections and 8789.7 person-years of follow-up. Overall HCV infection incidence ranged between 0.09 and 42 cases per 100 person-years across the studies.


### Excluded studies

A total of 101 studies (104 articles) were excluded in which there was no outcome of interest assessed (43 studies); no intervention of interest (32 studies); no comparison of interest (all participants on OST) (nine studies); no outcome and no intervention of interest (11 studies); no outcome and no comparison of interest (four studies); or when the study was an editorial or overview (two studies).

### Description of studies

#### Participants and setting

We included studies undertaken in the USA ( $n = 8$ ), the UK ( $n = 5$ ), Canada ( $n = 5$ ), the Netherlands ( $n = 1$ ), France ( $n = 1$ ), Italy ( $n = 1$ ), Spain ( $n = 1$ ), Australia ( $n = 5$ ) and China ( $n = 1$ ). Twenty-five studies reported the sex of participants, for which the mean proportion of female participants was 32% (range 2.8–55.9%). Across 14 studies, on average, 40.7% (range 9.2–69.2%) of participants had experience of recent or past homelessness and 35% (range 18.2–90%) had past or recent experience of prison ( $n = 12$  studies). The mean reported use of stimulants was 32.7% (range 0–75%,  $n = 19$  studies) and a mean of 50.5% (range 18.2–100%) of participants reported heroin use ( $n = 13$ ). Across 14 studies, a mean of 50.6% of participants reported injecting daily (range 18.2–84%).



**FIGURE 1** Flow chart of included studies. CDAG, Cochrane Drug and Alcohol Register; CENTRAL, Cochrane Central Register of Controlled Trials; CINAHL, Cumulative Index to Nursing and Allied Health Literature; CLib, Cochrane Library; DARE, Database of Abstracts of Reviews of Effects; HTA, Health Technology Assessment; NHS EED, NHS Economic Evaluation Database; WOS, Web of Science. Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

## Type of interventions

Twenty-one of the included studies reported the impact of OST,<sup>14,20,39,40,45–47,49,51–53,55,57,58</sup> including seven unpublished estimates.<sup>33–37,59,60</sup> Seventeen studies reported the impact of NSPs,<sup>14,20,41–44,47,48,50,54,56,58</sup> including five unpublished sources,<sup>33–35,59,60</sup> and four reported combined measures of NSPs with OST,<sup>14,33,44,47</sup> including one unpublished data source.<sup>33</sup> One study looked at the impact of distributing injecting paraphernalia (defined as spoons and filters) by itself, with needles/syringes and in combination with OST.<sup>47</sup>

## Study design

There was much variation in the included studies in terms of sample size (range 46–2788), method of recruitment involving street outreach ( $n = 12$ ), respondent-driven sampling (RDS) alone ( $n = 2$ ), street outreach, snowball sampling or RDS combined ( $n = 4$ ), and service attenders ( $n = 7$ ). A range of study



designs were included, such as case-control studies ( $n = 2$ ), cross-sectional studies ( $n = 3$ ), prospective cohort studies ( $n = 20$ ), retrospective cohort studies ( $n = 2$ ) and serial cross-sectional surveys ( $n = 1$ ). For cohort studies, the duration of follow-up time ranged between 1 and 22 years. Included studies were published between 1995 and 2014. Key study characteristics are included in *Table 1*.

### Methodological quality: risk-of-bias assessment

Twenty-one original non-randomised published studies were assessed. Two were judged as being at moderate overall risk of bias, 17 were judged as being at serious risk of bias and seven were judged as being at critical risk of bias. For two studies, we did not have sufficient information to make a judgement. A summary of the risk-of-bias assessment is included in *Table 2*.

## Effects of interventions

### Current use of opioid substitution therapy versus no current opioid substitution therapy

Of the 28 studies, we pooled data from a total of 17 studies to assess the impact of current OST use on HCV infection incidence,<sup>14,39,40,45–47,49,52,53,55,56,58</sup> including five unpublished estimates.<sup>33,36,37,59,60</sup> Current use of OST was defined as reporting use of OST within the past 6 months (yes or no)<sup>33,46,49,58,60</sup> or as reporting use of OST either within 6 months or > 6 months ago,<sup>36</sup> use of methadone at the time of survey,<sup>39,47,52,59</sup> continuous use of OST throughout the follow-up period,<sup>40,45,53</sup> with one study defining continuous use as daily use of methadone (any dosage) in the past 6 months<sup>14</sup> or in the past month.<sup>37</sup> One study used a 3-month time frame to measure the use of opioid agonist therapy maintenance treatment.<sup>55</sup> One study measured current use of buprenorphine.<sup>34</sup>

All comparison groups were made against no intervention. All the included studies were longitudinal studies, with the exception of one case-control study<sup>49</sup> and two cross-sectional surveys.<sup>47,59</sup>

The 17 studies included a minority of women (range 3–53%), a high proportion of the samples had experience of prison (range 18–60%) and homelessness (9–70%), and use of stimulants ranged between 1% and 51% across the studies. A total of 1073 HCV infection incident cases were included over 4990.29 person-years of follow-up.

Of these 17 studies, 12 presented adjusted estimates on which the primary analyses were focused. Adjusted estimates controlled for potentially confounding effects of the following factors: duration of injection; frequency of injection;<sup>33,36,60</sup> area of residence, homelessness, sharing injecting equipment or needles;<sup>2</sup> sex, geographical region, use of condoms, injection of cocaine, duration of injection and sharing injecting equipment;<sup>45</sup> duration of injection, frequency of injection and age of whole cohort;<sup>34</sup> unstable housing, cocaine, heroin or methamphetamine injection, cohort of recruitment, year of recruitment and follow-up time;<sup>46</sup> survey year, homelessness, stimulant injection and duration of injection;<sup>47</sup> sex, age, duration of drug use and injection of cocaine;<sup>49</sup> age, duration of injection, sex, ethnicity, homelessness or prison in the past 3 months;<sup>55</sup> sex, ethnicity, age, frequency of injecting, sharing needles/syringes, not receiving OST while reporting opioid use,<sup>58</sup> injected at follow-up, pooled money to buy drugs, injection with used needles and backloading.<sup>53</sup>

Random-effects meta-analysis of multivariable estimates shows that OST was associated with a 50% reduction in the risk of HCV infection [rate ratio (RR) 0.50, 95% CI 0.40 to 0.63] with little evidence of heterogeneity between studies ( $I^2 = 0$ ;  $p = 0.889$ ) (*Figure 2*).

### Sensitivity analyses

This effect was increased when excluding estimates from four unpublished data sources<sup>33,34,36,53</sup> (RR 0.42, 95% CI 0.31 to 0.58) and little evidence of heterogeneity between studies ( $I^2 = 0\%$ ;  $p = 0.96$ ). The effect was maintained when limiting the analysis to exclude all unpublished data sets as well as one study that was judged to be at critical risk of bias<sup>49</sup> (RR 0.43, 95% CI 0.31 to 0.59;  $I^2 = 0\%$ ;  $p = 0.93$ ). The effect was

TABLE 1 Characteristics of included studies

Author and year	Country	Study design	Sex (% female)	Age (years)	Sample	HCV per 100 person-years	New HCV cases/ person-years	Interventions	Comparison
Aitken <i>et al.</i> , 2017 <sup>37</sup>	Australia	Cohort	31.7	29.4 (median)	98	8.6	17/196	OST current Use of OST in past month	No OST in past month
Bruneau, 2015 <sup>33</sup>	Canada	Cohort	NA	< 30 (37.4%)	285	17.3	102/589.35	OST; NSP (high); combined NSP/OST (1) Use of OST in past 6 months; (2) high NSP (> 100% coverage); (3) OST in past 6 months and high (> 100% coverage)	No OST in past 6 months; low (< 100%) NSP coverage
Craine <i>et al.</i> , 2009 <sup>39</sup>	Wales	Cohort	29.0	27.2 (mean)	286	5.9	17/287.33	OST current In OST at interview	Not in OST
Crofts <i>et al.</i> , 1997 <sup>40</sup>	Australia	Cohort <sup>a</sup>	41.9	29.2 (mean)	73	22.2	13/85.4	OST current Continuous OST during follow-up	Not on OST
Hagan <i>et al.</i> , 1995 <sup>41</sup>	USA	Case-control	45.0	< 25 (24%)	46		20/NA	NSP (low) Ever used NSP	Never used NSP
Hagan <i>et al.</i> , 1999 <sup>42</sup>	USA	Cohort	38.0	< 25 (19%)	187	20.8	26/209	NSP (high, low) Current, regular or sporadic NSP use	Never used NSP
Holtzman <i>et al.</i> , 2009 <sup>43</sup>	USA	Cohort	38.0	< 21 (28%)	1288		139/NA	NSP (low) NSP participation in the past 6 months	No use of NSP in past 6 months
Hope <i>et al.</i> , 2011 <sup>44</sup>	UK	Cross-sectional	23.0	< 25 (17%)	119	40	14/35	OST current; NSP alone (low, high); NSP/OST combined Use of OST in past 4 weeks; high NSP ( $\geq$ 100% coverage) or low NSP (< 100% coverage)	No OST, low or no NSP coverage
									continued

**TABLE 1** Characteristics of included studies (*continued*)

Author and year	Country	Study design	Sex (% female)	Age (years)	Sample	HCV per 100 person-years	New HCV cases/ person-years	Interventions	Comparison
Hope, 2015 <sup>59</sup>	UK	Cross-sectional	25.0		919	9.9	30.3	OST current; NSP Use of OST in past 4 weeks; high NSP coverage ( $\geq 100\%$ coverage)	Low NSP, no OST
Judd, 2015 <sup>36</sup>	UK	Cohort	29.0	27.4	149	42	49/116.7	OST current Use of methadone in past 6 months or longer	
Lucidarme <i>et al.</i> , 2004 <sup>45</sup>	France	Cohort	17.6	26.9 (mean)	165	11	16/178.4	OST current No definition	No OST
Maher, 2015 <sup>60</sup>	Australia	Cohort	38.0	24 (median)	368	24.9	53/212.86	OST current OST in past 6 months	No OST
Mehta, 2015 <sup>34</sup>	USA	Cohort		34 (median, baseline)	324	17.8	27/166.5	OST current OST in past 6 months	No OST
Nolan <i>et al.</i> , 2014 <sup>46</sup>	Canada	Cohort	30.4	23–34	1004	6.32	184/2108.4	OST current Active participation in MMT in past 6 months	No OST
Page, 2015 <sup>35</sup>	USA	Cohort	21.7	33.7 (mean)	552	25.1	171/681.3	NSP (low) NSP use in the past 3 months	No NSP
Palmateer <i>et al.</i> , 2014 <sup>47</sup>	Scotland	Cross-sectional	27.5	34 (mean)	2788	7.3	392/602.7	OST current; NSP (high) OST/NSP combined; OST at time of survey; high NSP ( $> 200\%$ ) coverage and not on OST; low NSP ( $< 200\%$ )	No OST; low NSP coverage
Patrick <i>et al.</i> , 2001 <sup>48</sup>	Canada	Cohort	30.3	34 (median)	155	29.1	62/207.95	NSP (high) Attendance at least once per week at NSP in past 6 months	No attendance at NSP

Author and year	Country	Study design	Sex (% female)	Age (years)	Sample	HCV per 100 person-years	New HCV cases/ person-years	Interventions	Comparison
Rezza <i>et al.</i> , 1996 <sup>49</sup>	Italy	Case-control	2.8	> 28 (21%)	106	28.6	21/73.4	OST current OST in past 6 months	No OST
Ruan <i>et al.</i> , 2007 <sup>51</sup>	China	Cohort		< 28 (44%)	86	33.0	47/258	OST other Ever used OST Use of NSP in past 6 months <sup>b</sup>	Never used OST
Roy <i>et al.</i> , 2007 <sup>50</sup>	Canada	Cross-sectional	27.0	31.8 (mean)	359	27.1	94/267	NSP (low)	No NSP use in past 6 months
Spittal <i>et al.</i> , 2012 <sup>52</sup>	Canada	Cohort	53.4	23 (median)	148	11.6	45/338.6	OST current In OST at time of survey	Not in MMT
Thiede <i>et al.</i> , 2000 <sup>53</sup>	USA	Cohort	48.9	< 25 (5.4%)	80	0.09	4/80	OST current and other Continuous treatment during follow-up. Interrupted treatment; left treatment at least once during follow-up but had re-entered by end of study	Left treatment and not enrolled at follow-up
Thorpe <i>et al.</i> , 2002 <sup>54</sup>	USA	Cohort	39.7	18–22 (52%)	353	10	29/327.2	NSP (low) Use of NSP in past 6 months	No use of NSP in last 6 months
Tsui <i>et al.</i> , 2014 <sup>55</sup>	USA	Cohort	31.9	15–18 (16%)	552	25.1	145/680	OST current and other Opioid agonist therapy maintenance treatment in past 3 months; OST other opioid agonist detoxification in past 3 months	No OST
Vallejo <i>et al.</i> , 2015 <sup>56</sup>	Spain	Cohort	27.3	≥ 25 (40%)	137	39.8	42/105.4	OST other Lifetime use of OST	Never used OST
									continued

**TABLE 1** Characteristics of included studies (*continued*)

Author and year	Country	Study design	Sex (% female)	Age (years)	Sample	HCV per 100 person-years	New HCV cases/ person-years	Interventions	Comparison
Van Den Berg <i>et al.</i> , 2007 <sup>14</sup>	The Netherlands	Cohort	33.0	31.4 (median)	168	6.78	57/598.56	OST current; NSP alone; combined OST/NSP  OST ≥ 60 mg of methadone daily  High NSP (100% coverage); low NSP (1–99% coverage)	No OST or no injecting; low (1–99%) or no NSP coverage (0%)
van Beek <i>et al.</i> , 1998 <sup>57</sup>	Australia	Cohort <sup>a</sup>	55.9	< 20 (61.5%)	152	20.9	26/148.2	OST other  Ever used OST	Never used OST
White <i>et al.</i> , 2014 <sup>58</sup>	Australia	Cohort	25.0	27 (median)	127	7.9	20/215.2	OST; NSP (low)  Accessed NSP in past 6 months; OST in past 6 months	No NSP. (1) No OST, mainly injected heroin, (2) no OST, mainly injected another drug

MMT, methadone maintenance therapy; NA, not applicable.

<sup>a</sup> Denotes retrospective cohort design.<sup>b</sup> This study was dropped because it did not report 95% CIs around the effect estimate or report new HCV cases in exposure and comparison groups to be able to estimate it.

**TABLE 2** Risk-of-bias assessment for included studies


Study	Confounding	Selection bias	Measurement of interventions	Departures from intended interventions	Missing data	Measurement of outcomes	Selection of reported result	Overall risk of bias
Aitken <i>et al.</i> , 2017 <sup>37</sup>	Critical	Critical	Serious	No information	Critical	Low	No information	Critical
van Beek <i>et al.</i> , 1998 <sup>57</sup>	Critical	Serious	Serious	No information	Critical	Low	Low	Critical
Bruneau, 2015 <sup>33</sup>	Moderate	Serious	Moderate	No information	No information	Low	Low	Serious
Craine <i>et al.</i> , 2009 <sup>39</sup>	Serious	Serious	Serious	No information	Serious	Low	Low	Serious
Crofts <i>et al.</i> , 1997 <sup>40</sup>	Critical	Serious	Low	No information	Serious	Serious	Low	Critical
Hagan <i>et al.</i> , 1995 <sup>41</sup>	Serious	Serious	Serious	No information	Low	Low	Low	Serious
Hagan <i>et al.</i> , 1999 <sup>42</sup>	Moderate	Serious	Low	No information	Low	Low	Low	Serious
Holtzman <i>et al.</i> , 2009 <sup>43</sup>	Serious	Serious	Moderate	No information	No information	Low	Low	Serious
Hope <i>et al.</i> , 2011 <sup>44</sup>	Moderate	Moderate	Serious	No information	Low	Low	Low	Serious
Hope, 2015 <sup>59</sup>	Moderate	Moderate	Serious	No information	No information	Low	Low	Serious
Judd, 2015 <sup>36</sup>	Moderate	Critical	Critical	No information	Critical	Low	Low	Critical
Lucidarme <i>et al.</i> , 2004 <sup>45</sup>	Moderate	Serious	Serious	No information	Serious	Low	Low	Serious
Maher, 2015 <sup>60</sup>	Moderate	Serious	Serious	No information	No information	Low	Low	Serious
Mehta, 2015 <sup>34</sup>	Moderate	No information	No information	No information	No information	Low	Low	No information
Nolan <i>et al.</i> , 2014 <sup>46</sup>	Serious	Serious	Moderate	No information	Low	Low	Low	Serious
Page, 2015 <sup>35</sup>	Moderate	No information	No information	No information	No information	Low	Low	No information
Palmateer <i>et al.</i> , 2014 <sup>47</sup>	Serious	Serious	Moderate	No information	Serious	Low	Low	Serious
Patrick <i>et al.</i> , 2001 <sup>48</sup>	Serious	Moderate	Serious	No information	Serious	Low	Low	Serious
Rezza <i>et al.</i> , 1996 <sup>49</sup>	Serious	Low	Serious	No information	Critical	Low	Low	Critical

continued

**TABLE 2** Risk-of-bias assessment for included studies (*continued*)

Study	Confounding	Selection bias	Measurement of interventions	Departures from intended interventions	Missing data	Measurement of outcomes	Selection of reported result	Overall risk of bias
Roy <i>et al.</i> , 2007 <sup>50</sup>	Serious	Serious	Serious	No information	Critical	Low	Low	Critical
Ruan <i>et al.</i> , 2007 <sup>51</sup>	Critical	Critical	Serious	No information	Serious	Low	Low	Critical
Spittal <i>et al.</i> , 2012 <sup>52</sup>	Serious	Serious	Moderate	No information	Low	Low	Low	Serious
Thiede <i>et al.</i> , 2000 <sup>53</sup>	Moderate	Moderate	Low	No information	Low	Low	Low	Moderate
Thorpe <i>et al.</i> , 2002 <sup>54</sup>	Serious	Serious	Serious	No information	Moderate	Low	Low	Serious
Tsui <i>et al.</i> , 2014 <sup>55</sup>	Moderate	Moderate	Low	No information	Moderate	Low	Low	Moderate
Vallejo <i>et al.</i> , 2015 <sup>56</sup>	Serious	Serious	Low	No information	Serious	Low	Low	Serious
Van Den Berg <i>et al.</i> , 2007 <sup>14</sup>	Serious	Serious	Moderate	No information	Serious	Low	Low	Serious
White <i>et al.</i> , 2014 <sup>58</sup>	Moderate	Serious	Moderate	No information	No information	Low	Low	Serious

Reproduced from Platt *et al.*<sup>28</sup> This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.



**FIGURE 2** Impact of current use of OST vs. non-OST use on HCV infection incidence from adjusted analyses. Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

slightly reduced when limiting the analysis to exclude two studies<sup>47,49</sup> that reported baseline measures of effect only (RR 0.51, 95% CI 0.40 to 0.65;  $I^2 = 0.0\%$ ;  $p = 0.807$ ) and two studies that reported incident RRs only<sup>34,39</sup> (RR 0.51, 95% CI 0.40 to 0.64;  $I^2 = 0\%$ ;  $p = 0.853$ ). These data are not shown.

A random-effects meta-analysis of 16 studies that presented univariable estimates suggests that OST was associated with a 40% reduction in the risk of HCV infection (RR 0.60, 95% CI 0.47 to 0.76), with only moderate evidence of heterogeneity between studies ( $I^2 = 31.7$ ;  $p = 0.09$ ) (Figure 3).

### Metaregression


Based on univariable metaregression of unadjusted estimates, we found no evidence that effectiveness varied by other covariates including geographical location. We did find evidence of differential impact in the proportion of female participants in the sample. With each 10% increase of female participants in the sample, the effect of intervention exposure was reduced (RR 1.59, 95% CI 1.13 to 2.29) (see Table 15).

### History of opioid substitution therapy

Three studies published unadjusted estimates of history of OST use, comprising 115 HCV infection cases over 511.6 person-years and from three prospective cohorts.<sup>51,56,57</sup> One study did not define the time frame and was coded as past experience of OST.<sup>56</sup>

Three studies published unadjusted estimates of interrupted OST use.<sup>40,46,53</sup> Two of these studies were prospective cohorts and one was retrospective, and a total of 200 HCV infection cases were included over






**FIGURE 3** Impact of current use of OST vs. no OST on HCV infection incidence findings from unadjusted analyses. Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

2273.8 person-years. Interrupted OST use was defined as use of OST at baseline but not at follow-up,<sup>46</sup> or leaving OST at least once during follow-up.<sup>40,53</sup> One prospective cohort study comprising 149 HCV infection cases over 680 person-years examined OST for detoxification,<sup>55</sup> and two studies measured high dosage ( $\geq 60$  mg) or low dosage (1–59 mg) of methadone for daily use<sup>14</sup> or use some time in the past 6 months.<sup>33</sup> Both these studies were prospective cohorts and included 148 HCV infection cases over 598.6 person-years.

A random-effects meta-analysis showed no impact among studies measuring historical use of OST (RR 0.81 95% CI 0.52 to 1.27) or among those measuring interrupted use (RR 0.80 95% CI 0.57 to 1.10).<sup>51,56,57</sup> The one study measuring the impact of OST used for detoxification was not associated with reduced HCV infection risk acquisition (RR 1.45, 95% CI 0.79 to 2.66).<sup>55</sup> High dosage with OST was associated with a reduction of HCV infection acquisition (RR 0.52, 95% CI 0.29 to 0.94) but low dosage was not (RR 0.85, 95% CI 0.44 to 1.65) (Figure 4).<sup>14,33</sup>



**FIGURE 4** Impact of other modes of OST on HCV infection risk acquisition. Reproduced from Platt *et al.*<sup>26</sup> This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

### Needle and syringe programmes versus lower or no needle and syringe programmes coverage

A total of 15 studies reported measures of NSP exposure and HCV infection incidence,<sup>14,20,41–44,47,48,50,54,58</sup> including five unpublished estimates.<sup>33–35,59,60</sup> Only five studies published adjusted estimates,<sup>33,42,44,47,48</sup> restricting the sensitivity analysis that could be conducted. We therefore focused our primary analyses on pooling unadjusted estimates.

Comparison groups consisted of non-attendance in the NSP<sup>14,34,35,41–43,48,50,54,60</sup> or lower coverage of injections covered by a clean needle or syringe,<sup>14,44,47,59</sup> or a needle or syringe obtained from a safe source.<sup>33</sup>

### High coverage versus non-attendance or lower coverage

We pooled data from seven studies that reported unadjusted measures of high NSP exposure and HCV infection incidence,<sup>14,42,44,47,48</sup> including two unpublished data sets.<sup>33,59</sup> High NSP coverage was defined as obtaining 100% of needles and syringes from a safe source<sup>33</sup> or reporting  $\geq 100\%$  of injections covered by a clean needle or syringe,<sup>14,44,59</sup> or  $\geq 200\%$  of injections covered by a clean needle/syringe.<sup>47</sup> Other measures of high coverage were defined as regular attendance at least once per week at a NSP<sup>48</sup> or obtaining most of all needles/syringes from a NSP in the past 6 months.<sup>42</sup> The seven included studies consisted of four prospective cohorts<sup>14,33,42,48</sup> and three cross-sectional surveys,<sup>44,47,59</sup> comprising 641 HCV infection cases over 1015.51 person-years.

The primary analysis focused on seven studies that measured high-level uptake of NSP coverage. This primary analysis compared the effect of high-level NSP coverage versus no intervention<sup>33,42,48</sup> or lower levels of coverage.<sup>14,44,47,59</sup> These seven studies included a median of 27% of women (range 23–38%), a high proportion of the samples had experience of prison (range 26–60%) and homelessness (range 2–58%), and use of stimulants ranged between 17% and 63% across the studies.


A random-effects meta-analysis suggested no evidence of high coverage of NSPs associated with a reduction in the risk of HCV infection (RR 0.77, 95% CI 0.38 to 1.54) with evidence of high heterogeneity between studies. ( $I^2 = 78.8$ ;  $p < 0.001$ ) (Figure 5).

### Sensitivity analyses

This effect remained the same when excluding the unpublished data sets (RR 0.71, 95% CI 0.23 to 2.19;  $p < 0.001$ ).<sup>33,59</sup> The effect was also maintained when limiting the analysis to a subset of four studies that excluded three studies assessed to be at critical risk of bias or that were unpublished data sets (RR 0.71, 95% CI 0.17 to 2.98), with evidence of within-study heterogeneity ( $I^2 = 89.6\%$ ,  $p < 0.001$ ).<sup>14,33,59</sup> The effect was increased when we excluded studies that reported only incident rate ratios (RR 0.78, 95% CI 0.35 to 1.74;  $I^2 = 80.3\%$ ;  $p < 0.001$ ).<sup>14</sup> The effect was further decreased when we excluded studies that reported baseline measures only (RR 1.26, 95% CI 0.55 to 2.93;  $I^2 = 87.0\%$ ;  $p < 0.001$ ).<sup>44,47,59</sup> Limiting the analysis to a further subset of four studies that adjusted for confounders, the effect remained the same (RR 0.79, 95% CI 0.39 to 1.61;  $I^2 = 77\%$ ,  $p = 0.022$ ;  $\tau^2 = 0.4482$ ) (data not shown).

### Metaregression

Based on univariable metaregression analyses, we found some evidence that the effectiveness of high NSP coverage varied according to geographical region. After removing studies from North America, high NSP coverage in Europe was associated with a 54% reduction in HCV infection acquisition risk (RR 0.44, 95% CI 0.24 to 0.80) with less heterogeneity ( $I^2 = 12.3\%$ ;  $p = 0.337$ ), whereas in North America it remained insignificant (RR 1.58, 95% CI 0.57 to 4.42,  $I^2 = 89.9\%$ ;  $p < 0.001$ ).



**FIGURE 5** Impact of high NSP coverage vs. low or no NSP coverage on HCV infection risk acquisition from unadjusted analysis. Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Based on univariable metaregression analyses, the differential impact of NSPs according to geographical region remained, with studies from North America having less impact (ratio of RRs 3.73, 95% CI 0.95 to 14.7;  $p = 0.06$ ). There was no differential impact by recruitment site ( $p = 0.89$ ), by proportion of participants reporting stimulant use, homelessness, injection of stimulants or sex. (These data are presented in *Appendix 1, Table 16*.)


### Low-level coverage of needle and syringe programmes versus no needle and syringe programme coverage

Ten studies reported unadjusted measures of low-level NSP coverage and HCV infection incidence. Eight were prospective cohorts<sup>14,34,35,42,43,54,58,60</sup> and one was a case-control study.<sup>41</sup> A total of 531 cases were included in the analyses over 1617 person-years. One prospective cohort was dropped because it did not report 95% CIs around the effect estimate or the number of new HCV infection cases in international and comparison groups required to estimate it.<sup>50</sup>

A random-effects meta-analysis showed no evidence of an intervention effect of low NSP coverage on HCV infection risk acquisition with moderate levels of heterogeneity (RR 1.41, 95% CI 0.95 to 2.09;  $I^2 = 62.3\%$ ;  $p = 0.007$ ;  $\tau^2 = 0.19$ ) derived from nine studies with a total of 3414 participants (*Figure 6*).

### Combined needle and syringe programmes with opioid substitution therapy versus low or no needle and syringe programme coverage and no opioid substitution therapy

A total of four studies reported combined exposure to both NSPs and OST,<sup>14,44,47</sup> including one unpublished data set.<sup>33</sup> These categories were defined as high coverage ( $\geq 100\%$  or  $\geq 200\%$ ) of injections using clean needles or syringes<sup>14,44,47</sup> or obtaining 100% of needles and syringes from a safe source<sup>33</sup> plus current use of OST at the point of survey<sup>44,47</sup> or within the past 6 months,<sup>33</sup> or daily use of methadone during the past 6 months.<sup>14</sup> OST use and low coverage ( $< 100\%$  of injections covered by a clean needle or syringe) was reported by three studies.<sup>14,44,47</sup> A total of 518 HCV infection incident cases were included in the analysis examining high NSP coverage and 449 for low NSP coverage. Only one study reported the number of person-years.<sup>14</sup> A random-effects meta-analysis showed that combined use of OST and high



**FIGURE 6** Impact of low NSP coverage on HCV infection risk acquisition. Reproduced from Platt *et al.*<sup>26</sup> This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

coverage of NSP was associated with a 71% risk reduction in HCV infection acquisition (RR 0.29, 95% CI 0.13 to 0.65). The effect of exposure to OST and low coverage of NSP was less and non-significant (RR 0.76, 95% CI 0.44 to 1.33) (Figure 7).


### Publication bias

A funnel plot of 13 estimates (12 studies) suggested no evidence of publication bias in studies of current OST exposure (Figure 8). A funnel plot of nine estimates (eight studies) suggested no evidence of publication bias in studies of high NSP coverage (Figure 9).


## Discussion

Text in this section is reproduced from Platt *et al.*<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.


A primary meta-analysis of 12 observational studies, adjusting for key confounders and enrolling 5910 anti-HCV negative participants, showed that current use of OST compared with no intervention reduced the risk of HCV infection acquisition by 50% (RR 0.50, 95% CI 0.40 to 0.63). The intervention effect is strong, but the evidence is considered to be of low quality because it was derived from observational studies with serious risk of bias. Nonetheless, the findings were robust to sensitivity analyses, excluding studies judged to be at critical risk of bias, studies drawing on unpublished data, case-control and cross-sectional studies reporting only baseline data and studies reporting only unadjusted estimates.



**FIGURE 7** Combined OST and high-coverage NSPs. Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.



**FIGURE 8** Funnel plot with pseudo-95% confidence limits assessing publication bias in 12 studies of current OST exposure. a, Unpublished data sets. IRR, incident rate ratio. Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.



**FIGURE 9** Funnel plot with pseudo-95% confidence limits assessing publication bias in 15 studies of high NSP exposure. The central line is plotted at the fixed-effect summary effect (RR 0.98, 95% CI 0.75 to 1.28). a, Unpublished data sets. IRR, incident rate ratio. Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

There also was no evidence of publication bias. All of these sensitivity analyses showed a statistically significant benefit of OST. A funnel plot (see *Figure 8*) showed no evidence of publication bias.

A few studies reported other types of exposure to OST. Three studies reported past exposure to OST,<sup>51,56,57</sup> three reported interrupted OST use,<sup>40,46,53</sup> one measured OST use for detoxification,<sup>55</sup> and two measured high dosage ( $\geq 60$  mg) or low dosage (1–59 mg) of methadone for daily use.<sup>14,33</sup> Among these exposures, only high dosage of OST was associated with a reduction in risk of HCV infection acquisition.

A primary meta-analysis of seven observational studies pooling unadjusted estimates and enrolling 5669 anti-HCV-negative participants show weak and low-quality evidence that NSP exposure did not reduce risk of HCV infection acquisition. This effect remained consistent in sensitivity analyses. After removing studies

from North America, high NSP coverage in Europe was associated with a 61% reduction in HCV infection acquisition risk (RR 0.39, 95% CI 0.24 to 0.64) with less heterogeneity ( $I^2 = 0\%$ ;  $p = 0.428$ ).

There was low-quality evidence for the impact of combined high coverage of NSP and OST from studies comprising 3356 anti-HCV-negative participants, which suggested a 71% reduction in risk of HCV infection acquisition (risk ratio 0.29, 95% CI 0.13 to 0.65). There were insufficient data to conduct a sensitivity analysis with this intervention group. A summary of key findings and quality of evidence is presented in *Table 3*.

### Overall completeness and applicability of evidence

There is a substantial body of observational evidence that reviews the effectiveness of NSPs and OST in reducing HCV infection acquisition among PWID. The majority of evidence was identified in North America and Western Europe. Only one study was identified from China<sup>51</sup> and no studies were identified from Eastern Europe or South-East Asia, where the largest populations of PWID are located and where there is a high prevalence of HIV, HCV and HIV/HCV co-infection among PWID.<sup>61–63</sup>

### Quality of the evidence

Many studies included in the review were assessed as being at severe risk of bias. Of the studies that were assessed, only two were judged as being at moderate overall risk of bias, 17 were judged as being at serious risk and seven were judged as being at critical risk. There is a need to improve transparency and consistency in the reporting of observational studies to facilitate systematic reviews of observational studies. Only a few studies report the effect of exposure to NSPs adjusted for confounders (5/7), which limited the sensitivity analyses that we could conduct. Therefore, efficacy estimates relating to NSP exposure are limited to unadjusted estimates.

### Potential biases in the review process

A potential bias in the review was the heterogeneity across the studies in the use of multiple effect measures. Effect measures were converted into risk ratios in the meta-analysis, but this may have introduced bias into our findings because we had to assume that risk ratios approximated odds ratios (ORs), which may be inappropriate for some sites given the high incidence of HCV seroconversion. We removed cross-sectional study designs that identified serological markers of incidence infection as part of our sensitivity analysis. Effect estimates remained the same for current use of OST versus no intervention, but not for high coverage of NSPs. The majority of studies recruited PWID currently or have done so recently, which may not be representative of all PWID exposed to OST and may lead to an underestimate of the effect of OST on HCV infection transmission. For example, in the Amsterdam cohort, people who reported being on OST and having ceased injecting had a lower risk of HCV infection transmission.<sup>14</sup>

**TABLE 3** Summary of findings for primary analyses

Outcomes	Comparison	Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)
HCV infection incidence adjusted analyses: number of HCV seroconversion follow-up – mean 440.5 patient-years	Current OST vs. no OST for PWID	Risk ratio 0.50 (0.40 to 0.63)	5910 (12 studies)	Low
HCV infection incidence unadjusted analyses: number of HCV seroconversion follow-up – mean 269 patient-years	High NSP coverage vs. no/low NSP coverage for PWID	Risk ratio 0.70 (0.38 to 1.54)	5669 (7 studies)	Very low
HCV infection incidence unadjusted analyses: number of HCV seroconversions follow-up – mean 356 patient-years	Combined OST and high NSP vs. no OST and low/no NSP	Risk ratio 0.29 (0.13 to 0.65)	3356 (4 studies)	Low



## Agreements and disagreements with other studies or reviews

Our review corroborates and underpins an earlier review that showed consistent and large effects of NSP and OST on injecting risk behaviours associated with blood-borne virus transmission.<sup>8</sup> Two recent reviews focused on the effectiveness of OST and NSPs in reducing HCV infection incidence.<sup>3,19</sup> Our findings corroborate the most recent pooled analysis, which suggested that receiving OST and high coverage of NSPs can reduce HCV infection risk alone, but that the effect of OST and NSPs is greater in combination.<sup>20</sup> The estimate for association between exposure to NSPs and HCV infection incidence was weak in the pooled analysis and focused on studies from the UK only. Findings from our subgroup analysis suggested a stronger effect of high NSP coverage in Europe. This finding builds directly on the Turner *et al.*<sup>20</sup> analysis through the addition of one earlier paper<sup>14</sup> and more recent studies and data sets<sup>59</sup> to the meta-analysis, and strengthens the effectiveness estimate for Europe suggesting reduced risk of HCV infection acquisition (risk ratio 0.44, 95% CI 0.24 to 0.80). We found no effect of high NSP coverage when pooling estimates from North America as well as greater heterogeneity across the studies. This corroborates findings from another review that found an increased risk of seroconversion associated with NSP attendance and that relied on evidence predominantly from North America.<sup>19</sup>

The lack of evidence for NSPs from studies in North America can be attributed to a mixture of confounding, differences in injecting patterns, potential selection bias and misclassification of exposure. It has been shown that people who attend NSPs regularly also report greater injecting risk behaviour and that, after adjustment for injecting risk, any positive association between HCV infection transmission and NSP attendance is removed. The effect of this residual confounding has been demonstrated in further analyses of a cohort of PWID in Vancouver, which demonstrated that higher HIV seroconversion rates observed among daily NSP attenders was associated with high-risk behaviours of attenders (including regular cocaine injection, sex work involvement and homelessness), rather than use of the NSP.<sup>64</sup> A study based in Seattle showed that people who were homeless or who injected with used needles or syringes were more likely to become new NSP users.<sup>65</sup> The higher proportion of stimulant injecting users in North America also means that the additional protective effect of OST is absent, which may contribute to the impact of NSPs on HCV infection risk in European studies. Potential selection bias may occur because samples of cohort studies are to some degree self-selected, particularly when participants are lost to follow-up over time; they may be inherently different in terms of the demographic characteristics and risk behaviours that can influence the outcome. Misclassification of exposure may also occur because it is difficult to make a clear distinction between exposed and unexposed groups: unexposed populations may have access to clean needles/syringes through other sources than NSPs. Consistent measures of NSP exposure through coverage of injections by clean needles/syringes were used across the European studies, whereas the North American studies drew on varied definitions of NSP use, which focused on the frequency of attendance at NSPs. Comparability in the measurement of intervention exposure is reflected in the higher heterogeneity observed among studies measuring exposure to NSPs ( $I^2 = 80.9\%$ ;  $p < 0.001$ ) compared with OST exposure ( $I^2 = 0\%$ ;  $p = 0.959$ ). This is particularly relevant in relation to measures of intervention exposure that focus on the frequency of attendance at an NSP rather than a measure of injections covered by clean needles and syringes, and further explains the lack of effect between high NSP coverage and HCV infection incidence observed in North America.

Findings also corroborate two recent systematic reviews that measured the impact of NSPs and OST on HIV transmission. These previous analyses of 12 observational studies estimated a moderate effect of NSPs on reducing HIV transmission by 48% (95% CI 3% to 72%) and strong evidence for OST reducing HIV transmission by 54% (95% CI 33% to 68%).<sup>16,17</sup>

A previous review of reviews from 2010 concluded that there was insufficient evidence to assess the effectiveness of NSPs in reducing HCV infection incidence. This 'meta' review synthesised findings from four primary reviews, three of which focused primarily on HIV as an outcome missing much of the relevant data and the fourth of which predominantly relied on weaker study designs.<sup>3</sup>



## Implications for practice

Opioid substitution treatment reduces the risk of HCV infection acquisition among PWID. The evidence for the effectiveness of high coverage NSP was more mixed, with good evidence from studies in Europe that NSPs reduce HCV infection transmission. The intervention effect is strengthened by the combination of OST and high-coverage NSP. OST and NSPs are recommended as key interventions for preventing drug-related harm, including HCV infection transmission, by the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS, the United Nations Office on Drugs and Crime, the European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and Drug Addiction. However, OST is not widely implemented in many countries, is prohibited in the Russian Federation and is often restricted by age or duration of dependence prior to treatment entry.<sup>23</sup>

Our findings show the need to remove restrictions on the concurrent use of both NSPs and OST to maximise reduction in HCV infection transmission. Distribution of needles/syringes through NSPs needs to be maintained alongside the provision of OST. NSP and OST services need to recognise the role of sex and to develop appropriate policies and practices to encourage women to use services addressing the specific injecting-related risk behaviours that they face and addressing other health and social welfare needs. We identified only three studies that examined effectiveness of interrupted use of OST, but effectiveness was reduced. Similarly, available evidence to examine differences in effect by dosage was limited.

## Implications for research

There is good evidence demonstrating the effectiveness of OST in reducing risk behaviour and the transmission of HCV and HIV. However, there is a need to understand the role of the duration of OST use in reducing the risk of both HIV and HCV. For NSPs, evidence needs to be strengthened, including more consistent measurement in the coverage of NSPs across epidemiological studies to obtain better effect estimates as well as to gain an understanding of how the injection of stimulants or prescription opioids changes their effectiveness. Given the body of observational evidence on the effect of OST and NSPs on reducing HIV and HCV infection incidence and other injecting-related harms, it is no longer ethical to individually randomise exposure to OST or NSPs, so future trial evidence can be derived only from stepped wedge clustered RCTs or using wait-list controls, if at all. Current guidance means that the quality of the evidence typically will be assessed as low.

However, priorities for research needs to turn to implementation, the delivery of services and their cost-effectiveness to ensure that existing services are maintained and to promote the introduction and scale-up of services in countries and settings with emerging or growing epidemics of injecting and opioid drug use. We need to understand the pathways between contextual factors and mechanisms of service delivery, and the extent to which these influence effectiveness across different outcomes and settings. For example, HIV and HCV infection epidemics continue unchecked in Eastern Europe, despite the implementation of OST and NSP in some countries.<sup>66</sup> Epidemics of HCV and HIV among PWID are growing in Sub-Saharan African countries, including Tanzania and Kenya, where OST is currently being implemented, but little formal evaluation is being undertaken. Research is needed here that does not employ experimental designs but rather designs that take into account the specific economic, social and political context and different epidemiology of HIV and HCV infection transmission in those contexts. We identified only one study conducted in a middle-income country (China) and no studies in low-income countries.

There was insufficient evidence to examine differences in effectiveness by NSP modality or setting of OST. This reflects a lack of evaluation of provision of OST or NSP in other settings. Further research is needed to examine how the effect of NSPs differs by service modality including pharmacies, mobile clinics or outreach services. Similarly, research into the effectiveness of OST delivered in specialist services, community settings and prisons is needed.

Although evidence for the combined effect of OST and high NSP coverage seemed to be of higher quality, we identified only four studies. Further evidence is needed to understand how effectiveness may differ by modality and duration of OST, as well as by its impact on other health outcomes associated with injecting drug use, such as bacterial infections and mental health.

Finally, given the low quality of evidence, there is a need to improve transparency and consistency in the reporting of observational studies to facilitate systematic reviews of observational studies.

### *Changes from original protocol*

We have changed the title of the review to refer to opioids instead of opiates. Opioid encompasses synthetic opiates as well as those derived from opium, whereas opiates includes only drugs derived from opium. The original protocol specified that one sensitivity analysis would be to remove studies that reported only incident rate ratios as effect estimates. We did not do this because only three studies used incident rate ratios. Instead, we removed estimates derived from unpublished data sets as part of our sensitivity analyses because seven estimates were derived in this way, making them a more substantive part of the analysis.

There was insufficient evidence to answer some of the research questions that sought to examine differences in effectiveness in terms of the following factors: duration of treatment, dosage of OST, type of substitution used, NSP modality (fixed vs. mobile site) or setting of OST. This reflects a lack of evaluation of the provision of OST or NSPs in other settings.



## Chapter 3 The impact of needle and syringe provision on hepatitis C transmission among people who inject drugs in the UK and Australia: an analysis of pooled data sets

The aim of the study was to update a previous analysis of pooled data sets to provide a more robust understanding of the extent to which OST and NSP, alone or in combination, can reduce the risk of HCV infection acquisition.

### Methods

We collated six data sets previously used in a pooled analysis, methods for which have been published previously.<sup>20</sup> We added an additional three data sets, including a community survey of PWID in Bristol ( $n = 336$ ), Public Health England's Unlinked Anonymous Monitoring Programme (UAMP) survey of PWID from England and Wales ( $n = 3408$ ), the Australian Needle Syringe Programme Survey (ANSPS) ( $n = 2391$ ) and replaced one of the studies with updated data from Public Health Scotland's Needle Exchange Surveillance Initiative (NESI) ( $n = 6988$ ), adding in an additional 6041 individuals. These data are presented in *Table 4*. We excluded one cohort data set used in the original analysis of recent initiates into injecting because the data set did not contain information on use of NSPs and the population focused on young and recent initiates into injecting, and were less comparable with the other samples.<sup>67</sup>

Two studies recruited PWID through NSPs (NESI, ANSPS) and one through both NSPs and drug treatment clinics (UAMP).<sup>68–70</sup> The remaining studies recruited via community settings (Wales) and through RDS (Bristol, Leeds, Birmingham).<sup>20,39,44</sup> Five of the studies included people who had injected in the past 4 weeks, whereas the UAMP, NESI and ANSPS included people who had ever injected drugs.

All studies, except for one, contained data on recent HCV infection, defined for cross-sectional surveys as individuals who tested HCV RNA-positive among those who tested HCV antibody-negative from dried blood spot (DBS) samples. The one cohort study defined incident infection as those who were HCV antibody negative at baseline and were retested as antibody positive at 12-month follow-up.<sup>39</sup> All samples from the UAMP survey were tested for the purpose of the analysis. Anti-HCV testing was performed using a previously published method, the accuracy of which is close to that achieved on venous blood specimens.<sup>71</sup> The residual DBS had been stored in the refrigerator with desiccant since anti-HCV antibody testing, which has been shown to stabilise both anti-HCV and nucleic acids in DBS. Nucleic acid was extracted from an area of approximately 28 mm<sup>2</sup> punched from each DBS, using an automated platform [Qiagen MDx (Qiagen, Hilden, Germany)]. Samples were tested for HCV RNA using nested polymerase chain reaction amplification of the NS5B (non-structural protein 5B) region, which provides a product suitable for differentiating different lineages of HCV infection.<sup>72</sup>

### Outcomes

The primary outcome was new HCV infection (yes/no) based on the definitions described above. Secondary outcomes were based on self-reported injecting risk behaviours (frequency of injecting, injecting with a used needle or syringe, use of shared spoons or filters for drug preparation, injecting site infection) and HIV/HCV infection testing.

### Interventions

We used previously published outcome measures of OST use and NSP coverage.<sup>20</sup> OST was defined as current use of OST for all cross-sectional surveys, whereas in the cohort study it was defined as > 6 months

**TABLE 4** Summary of demographic, injecting risk behaviour, intervention coverage and outcome measures by study site

Characteristic	Bristol 1 <sup>44</sup>	Leeds <sup>59</sup>	Birmingham <sup>59</sup>	<sup>a</sup> Bristol 2 <sup>59</sup>	Wales <sup>39</sup>	<sup>a</sup> England and Wales, UAMP <sup>70</sup>	<sup>a</sup> Scotland, NESI <sup>68</sup>	<sup>a</sup> Australia, ANSP <sup>69</sup>
Year	2006	2008	2009	2009	2004–6	2011–12	2008–12	2012
Study design	Cross sectional: RDS				Cohort: NSP and community	Cross-sectional: NSP, treatment	Cross-sectional: NSP	
<i>Inclusion criteria</i>	<i>Injected in past 4 weeks</i>					<i>Injected in past 12 months</i>	<i>Ever injected</i>	<i>Ever injected</i>
Total participants	299	302	310	336	406 (700)	3408	6988	2391
HCV infection prevalence, % (n/N)	59 (177/299)	60 (182/302)	42 (130/310)	60 (201/336)	26 (184/700)	46 (1567/3408)	54 (3709/6909) <sup>b</sup>	53 (1184/2243)
Female (%)	23	24	12	22	26	24	28	32
Age, years (median)	32 (26–37)	32 (27–37)	32 (28–38)	34 (29–39)	29 (24–34)	34 (29–40)	34 (29–39)	38 (31–45)
Duration injecting, median (IQR)	10 (6–16)	11 (7–16)	9 (4–13)	13 (7–18)	6 (3–12)	12 (6–18)	10.4 (6–16)	17 (11–25)
Ever homeless, % (n/N)	90 (270/299)	86 (260/301)	93 (287/310)	88 (295/336)	39 (158/405)	80 (2664/3331)	68 (4748/6985)	NA
Homeless in past 12 months, % (n/N)	58 (174/299)	52 (156/301)	63 (194/310)	60 (175/295)	39 (158/405)	36 (1209/3331)	24 (1654/6980)	NA
Ever exchanged sex, % (n/N)	11 (34/299)	5 (16/302)	2 (5/310)	7 (24/336)	3 (18/599)	14 (343/2370)		5 (119/2314)
Ever been in prison, % (n/N)	81 (242/299)	81 (245/301)	85 (263/310)	77 (260/336)	71 (494/693)	72 (2401/3329)	60 (4188/6973)	51 (1192/2354)
Prison in the past 12 months, % (n/N)	42 (101/240)	36 (89/245)	43 (114/263)	32 (82/260)	46 (225/489)	NA	15 (1070/6988)	23 (2206/9621)
New HCV infection <sup>c</sup>	14/115	2/120	2/180	3/135	17/285	34/1809	51/3104	62/477
HCV infection incidence (per 100 person-years)	40	7.6	5.2	9.9	5.6	8.5	7.5	42.0
Abscess or sore at injection site, % (n/N)	59 (176/299)	45 (135/302)	49 (153/310)	46 (155/336)	72 (505/700)	28 (866/3092)		

Characteristic	Bristol 1 <sup>44</sup>	Leeds <sup>59</sup>	Birmingham <sup>59</sup>	<sup>a</sup> Bristol 2 <sup>59</sup>	Wales <sup>39</sup>	<sup>a</sup> England and Wales, UAMP <sup>70</sup>	<sup>a</sup> Scotland, NESI <sup>68</sup>	<sup>a</sup> Australia, ANSP <sup>69</sup>
Injection risk (past 4 weeks)								
Injection in past 4 weeks, % (n/N)	100	100	100	100	100	75 (2500/3346)	79 (5512/6987)	91 (2166/2379)
Number of injections, median (IQR)	39 (14–84)	33 (12–60)	28 (8–83)	42 (18–84)	35 (8–84)	27 (8–63)	20 (4–76)	22 (9–50)
Injection with used needle/syringe, % (n/N)	28 (83/299)	7 (20/302)	3 (10/310)	8 (28/335)	35 (35/407)	11 (231/2187)	69 (209/304)	16 (342/2073)
Shared filters, % (n/N)	47 (141/298)	28 (83/301)	33 (103/307)	49 (165/334)	40 (279/690)	23 (570/2454)	15 (199/1338) <sup>d</sup>	11 (228/1987)
Shared spoon/container, % (n/N)	94 (279/297)	96 (289/301)	41 (125/308)	86 (285/333)	50 (343/688)	27 (672/2465)	18 (299/1639)	23 (454/1987)
Injected while in prison, % (n/N)	21 (52/242)	17 (41/245)	12 (31/263)	24 (62/260)	7 (32/486)	16 (394/2451)	12 (509/4187)	34 (90/261) <sup>e</sup>
Injected crack cocaine, % (n/N)	62 (178/299)	61 (185/302)	56 (174/310)	75 (251/336)	12 (86/700)	55 (1840/3372)	6.5 (458/5581)	27 (642/2391)
Access to services								
Tested for HIV, % (n/N)	77 (230/299)	73 (220/301)	71 (219/309)	83 (274/329)		79 (2563/3251)	73 (4911/6650)	87 (1997/2296)
Tested for HCV, % (n/N)	81 (235/291)	83 (250/301)	76 (231/303)	91 (303/332)	47 (317/669)	84 (2654/3169)	80 (5364/6694)	92 (2086/2267)
Never used a NSP, % (n/N)	8 (41/299)	5 (26/275)	5.7 (29/310)	5 (25/336)	18 (92/696)	32 (165/3378)	0	0
Low NSP coverage: (< 100%), % (n or n/N) <sup>f</sup>	46 (137)	36 (108)	36 (111)	51 (172)	39 (126/325)	49 (1214)	22 (1180)	25 (500)
High NSP coverage: (> 100%), % (n)	54 (160)	64 (190)	64 (198)	49 (163)	54 (177)	51 (1222)	78 (4307)	74 (1466)
Currently on OST, % (n)	57 (172)	60 (180)	65 (203)	81 (241)	52 (149)	69 (2535)	82 (5106)	43 (1029)

IQR, interquartile range; NA, not applicable.

<sup>a</sup> Denotes additional data sets introduced to the analysis from previous pooled analysis by Turner *et al.*<sup>20</sup>

<sup>b</sup> NESI HCV-antibody positives: 161 tested weakly positive, coded here as HCV antibody positive.

<sup>c</sup> New HCV infection for all cross-sectional studies defined as HCV RNA positive in those antibody negative at baseline, for cohorts (Wales) defined as anti-HCV positive at follow-up. HCV incidence for cross-sectional surveys calculated as  $I = [(365/T)n]/[(N-n) + (365/T)n]$  where  $I$  = incidence,  $T$  = estimated mean duration of the HCV antibody-negative/RNA-positive 'window period' = 75 days,  $n$  = number of HCV incident infections (HCV antibody negative and HCV RNA positive) and  $N$  = number susceptible (HCV antibody negative).

<sup>d</sup> 76% missing data.

<sup>e</sup> This is for in prison in the past 12 months.

<sup>f</sup> NSP coverage is coded so that those with missing data for number of needles obtained in the past 4 weeks but reporting injecting in past 4 weeks are coded as low coverage.

of OST in the past year (yes/no). An internationally used standardised measure of an individual's NSP coverage was defined as the percentage of injections for which a new needle had been obtained (calculated as the average number of new needles obtained divided by the average number of injections in past four weeks, with the exception of the NESI survey, which measures coverage over 6 months, and the Birmingham study, which uses a 2-week time frame).<sup>5,73,74</sup> The total number of needles or syringes obtained from any source was taken, not limiting data to those needles/syringes obtained from a NSP. We examined the effect of both interventions in two ways. First, we measured the impact of binary measures of NSP and OST to assess their individual effect without considering the influence of the other intervention. Second, we combined these binary measures to form a measure of harm reduction coverage with four categories as used in the original analysis and comparable studies with high coverage defined as  $\geq 100\%$  of injections covered by a clean syringe for all sites (*Table 5*).<sup>14,20,68</sup>

### Statistical analyses

Of the total 14,734 included participants across the eight studies, a total of 7173 were considered in the primary analysis with an initial HCV antibody-negative result. The analysis involved (1) a meta-analysis of the (unadjusted) effect of OST on new HCV infection incidence limited to 5543 participants; (2) a meta-analysis of the (unadjusted) effect of high NSP coverage limited to 4947 participants; (3) a pooled analysis of the (unadjusted and adjusted) effects of NSP and OST on new HCV incident infections confined to 5280 estimates; and (4) a meta-analysis of the pooled effect estimates alongside estimates from a recent systematic review.<sup>26</sup> A flow chart summarising the numbers of HCV infection cases included in analyses (1) to (3) is summarised in *Figure 10*. We also conducted a pooled analysis focusing on the effects of NSP and OST on secondary outcomes (see below).

### Meta-analysis


We conducted a meta-analysis to test for study heterogeneity in the effects of OST and high NSP coverage on new HCV infection. Separate logistic regression models using fixed-effect meta-analyses were used to estimate the study-specific associations of the (unadjusted) effects of OST and NSP on new HCV infection and to examine levels of heterogeneity between study sites. As published elsewhere, counts of new HCV infection cases were small, resulting in no cases in one intervention group in Birmingham<sup>20</sup> and in the 2009 Bristol survey. We added one case and three controls to the intervention group with zero cases.<sup>75,76</sup> We used the  $I^2$ -statistic to assess between-study heterogeneity in the effects of the interventions on new HCV infection.<sup>77</sup>

### Pooled analysis of the effects of opioid substitution therapy and needle and syringe programmes on new hepatitis C infection

There was no evidence of heterogeneity between the studies for OST ( $I^2 = 13.6\%$ ;  $p = 0.324$ ) or NSP ( $I^2 = 0\%$ ;  $p = 0.659$ ) so the data were pooled in subsequent analyses and the augmented data points were removed. We used logistic regression to model the odds of recent infection by NSP and joint effects of OST exposure adjusting for key confounders of HCV infection risk including sex,<sup>41,45,51,67</sup> injecting duration,<sup>41,44,45,67</sup> injecting crack cocaine<sup>45,67</sup> and experience of prison.<sup>55</sup>

**TABLE 5** Definition of combined harm reduction intervention

Intervention		NSP coverage $\geq 100\%$	
		Yes	No
OST	<b>Yes</b>	Full harm reduction	Partial harm reduction
	<b>No</b>	Partial harm reduction	Minimal harm reduction
Full harm reduction includes individuals currently receiving OST but not injecting.			



**FIGURE 10** Flow chart summarising the combined HCV antibody and RNA test results among PWID in the UK and Australia. +, positive.

## Secondary outcomes

We also examined the risk of self-reported injecting risk behaviour and access to services according to exposure to different levels of harm reduction (OST and NSP) as defined above. Measures of risk included: (1) the proportion of needle/syringe sharing ( $n = 6217$ ); (2) the frequency of injecting ( $n = 11,786$ ); (3) reuse of the same needle/syringe more than once for injecting ( $n = 1242$ ); (4) used of shared filters or spoons for the preparation of drugs ( $n = 7223$ ); (5) self-reported symptoms of bacterial infections ( $n = 5039$ ); (6) receiving testing for HIV ( $n = 13,435$ ); and (7) receiving testing for HCV infection ( $n = 14,026$ ). We used logistic regression for binary outcomes (measures 1, 2, 4–7) and linear regression for continuous variables (measure 3). All models were adjusted for key confounders listed in the previous analysis (sex,<sup>41,45,51,67</sup> injecting duration,<sup>41,44,45,67</sup> injecting crack cocaine<sup>45,67</sup> and experience of prison<sup>55</sup>).



### Pooled effects and systematic review findings


We conducted a meta-analysis using fixed-effects models to assess the pooled effects of study-level associations between intervention exposure and new HCV infection incidence cases with findings from the Cochrane systematic review reported in *Chapter 1*. Estimates from the review of European studies that employed the same definition of high NSP coverage were extracted and combined with our additional estimates from the UAMP and ANSP surveys. We used the  $I^2$ -statistic to assess between-study heterogeneity in the effects of the interventions on new HCV infection.

## Findings


The eight studies in *Table 4* summarise the characteristics of participants in each study. Approximately 26% of the participants were female, the median age ranged between 29 and 38 years, and the median duration of injecting ranged between 6 and 17 years. The majority of participants had experience of homelessness, ranging from 39% in Wales to 90% in the Bristol 2006 data set. Similar proportions had experience of prison, ranging between 51% in the Australian data set and 90% in the Bristol 2006 data set. Between 2% and 14% had ever engaged in sex work. The background prevalence of HCV infection was highest in the 2009 survey in Bristol and Leeds (60%) and lowest in Wales (26%). Incidence of HCV infection was highest in the Australian data set (42 per 100 person-years) and in the Bristol 2006 data set (40 per 100 person-years) and between 5 and 10 per 100 person-years in all the other sites. Approximately 66% of participants currently injecting reported obtaining at least as many clean needles/syringes as injections and 70% were currently receiving OST.

### Meta-analysis to test for study heterogeneity in the effect of opioid substitution therapy and needle and syringe programmes on the risk of hepatitis C acquisition

The meta-analysis shows that high NSP coverage was associated with a slight reduction in the risk of HCV infection but this was not significant (OR 0.76, 95% CI 0.54 to 1.06). Exposure to OST was associated with a 45% reduction in the risk of HCV infection (OR 0.55, 95% CI 0.40 to 0.77). There was no evidence of heterogeneity between the studies for the effect of either intervention (NSP:  $I^2 = 0.0\%$ ;  $p = 0.659$ ; OST:  $I^2 = 13.6\%$ ;  $p = 0.324$ ). (These findings are summarised in *Figures 11* and *12*.)



**FIGURE 11** Meta-analysis summarising study-level estimates of the effect of high NSP coverage (> 100%) on HCV infection incidence.



**FIGURE 12** Meta-analysis summarising study-level estimates of the effect of current OST use on HCV infection incidence.

### **Pooled analysis of the effect of opioid substitution therapy and needle and syringe programmes on new hepatitis C infection**

The impact of OST and NSP coverage on new HCV infections is summarised in *Table 6* for the complete case data ( $n = 5280$ ). In the unadjusted analysis, PWID currently using OST had only a 65% reduced odds of HCV infection (OR 0.35, 95% CI 0.26 to 0.48). High coverage with needle/syringes ( $\geq 100\%$ ) alone was not significantly associated with reduced odds of HCV infection (OR 0.83, 95% CI 0.60 to 1.16). Following adjustment for sex, experience of prison or injecting crack cocaine, the intervention effects of OST alone was reduced [adjusted odds ratio (AOR) 0.61, 95% CI 0.43 to 0.87], but the effect of NSP alone was not altered.

When examining the effects of combined harm reduction interventions, the risk of new HCV infection was halved among those on full harm reduction (defined as receiving OST and  $\geq 100\%$  NSP coverage) (AOR 0.44, 95% CI 0.27 to 0.71) compared with those on minimal harm reduction ( $\leq 100\%$  NSP coverage). There were reduced odds of HCV infection acquisition among those on partial harm reduction exposed to high NSP coverage but not among those on OST (AOR 0.59, 95% CI 0.36 to 0.96) and a higher effect for those on OST but with low NSP coverage (AOR 0.41, 95% CI 0.22 to 0.75).

### **Pooled analysis of the effect of opioid substitution therapy and needles/syringe programmes on injecting risk behaviours**

A total of 15% of the sample reported injecting with a used needle/syringe in the past 4 weeks (958/6217), 20% had shared spoons or filters during the preparation of drugs (3018/14,734) and 30% had injected with the same needle/syringe more than once (377/1242). The mean number of injections in the past month was 44. Across five studies, 39.5% of participants had an abscess or sore at the injection site (1990/5039). The majority (77.5%) reported ever having an HIV test (10,414/13,435) and a test for HCV infection (81%, 11,440/14,026).

#### **Injecting with a used needle or syringe**

Participants in full harm reduction ( $\geq 100\%$  NSP, OST) or partial harm reduction ( $\geq 100\%$  NSP, no OST) had a 50% lower risk of injecting with a used needle/syringe (AOR 0.5, 95% CI 0.38 to 0.62) than those in minimal harm reduction ( $< 100\%$ , no OST; AOR 0.5, 95% CI 0.41 to 0.65). Participants on OST but with lower NSP coverage had a 30% reduced risk of injecting with a used needle/syringe (AOR 0.7,

**TABLE 6** Association between intervention coverage defined as (a) combination harm reduction interventions and (b) NSP coverage and OST alone and new HCV infection cases

Explanatory factors	<i>n</i>	Total	%	OR	95% CI	<i>p</i> -value	AOR	95% CI	<i>p</i> -value
< 100 NSP, no OST	36	577	6	1.0			1.0		
> 100 NSP, no OST	47	905	5	0.8	0.53 to 1.29	0.39	0.6	0.36 to 0.96	0.03
< 100 NSP, OST	19	896	2	0.3	0.18 to 0.57	< 0.001	0.4	0.22 to 0.75	< 0.001
> 100 NSP, OST	56	2902	2	0.3	0.19 to 0.45	< 0.001	0.4	0.27 to 0.71	< 0.001
Female				1.3	0.92 to 1.74	0.14	1.1	0.73 to 1.56	0.73
History of prison				0.9	0.69 to 1.24	0.59	1.4	0.98 to 2.05	0.06
Injection of crack cocaine				1.8	1.35 to 2.49	0.00	1.6	1.09 to 2.40	0.02
Duration of injection (years)									
0–3				1.0			1.0		
3.1–5				0.9	0.55 to 1.36	0.54	1.0	0.67 to 1.47	0.953
6–10				0.5	0.30 to 0.75	0.00	1.1	0.78 to 1.45	0.6853
11+				0.8	0.53 to 1.10	0.15	1.1	0.86 to 1.49	0.361
Study									
Bristol 1				1.0			1.0		
Leeds				0.1	0.03 to 0.55	0.01	0.1	0.03 to 0.54	0.01
Birmingham				0.1	0.02 to 0.36	< 0.001	0.1	0.02 to 0.35	< 0.001
Wales				0.5	0.22 to 0.96	0.04	0.6	0.26 to 1.21	0.14
Bristol 2				0.2	0.05 to 0.59	0.01	0.2	0.06 to 0.75	0.02
NESI				0.1	0.06 to 0.22	< 0.001	0.2	0.10 to 0.38	< 0.001
UAMP				0.1	0.07 to 0.27	< 0.001	0.2	0.08 to 0.31	< 0.001
ANSP				1.1	0.58 to 2.00	0.81	1.3	0.64 to 2.54	0.49
On OST				0.4	0.26 to 0.48	< 0.001	0.6	0.43 to 0.87	0.007
High NSP coverage				0.8	0.60 to 1.16	0.27	0.8	0.55 to 1.12	0.182

AOR, adjusted odds ratio.

95% CI 0.57 to 0.94) compared with those without OST. Current use of OST without taking into account NSP coverage was not associated with reduced odds of injecting with a used needle/syringe (AOR 0.9, 95% CI 0.76 to 1.07). High compared with low needle/syringe programme coverage was associated with a reduced odds of sharing a used needle/syringe (AOR 0.6, 95% CI 0.50 to 0.69). (These findings are presented in *Appendix 2, Table 18*.)

### Reuse of the same needles or syringes for injection

Across the five community cross-sectional surveys ( $n = 1195$ ), full harm reduction compared with minimal harm reduction was associated with a 40% reduction in the odds of reusing the same needle/syringe for injection more than once (AOR 0.59, 95% CI 0.40 to 0.88). Partial measures of harm reduction were not significantly associated with reuse of the same needle/syringe. Current use of OST alone was not significantly associated with a reduction in reuse of the same needle/syringe (AOR 0.93, 95% CI 0.70 to 1.22). However, high coverage ( $\geq 100\%$ ) with needle/syringes was associated with a 40% reduction in reuse of the same needle/syringe more than once (AOR 0.59, 95% CI 0.46 to 0.76). (These findings are presented in *Appendix 2, Table 19*.)

## Frequency of injecting

Among 10,514 participants reporting frequency of injection, we found that participation in full harm reduction was associated with a mean reduction in injecting frequency compared with those in minimal harm reduction (AOR -41.2, 95% CI -45.5 to -38.0). Participation in partial harm reduction with  $\geq 100\%$  NSP coverage but no OST was associated with a reduction in injecting frequency compared with lower NSP coverage and no OST (i.e. minimal harm reduction AOR -21.6, 95% CI 26.2 to -17.0). (These findings are presented in *Appendix 2, Table 20*.)

## Shared used of spoons and filters

Participants on full harm reduction had a 28% lower odds of sharing filters or spoons to prepare drugs (AOR 0.78, 95% CI 0.66 to 0.98). The effect of partial harm reduction with or without OST or higher coverage of needles/syringes results in the same proportional decrease in the risk of sharing filters or spoons. Current use of OST without taking into account NSP coverage was not associated with a reduction in the risk of sharing spoons and filters (AOR 0.94, 95% CI 0.83 to 1.06). High compared with low NSP coverage was associated with a 12% reduction in the use of shared spoons and filters (AOR 0.88, 95% CI 0.78 to 0.98). (These findings are presented in *Appendix 2, Table 21*.)

## Injecting site infections

There was a weaker association between the harm reduction intervention variable and injecting site infections across the four community surveys, the Welsh cohort and the UAMP data set ( $n = 4259$ ). There was some evidence that current use of OST was associated with increased odds of an injecting site infection (AOR 1.3, 95% CI 1.11 to 1.50). There was no association with the NSP coverage variable. (These findings are presented in *Appendix 2, Table 21*.)

## Hepatitis C and human immunodeficiency virus testing


Full harm reduction was associated with increased odds of testing for HCV infection. Odds of HCV infection testing increased with greater harm reduction coverage, with participants on full harm reduction having almost twice the odds of reported testing for HCV infection compared with those on minimal harm reduction (AOR 1.9, 95% CI 1.56 to 2.23). Participants on OST had 1.5 times higher odds of being tested for HCV infection (95% CI 1.36 to 1.71) and those with  $\geq 100\%$  NSP coverage had a 20% higher chance of being tested for HCV infection (AOR 1.2, 95% CI 1.04 to 1.31). Similar associations were observed with HIV testing. Participants on full harm reduction had twice the odds of reporting undergoing testing for HIV (AOR 1.9, 95% CI 1.6 to 2.20) and odds of testing for HIV were 50% higher among those on OST (AOR 1.5, 95% CI 1.36 to 3.04) and 20% higher among those with high NSP coverage (AOR 1.2, 95% CI 1.05 to 1.30). (These findings are presented in *Appendix 2, Tables 22 and 23*.)

## Pooling estimates with systematic review findings


Combining estimates of NSP coverage from the systematic review with two data sets<sup>69,70</sup> not already represented in the review strengthened the evidence for the effect of high needle syringe programme coverage on reducing the risk of HCV infection acquisition to 39% (RR 0.61, 95% CI 0.43 to 0.87) with moderate heterogeneity ( $I^2 = 30\%$ ;  $p = 0.189$ ). The systematic review data comprised a total of 438 new HCV infection cases from a sample of 3990. Similarly, the addition of 12 estimates from a systematic review that examined the effectiveness of current use of OST comprising 998 new HCV infection cases from a sample of 5910 supported the evidence for the effect of OST in reducing HCV infection risk acquisition (RR 0.56, 95% CI 0.45 to 0.69;  $I^2 = 0\%$ ;  $p = 0.620$ ). These findings are summarised in *Figures 13 and 14*.

## Conclusion

The analyses of pooled data sets from the UK and Australia showed strong evidence for the impact of full harm reduction (OST with  $\geq 100\%$  NSP coverage) in reducing the risk of HCV infection acquisition, injecting with used needles/syringes, frequency of injecting and increasing access to HIV/HCV infection testing among PWID in the UK and Australia. The impact of high ( $\geq 100\%$ ) NSP coverage without OST



**FIGURE 13** Meta-analysis combining pooled analyses with systematic review findings to measure the impact of high NSP coverage (> 100%) on HCV infection incidence.



**FIGURE 14** Meta-analysis combining pooled analyses with systematic review findings to measure impact of current OST exposure on HCV infection incidence.

reduced the risk of HCV infection acquisition by 40% compared with no OST and low (< 100%) NSP coverage. Our meta-analysis showed a weaker effect of the effect of NSP coverage on HCV infection incidence at the study level (OR 0.76, 95% CI 0.54 to 1.06). However, when this was combined with the systematic review, the effect was stronger (OR 0.61, 95% CI 0.42 to 0.87).

### Limitations

Our findings suggest a weaker effect of full harm reduction than reported previously, despite having a sample size five times larger and greater study power. One reason for this may be that the majority of new observations were derived from routine surveillance sets (UAMP, ANSP, NESI) that recruit from NSPs and drug treatment centres. First, these data sets cover wide geographic areas for which the effectiveness of

interventions is likely to differ, and this variation is not accounted for in the analysis. Second, the reported numbers of needles/syringes obtained from the UAMP were 3–4 times lower than those reported by community surveys, reflecting different inclusion criteria and settings. The community surveys were undertaken in larger urban areas, whereas the UAMP include smaller towns and rural areas. Third, findings clearly point to difficulties in accurately measuring the use of NSP coverage, which relies on correct recall of the frequency of injecting and the numbers of needles/syringes obtained in a time period and does not take into account secondary distribution (people taking additional needle/syringes to give to their peers).

### Concluding remarks

This is the largest national UK-wide analysis of the effectiveness of OST and NSP among PWID on HCV infection incidence. Findings clearly underline the importance of OST in combination with NSP as cornerstone interventions to reduce HCV transmission among PWID and the need to prioritise these interventions to prevent HCV. Findings also provide important new evidence of the role of high NSP coverage in reducing not only HCV incidence but also injecting with used needles/syringes and show that increasing the circulation of clean needles/syringes does not increase injecting frequency among PWID. The inclusion of the Australian data set shows that findings are generalisable to other contexts.



# Chapter 4 Costing of needle and syringe programmes

## Introduction

Needle and syringe programmes have been shown to be cost-effective for the reduction of HIV transmission in a wide range of settings.<sup>13,78,79</sup> Recent studies indicate that NSPs could also substantially reduce HCV infection rates.<sup>20,80</sup> To date, there have been no economic evaluations of NSPs for HCV infection reduction in Western Europe. This chapter aims to fill this gap by providing robust estimates of the cost of NSP programmes in order to facilitate a cost-effectiveness analysis (see *Chapter 5*).

## Methods

### *Needle and syringe programme costing*

#### Description of the intervention

The intervention evaluated is NSPs. NSPs in England are funded through Drug Action Teams and Local Strategic Partnerships, which are multiagency bodies involving local government, the police and health services, and that can be provided through pharmacies, mobile vans or specialist fixed sites. In Scotland, regional commissioning bodies are responsible for commissioning co-ordinated services for the region.

Needle and syringe distribution takes place through a range of modalities in the UK. There are three levels of needle distribution detailed in NICE guidance.<sup>81</sup> Level 1 includes the distribution of either loose or packaged injecting equipment. Level 2 includes the distribution of injecting equipment in a bespoke 'pick and mix' style and the dissemination of health promotion advice. Finally, Level 3 includes the distribution of 'pick and mix' injecting equipment and health promotion advice, as well as the provision of 'specialist services' (e.g. vaccinations, drug treatment and secondary care, including treatment for HCV and HIV).

The two most common modalities include pharmacy distribution and fixed-site distribution. Fixed-site NSP programmes are contracted by commissioning bodies to provide needle and syringe exchange at Level 3 as described in the NICE guidance. Fixed sites are generally contained within substance misuse services, which offer a wide range of drug and alcohol treatment interventions. These may include blood-borne virus testing and treatment, pregnancy testing, one-to-one support, structured day care and group-work programmes, OST prescription, relapse prevention services, and training volunteering and employment services. All injecting equipment is offered free of charge, usually in a 'pick and mix' style, from which clients may choose their own equipment to take away. Fixed sites also accept used injecting equipment for safe disposal and provide health promotion advice regarding the location and care of the injecting site, overdose avoidance and general welfare.

Pharmacies are contracted by local commissioning bodies to provide needle and syringe exchange, usually at Levels 1 and 2 as described in the NICE guidance. Injecting equipment is distributed to clients free of charge, either in a 'pick and mix' style or in pre-made pharmacy packs. Pharmacy packs contain various size needles depending on the colour of the pack and usually come in quantities of 5, 10 or 20 needles per pack. Some pharmacies are also now beginning to provide 'one-hit kits', which contain one needle and are intended to reduce drug-related litter. Pharmacies also accept used injecting equipment for safe disposal. Pharmacies may also provide health promotion advice, either verbally or in the form of health education materials, which are distributed alongside injecting equipment. Pharmacies are usually paid an 'incentive' by commissioning bodies to distribute needles and syringes, which can range from £1 to £3 per



exchange. Pharmacies also receive administrative and overhead support either from local commissioning bodies or from fixed sites operating in the area; this support includes ordering and delivery of pre-made needle packs, the collection and disposal of waste, and the administration and collation of service statistics.

Alternative modes of delivery not mentioned by the NICE guidance include peer-led and drop-in centre distribution, mobile outreach, vending machines and drop-box schemes. Peer-led and drop-in centres function as places for those with drug and alcohol dependencies to feel safe and comfortable, receive support in the form of hot meals, washing facilities and/or clean clothes, and find referrals for medical, legal or housing services. Mobile outreach services have the capability to visit sites in the outer areas of the city during afternoons and evenings, targeting areas where pharmacy NSP provision is less accessible or where there is a particularly high need for services. Vending machines are potential mechanisms by which to allow people to access injecting equipment out of hours and can complement or supplement existing services.

### Sites and settings

Cost data collection took place in three UK cities, namely Bristol, Dundee and Walsall. Sites were selected through a combination of convenience sampling based on the availability of impact data for the cost-effectiveness analysis, existing relationships with service managers and the feasibility of conducting a costing study. The three settings reflected variation in the primary modality through which needles were distributed, and a range of 'other' modalities intended to expand coverage.

The Bristol Drugs Project (BDP) is responsible for all harm reduction and substance misuse treatment in the Bristol area. They have a fixed site providing a needle exchange as well as other services. Pharmacy co-ordination is carried out by the BDP, and pharmacy-distributed NSP supplies are provided by the BDP. Pharmacies in Bristol exclusively distribute equipment in pre-made packs, rather than in a pick and mix style. Packs are available in two sizes: 10 needles or 20 needles. Most pharmacies in Bristol will also distribute OST, although commissioning for this is managed separately.

Services in Dundee are commissioned through NHS Tayside and the Sexual Health & Blood-Borne Virus Managed Care Network Prevention Sub-Group. The Managed Care Network Sub-Group is a multiprofessional group with representation from secondary care, primary care, the local authority, the voluntary sector and patient/carer/client representatives throughout Tayside, which has a remit for blood-borne virus prevention and sexual health improvement. This includes public awareness, education and harm reduction. The Tayside Substance Misuse Service is made up of two specialist harm reduction nurses, an administrator and a lead pharmacist. The service helps to co-ordinate pharmacy-based NSP services in addition to having several other responsibilities. The Cairn Centre is the busiest fixed-site injecting equipment provider in the Dundee area. Needle exchange services within CAIR Scotland are funded exclusively by the Managed Care Network. There are 15 pharmacies providing needle exchange services throughout Tayside, six of which are in Dundee. Pharmacies will offer injecting equipment either in packs or in pick and mix format. Most pharmacies in Dundee will also distribute OST; however, commissioning for this is managed separately.

Finally, in Walsall, the council commissions all NSP/harm reduction services through Public Health England. During the period of data collection, Addaction was commissioned to provide all needle/syringe exchange services in Walsall. Owing to recommissioning occurring after the period of data collection, Addaction Walsall are no longer in operation. Addaction co-ordinated other agencies providing NSP, including pharmacies and Hi's 'n' Lows (a drop-in centre; Walsall, UK). There are 12 pharmacies in Walsall offering needle and syringe exchange services. Most pharmacies in Walsall also distribute OST, although commissioning for this is managed separately. Hi's 'n' Lows is a peer-run drop-in service, offering a safe space for people to be and also offering a number of different services including a cheap meal, advice and counselling, and clothes. They provided needle exchange in co-operation with Addaction (which provided the needles and handled waste management).

## Data collection

Data collected incorporates the costs for different modalities of NSP provision (pharmacy, specialised and mobile sites) within each city. In total, we collected cost data for three fixed sites, six pharmacies and three 'other' modalities, which could potentially enable scale-up of output and coverage levels. Other modalities include a mobile outreach service, a drop-in centre and an out-of-hours pharmacy. For pharmacies, only a subsample was costed in detail owing to the existence of multiple pharmacy NSPs in each setting. The costs of other pharmacies in each city were estimated using their output data and unit cost data from the pharmacies where detailed costings were undertaken to give an overall cost estimate per city. The cost analysis covers a period of 1 financial year (2013–14), the most recent year for which data were fully available, and takes a provider perspective.

We estimated the total and unit economic costs for distributing clean needles to PWID. Our approach to costing was incremental to existing services and was particularly focused on needle and syringe exchange. We followed standard methods for costing in an economic evaluation of a health intervention; we include all costs regardless of the payer and estimate a 'shadow cost' when the price does not accurately represent the value of resources.<sup>82,83</sup>

In collecting resource use data, when possible, data were extracted from existing reporting mechanisms, including budget and expenditure records, human resources records and the management information system. In addition, we carried out direct observations of staff time and activities in order to confirm supply use estimations and to allocate resources that are shared between the NSP and other harm reduction services (such as staff time, building space, equipment or vehicle operation). Shared resources were allocated to services as a proportion of total services delivered and total time spent on each service. Current market prices [2014 UK pounds sterling (GBP)] were applied to all resources in order to estimate a cost. Overhead and support costs were estimated from programme records and a portion allocated to NSP services. Data were collated in a standardised Microsoft Excel® Version 3 (Microsoft Corporation, Redmond, WA, USA) spreadsheet. Data collection was primarily conducted by one researcher and quality-controlled by a second researcher.

Owing to the nature of pharmacy-based needle exchange, there was far less detailed output data available within pharmacies. We therefore made a number of assumptions in estimating the outputs at pharmacies. The type of data available for pharmacy-based needle distribution in each city varied: in Bristol, pharmacies reported on the total number of visits, whereas in Dundee, pharmacies reported on both the number of visits and the total number of needles distributed. Walsall pharmacies reported on the number of packs distributed. Based on feedback from both pharmacies and fixed sites, we assumed that 100% of clients obtaining needles at pharmacies were opioid users. Information on the distribution by sex of clients accessing pharmacies was available at two sites; this distribution was used to estimate the approximate breakdown between male and female clients at the other two sites. In order to estimate the total number of clients at pharmacies, we further assumed that an average of eight visits were made per client at pharmacies over the course of 1 year; again, this assumption was based on observations at two pharmacies for which this information was available. We assumed that pharmacies distributed an average of 1.12 needle packs per transaction. The out-of-hours pharmacy had begun the distribution of 'one-hit kits' shortly before the data collection period; as there was very little information on the quantity of 'one-hit kits' distributed per visit, we varied our assumption of 'one-hit kits' per transaction between 1 and 10 (the minimum and maximum quantities distributed per visit in the 2 weeks prior to the site visit).

Similarly, data on the proportion of needles distributed to opioid versus image and performance enhancing drug (IPED) clients at Addaction Walsall were unavailable. We therefore assumed a proportion based on data in other fixed sites. Detailed information on the sex distribution at the out-of-hours pharmacy and the peer-led site was also not available; we therefore estimated the same sex distribution as observed in the two pharmacies for which information on the sex breakdown was available.

## Data analysis

### *Fixed and variable costs*

Costs at all sites were classified as fixed and variable costs to facilitate analysis. Fixed costs are defined as those costs that are not easily changed in the short term. Fixed costs included the following ingredients:

- Overhead costs for pharmacy/fixed-site management – estimated as the percentage of needle exchange services delivered compared with other services delivered in the pharmacy/the local area.
- Co-ordination by commissioners – included as an overhead and allocated to the site as the percentage of needle exchange services delivered, compared with other services delivered in the pharmacy/the local area.
- Training as a minimum – includes awareness of the need for discretion, but this should also include an understanding of how to treat people in a non-judgemental way, and may include further education on common injecting practices and harm reduction messages. Training costs were estimated using an ingredients-based approach.
- Health and safety training – included as a cost for fixed-site staff but not for pharmacists, who as a part of their normal job will already have received health and safety training (e.g. needle stick injuries) and hepatitis B vaccines.
- Vehicle purchase – estimated using an ingredients approach and allocated as the proportion of mileage used for NSP services compared with for other services.

Variable costs are those costs that vary depending on the volume of services provided and can change in the short term. Variable costs included in the analysis are:

- Injecting equipment in pre-made packs or 'pick and mix' as appropriate to the site/service. Equipment and paraphernalia distributed varied between pharmacies and fixed sites and from site to site. Equipment distributed includes pots, water, citric acid, needles/syringes (various types and sized), condoms and sharps bins. The cost of this equipment will be estimated using a combination of the ingredients-based approach and step-down accounting. For pharmacies distributing needle packs, the base-case analysis assumes that packs of 10 are routinely distributed. This is varied to packs of 20 needles in the sensitivity analysis.
- Staff time costs, including service and administrative staff, allocated to NSP services as a percentage of their time use for NSP services compared with other services, using a combination of observational and interview data.
- Waste management and disposal of returned needles.
- Vehicle fuel, insurance and maintenance costs, estimated using an ingredients approach, and allocated as the proportion of mileage used for NSP services compared with for other services.

### *Estimating city-level costs*

In order to input into the cost-effectiveness model, we estimated the total cost for distribution of needles to opioid users in each of the three commissioning areas included in the study. We take the assumption that IPED users are at less risk of HCV infection via shared needles.<sup>84</sup> This is based on low reported prevalence of HCV infection in IPED users.

Our estimate of total costs for distributing needles to non-IPED users is estimated using total fixed costs at the city level, plus a weighted average variable cost per needle distributed to opioid clients. This estimation approach is intended to proxy the equivalent costs of providing needles only to opioid users (i.e. it represents the full fixed cost of the infrastructure necessary to provide needle and syringe exchange, and the variable cost attributable to non-IPED users). We anticipate this to be a conservative approach, which does not account for the benefit of distributing needles to IPED users.

Total fixed costs at city level are estimated accounting for the fixed site in each city, as well as all pharmacies and other modalities operating in each city. For pharmacies not included in our costing sample, we

estimated an average fixed cost per pharmacy for each commissioning area using the two or three pharmacies sampled for detailed cost data collection. We then applied an average fixed cost to all pharmacies across the commissioning area; this information was provided by fixed sites in each city. When incentive payments were less than or equal to the costs of staff time for transactions, these were treated as a transfer and not included as an additional cost. When incentive payments were greater than the costs of staff time, any additional amount was considered an additional cost and was factored into the total cost estimate.

Average variable costs per opioid needle distributed were estimated for each service modality in each city and weighted to reflect the total proportion of opioid needles distributed through that service modality citywide. This weighted average variable cost was then applied to the total number of needles distributed citywide to come to an estimate of the total citywide variable cost.

### ***Uncertainty analysis***

In order to reflect the uncertainty encountered in collecting NSP costs, we conducted a univariate sensitivity analysis. We included factors in the sensitivity analysis that could not be directly observed or that varied substantially between sites, including supply wastage, staff time taken for needle distribution, opportunity costs of volunteer time, equipment wastage, opioid/IPED client mix, number of needles distributed per visit and discount rate. In addition, we conducted a multivariate analysis of all factors mentioned above, simultaneously varying all factors with uniform distribution between the minimum and the maximum values observed over 1000 iterations. (The costing parameters varied in the uncertainty analysis, along with their minimum and maximum values, are located in *Appendix 3, Table 25*.)

## **Results**

### ***Needle and syringe programme outputs***

The size of fixed-site services varied substantially across the three cities. The largest fixed site handled > 10,000 visits in the financial year, whereas the smallest fixed site handled only 1756 visits in the same year (see *Appendix 3, Table 26*). The client mix at fixed sites also varied between sites. The majority of clients attending BDP and CAIR Scotland were users of opioids and other drugs, whereas the majority of clients at Addaction Walsall were IPED users. The total number of clients in 1 year at fixed sites varied from 569 to 1134; however, it is possible that the number of clients was distorted within fixed sites by clients giving different names on different visits.

The majority of clients at all sites were male: 87% of clients visiting BDP, 62% of clients at CAIR Scotland and 91% of clients at Addaction Walsall. At BDP, detailed information on the sex breakdown was available by opioid vs. IPED users. When looking at this breakdown, the sex balance is much more extreme among IPED users, with 98% of IPED users being male. It is possible that the large number of IPED users at Addaction Walsall will have resulted in a greater majority of male clients.

There was considerably less variation in outputs within the pharmacies sampled for the collection of cost data (see *Appendix 3, Table 27*). The pharmacies for which detailed data were collected reported between 1405 and 2316 visits per year. Pharmacies distributed between 18,518 and 36,100 needles. Two pharmacies distributed needles in 'pick and mix' form; the remaining pharmacies distributed needles in pack form only.

Finally, the three 'other' modalities distributed a wide range of needles – between 6816 and 101,326 needles per year (see *Appendix 3, Table 28*). Although detailed information was not available in the out-of-hours pharmacy or the drop-in centre on the breakdown of clients using either opioid and IPEDs, based on feedback from the sites we assumed that 100% of clients at these two sites were opioid users. The outreach service saw a greater mix of opioid/IPED users, with 72% of clients using opioids and 28% of clients using IPEDs. The outreach service saw mostly male clients; this imbalance was more exaggerated among IPED users (at 98% male) than opioid users (84% male).

## Needle and syringe programme costs


### Total costs

Total annual costs for the distribution of needles to all users (of both opioids and IPEDs) at fixed sites ranged from £25,613 to £65,630 per year, depending on the different sizes and reaches of the different fixed sites (*Table 7*). Pharmacies saw much less variation in total costs, ranging from £6815 to £10,690 per annum. Total annual costs for the out-of-hours pharmacy in Walsall were slightly less than the total costs for day pharmacies, at £5235. The costs for the distribution of needles using the mobile outreach service in Bristol were £32,887. Total costs for the drop-in centre in Walsall (Hi's 'n' Lows) were lowest, at £2138.

The primary cost driver in most settings was the cost of supplies; this accounted for an average of 60% of total costs across sites (range 23–80%) (*Figure 15*). Supplies costs for the out-of-hours pharmacy were less than those for day pharmacies, owing to the fact that this pharmacy distributed only one-hit kits, whereas the remaining pharmacies all distributed packs of 5, 10 or 20 needles during the costing period. This was followed in most cases by administrative and overhead costs, which accounted for 6–45% of total costs. Mobile outreach service costs were largely driven by transport costs, making up 47% of total costs.

**TABLE 7** Total and unit costs by site

Site	Total annual cost (£)	Total fixed costs (£)	Total variable costs (£)	Total opioid cost (£)	Unit cost per opioid needle (£)	Unit cost per opioid client (£)
Fixed site						
BDP	55,854.41	12,229.50	43,624.91	51,860.77	0.21	68.69
CAIR Scotland	65,630.81	5859.49	59,771.32	60,285.41	1.65	86.49
Addaction Walsall	25,613.22	1347.35	24,265.87	23,584.95	0.37	124.13
Other						
Out-of-hours pharmacy (Walsall)	5235.09	519.79	4715.30	5235.09	0.77	24.58
Outreach service (Bristol)	32,887.50	536.63	32,350.87	22,361.89	0.24	78.19
Drop-in centre (Walsall)	2138.19	421.68	1716.51	2138.19	0.27	19.01
Pharmacy						
Pharmacy 1 (Bristol)	8541.67	860.31	7681.36	9802.99	0.31	48.81
Pharmacy 2 (Bristol)	10,276.01	1262.25	9013.76	11,171.30	0.29	48.36
Pharmacy 3 (Dundee)	6814.59	901.52	5913.07	6814.59	0.31	23.74
Pharmacy 4 (Dundee)	9019.88	2449.12	6570.76	9019.88	0.37	31.15
Pharmacy 5 (Walsall)	10,690.48	650.80	10,039.68	10,690.48	0.58	50.91
Pharmacy 6 (Walsall)	7506.43	443.77	7062.66	7506.43	0.43	36.27



**FIGURE 15** Cost drivers as a proportion of total costs.

Table 7 shows the fixed and variable costs per site, and the total cost for needle distribution to non-IPED users at each site (methods for this estimation are described previously; see *Methods*). The total opioid cost varied from £23,584 at Addaction Walsall to £60,285 at CAIR Scotland, and from £6815 at Pharmacy 3 in Dundee to £10,690 at Pharmacy 5, also in Dundee.

The unit cost per opioid needle distributed varied from £0.21 to £1.65, and the unit cost per non-IPED client (annually) varied from £19.01 to £124.13. There was no consistent ranking across sites in terms of unit costs; sites that had high unit costs per client did not necessarily also have high costs per needle, and vice versa.

### City-level costs: non-IPED users

Table 8 shows estimates of the total number of needles distributed to non-IPED users at the city level, total fixed costs and average variable costs per needle, and estimated total annual costs for needle distribution to non-IPED users by mode of distribution. Bristol and Walsall spent proportionally more on pharmacies (68% and 69% of total city-wide costs, respectively) than on fixed-site distribution (22% and 24% of total city-wide costs, respectively). In contrast, Dundee spent 58% of total city-wide costs on fixed-site distribution, and only 42% of total city-wide costs on pharmacy distribution. Pharmacies in all three cities distributed the majority of needles; pharmacies accounted for 59%, 73% and 66% of total citywide needle distribution in Bristol, Dundee and Walsall, respectively. The fixed site in Dundee had the highest average variable cost per opioid needle at £1.49. The lowest cost per needle was observed at the fixed site in Bristol, at £0.16 per needle.

Total city-wide costs for distribution to non-IPED users varied from £104,496 in Dundee to £232,117 in Bristol. Table 9 presents the total number of needles and total costs distributed compared with the total opioid injecting population in 2014, as predicted by the impact model. Looking at the total costs incurred in each city compared with the 2014 population size estimates included in the cost-effectiveness model, the amount of investment per person injecting non-IPEDs varied across cities (see Table 9). Bristol spent between £89 and £126 annually per person in the total non-IPED injecting population citywide, whereas Dundee spent £127–155 per person and Walsall spent £60–86 per person. The variation in investment at the city level is to some extent a reflection of varying coverage and intensity of interaction. Walsall

**TABLE 8** Total costs and needles by city

City and site type	Total needles	Total fixed costs (£)	Average variable cost per needle (£)	Total cost (£)
Bristol				
Fixed site	252,039	12,229.50	0.16	51,861
Pharmacies ( <i>n</i> = 25)	495,500	28,392.32	0.26	157,894
Other	92,171	536.63	0.24	22,362
Total citywide	839,710	41,158.44	0.23	232,117
Dundee				
Fixed site	36,455	5859.49	1.49	60,285
Pharmacies ( <i>n</i> = 5)	100,604	3880.79	0.41	44,210
Other	NA	NA	NA	NA
Total citywide	137,059	9740.28	0.69	104,496
Walsall				
Fixed site	63,644	1347.35	0.35	23,585
Pharmacies ( <i>n</i> = 12)	151,460	17,357.32	0.46	67,690
Other	14,628	941.47	0.34	7373
Total citywide	229,732	19,646.14	0.35	98,649
NA, not applicable.				

**TABLE 9** Total investment per opioid user, by city


City	Total number of needles	Average variable cost per opioid needle (£)	Total cost (£)	Population size	Visits per user	Cost per user (£)	Needles per user
Bristol	883,524	0.23	232,116.78	1847–2595	13–18	£89.45–125.67	340–478
Dundee	150,790	0.69	104,495.75	675–825	17–20	£126.66–154.81	183–223
Walsall	245,002	0.35	98,649.03	1144–1646	12–17	£59.93–86.23	149–214

distributed an average of 12 needles per visit but had the lowest number of visits per user overall in the city (12–17 visits per person in the injecting population citywide). In comparison, Dundee distributed an average of only 10 needles per visit, but saw clients much more frequently (17–20 visits per person). Finally, Bristol had between 13 and 18 visits per person citywide, but distributed an average of 26 needles per visit.

### Uncertainty analysis

Figure 16 provides an illustration of our univariate and multivariate uncertainty analyses for the NSP costing, showing the impact of varying each parameter for which there was uncertainty on the estimated unit cost per opioid needle. The parameter with the greatest effect on costs was that of equipment wastage; this is to be expected, as injecting equipment is the primary cost driver at most sites. Similarly, varying assumptions of the total number of ‘one-hit kits’ distributed per client at the out-of-hours pharmacy impacted the cost per needle substantially. Varying all parameters simultaneously gave a relatively wide estimate of unit costs per needle. The out-of-hours pharmacy was most sensitive to assumptions, with the unit cost per needle varying between –229% and +56% of the base-case cost in the multivariate sensitivity analysis.





**FIGURE 16** Needle and syringe programme costing uncertainty analysis.



## Conclusions

We observed a degree of variation in costs across the three different commissioning areas evaluated, with variation in cost and outputs being observed across fixed sites and pharmacies. This was due to substantial variation in the set-up of NSP services. There is no 'standard' for NSP administration in the UK and, as such, each setting had different types of services, with different degrees of interaction with opioid users. Although cities varied in their modality of focus (i.e. pharmacy vs. fixed site), there was not a clear correlation between the primary modality through which needles were distributed in the city and the estimated cost per opioid user citywide.

Some variation was also due to case mix across the three cities. Addaction Walsall handled a larger number of IPED users who made very few visits each. This increased the fixed costs, resulting in a greater cost per opioid client. However, providing needles to IPED users did not necessarily increase the unit cost per opioid needle distributed; for example, Addaction Walsall distributed a large number of needles to opioid users, so the unit cost per opioid needle was relatively small.

The difference in costs observed between cities is likely to be driven partly by the type of needle distribution and ease of access to needles for people injecting drugs. We observed a large variation in the number of visits per user across cities and in the number of needles distributed at each visit. The variation observed, however, should be taken in the context of the different characteristics of the injecting population in each setting and not necessarily reduced efficiency in distribution. A higher number of visits per person in the injecting population citywide did appear to increase the costs of distribution; however, an increase in the level of investment per user citywide did not necessarily lead to reduced cost-effectiveness. In fact, the city with the greatest investment per user (Dundee) also saw the greatest savings as a result of implementing NSPs in the long term.

## Limitations

The primary outcome of interest for this study is needle exchange for the prevention of HCV infection transmission; we therefore include only those costs and benefits that are relevant to this outcome in this costing study. We do not include any costs or benefits from other engagement programmes as delivered by the fixed sites and the peer-led service, such as one-to-one support, sexual health services, legal advocacy, etc. A larger number of visits per person in the injecting population may be necessary for these benefits; further research on the impact of these services is required in order to come to any recommendation on the optimal frequency of visits for injecting populations. These additional services are also likely to bring in more clients to the needle exchange. This may especially be the case for women, who might access sexual health-related services at the sites.

We also do not estimate the costs for the clean-up of drug-related litter, which can also be a substantial investment, and without which some councils would not politically be able to continue the provision of needle exchange. Drug-related litter is a key reason for implementing the distribution of 'one-hit kits' in some pharmacies, including the out-of-hours pharmacy, as there have been a number of discarded unused needles found in some study sites. Councils may need to consider the additional costs of litter pick-up schemes; this can vary widely depending on the number of staff employed and the size of the city. In one city, we estimated the salary costs for litter pickup to be approximately £4064 per year, not including transport and equipment costs. In another (larger) city, the overall costs of a dedicated sex- and drug-related litter pickup scheme are reported to be £80,000 per year.

Our analysis also does not consider any potential impact of the prevention of HCV cases in people injecting IPEDs, and excludes variable costs encountered by NSPs in providing needles and syringes for IPED use. Research from Australia indicates that IPED users are at some, albeit reduced, risk of HCV transmission.<sup>85</sup>

Finally, we encountered a lack of detailed information on the client mix receiving needle exchange services through pharmacies and we could not obtain any estimates on the relative proportion of IPED to opioid

injectors accessing pharmacy needle exchanges. Moreover, we could not find information on male-to-female ratios in pharmacies. Feedback from pharmacies and fixed sites during the costing process indicated that IPED users rarely access pharmacies and that the proportion of opioid visits to pharmacies is likely to be close to 100%.

All findings were presented to each site mid-way through the project, when results were presented and plausibility was discussed. Permission was sought to present the potentially sensitive nature of the findings. It was agreed not to publish the costings separately but to present these alongside cost-effectiveness analyses in any public dissemination or peer-reviewed output.



# Chapter 5 Impact modelling

## Introduction

Previous modelling for the UK has shown that OST and NSP is likely to have had a large impact on reducing HCV infection prevalence in the past, whereas further scaling up of these interventions will have only a modest effect on HCV infection prevalence.<sup>86</sup> However, this analysis did not estimate the current ongoing impact of NSPs and how that may vary in specific UK settings, or assess the impact of scaling up OST and NSP in terms of HCV infection incidence and HCV infections averted.

The prevalence of HCV infections and the coverage of harm reduction interventions such as NSPs and OST varies across the UK,<sup>16,20,39,44,70,73,87–90</sup> and although the coverage of OST has increased in the past 10 years, the level of high-coverage NSPs has remained relatively constant.<sup>70</sup> In this chapter, a HCV infection transmission and progression model, incorporating new evidence on intervention effectiveness, is used to assess the impact of current levels of OST and NSP on HCV infection prevalence, incidence and HCV-related morbidity among current and ex-injecting drug users in three UK settings, and the probable impact of scaling up NSP coverage.

## Methods


### Model description

We developed a dynamic ordinary differential equation model of HCV infection transmission and disease progression among PWID and ex-injecting drug users. The model simulates the movement of PWID through different injecting durations, intervention, risk and HCV infection disease states, and also follows them after they have ceased injecting to capture HCV morbidity outcomes.

Stratifications by injecting duration are included in the model to capture higher rates of injecting cessation during the first few years of injecting,<sup>91</sup> and the heightened level of HCV infection acquisition risk among recently initiated PWID.<sup>20,92</sup> There are four injecting duration categories: < 3 years,  $\geq 3$  years to < 10 years,  $\geq 10$  years and ex-injecting drug users. All PWID enter the model as recently initiated PWID (< 3 years injecting category) at a constant rate  $\theta$ , and then transition to non-recent PWID (at rate  $1/3$  year<sup>-1</sup>) and then to long-term PWID (at a rate of  $1/7$  year<sup>-1</sup> from the non-recent PWID). Each of these categories also has specific cessation rates of injecting, which results in users entering the ex-injecting drug user class, as well as death rates that vary by injecting duration, giving a total proportion of PWID leaving the current injector category,  $\mu_i$ . (Figure 17 shows the schematic for this aspect of the model structure. Ex-injecting drug users are also stratified by the same infection and disease progression states so that morbidity benefits can be tracked.)

People who inject drugs are also tracked through different intervention states: no intervention, on OST only, > 100% NSP only, and on both OST and > 100% NSP. When PWID start injecting they are assumed to be in the 'no intervention' state. Recruitment on to OST and > 100% NSP occurs at per capita rates  $\beta$  and  $\eta$ , respectively, with both being assumed to be independent of current risk state for simplicity and lack of data. The rates of leaving OST and > 100% NSP are  $\gamma$  and  $\kappa$ , respectively. (See Figure 17b for the schematic for this component of the model structure.)


The model is further stratified by high and low injecting risk, with high-risk behaviours being defined by characteristics that have been shown to increase the risk of HCV infection acquisition among PWID in the UK. High risk is defined as being homeless and/or a crack cocaine injector, and low risk is defined as being neither homeless nor a crack cocaine injector. A proportion of individuals,  $\phi$ , enter the model in the high-risk category. Movement from the low- to the high-risk category and vice versa occurs at per capita rates  $\sigma$  and  $\zeta$ , respectively.



**FIGURE 17** Schematic of injecting duration and infection components of model. (a) Injectors cease injecting (cessation or death) at rate  $\mu_i$ , where  $i = 1, 2$  or  $3$  for recent, non-recent and long-term injectors, respectively. Injecting duration is modelled in three categories with progression at rate  $\tau_i$ , where  $i = 1$  or  $2$  for recent and non-recent injectors, respectively; (b) schematic of the intervention component of the model. It is assumed that the recruitment rates  $\beta$  and  $\eta$  are independent of the current intervention state; and (c) schematic of disease progression component of the model. Each of the disease states is stratified by injecting duration,  $n$ ; risk category,  $m$ ; OST category,  $i$ ; and NSP category,  $j$ . Progression through the disease states is by a rate determined by the current disease state, as are disease-related death rates. In addition to current injectors, ex-injecting drug users are followed through the model when they cease injecting with an identical pathway, except that reinfection is excluded. All states have a cessation rate from injecting and a background death rate that is not disease related. Reinfection can occur at any stage but these lines are not shown after compensated cirrhosis. C, chronically infected; DC, decompensated cirrhosis; F0, F1, F2, F3, chronic infection states; F4, compensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant; PLT, post liver transplant; S, susceptible. (continued)

All PWID enter the model as susceptible individuals and become infected at a per capita rate,  $(\lambda_{ij}^{n,m})$  or force of infection, which depends on the intervention state, injecting duration category and risk category of the individual, as well as the prevalence of infection. The force of infection for each susceptible state is defined by the relative risk in that state, such that infectivity and susceptibility are multiplied by the following factors:  $\Gamma$ ,  $\Pi$ ,  $B$  if the injecting drug user is on OST,  $\geq 100\%$  NSP or both, respectively;  $X_1$  and  $X_2$  if the injecting drug user is a recent injector or non-recent injector, respectively; and  $\Xi$  if the injecting drug user is a high-risk individual. Because assortative mixing has been shown to have little effect on transmission when there is movement between high- and low-risk groups, we do not include it here.<sup>86</sup> In addition, evidence from Bristol<sup>88</sup> suggests that there is little assortative mixing by injecting duration, so we assumed random mixing between all categories. For this, the chance of an injecting drug user having a transmission event with an injecting drug user in a specific risk category is assumed to be proportional to the overall transmission risk of PWID in that state.

(c)



**FIGURE 17** Schematic of injecting duration and infection components of model. (a) Injectors cease injecting (cessation or death) at rate  $\mu_i$ , where  $i = 1, 2$  or  $3$  for recent, non-recent and long-term injectors, respectively. Injecting duration is modelled in three categories with progression at rate  $\tau_i$ , where  $i = 1$  or  $2$  for recent and non-recent injectors, respectively; (b) schematic of the intervention component of the model. It is assumed that the recruitment rates  $\beta$  and  $\eta$  are independent of the current intervention state; and (c) schematic of disease progression component of the model. Each of the disease states is stratified by injecting duration,  $n$ ; risk category,  $m$ ; OST category,  $i$ ; and NSP category,  $j$ . Progression through the disease states is by a rate determined by the current disease state, as are disease-related death rates. In addition to current injectors, ex-injecting drug users are followed through the model when they cease injecting with an identical pathway, except that reinfection is excluded. All states have a cessation rate from injecting and a background death rate that is not disease related. Reinfection can occur at any stage but these lines are not shown after compensated cirrhosis. C, chronically infected; DC, decompensated cirrhosis; F0, F1, F2, F3, chronic infection states; F4, compensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant; PLT, post liver transplant; S, susceptible.

Once infected, a proportion of newly infected PWID,  $\delta$ , spontaneously clear the infection and remain in the susceptible category, and the remainder enter the chronically infected category ( $I_{ij}^{n,m}$ ) and remain infected until they die or are treated. The progression of HCV infection for any PWID who enters the chronically infected PWID category is modelled as shown in Figure 17c. The disease states modelled are METAVIR stages F0, F1, F2, F3 (chronically infected), F4 (compensated cirrhosis), decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplant and post liver transplant. Individuals progress from F0 through each METAVIR stage to compensated cirrhosis, from which they progress either to decompensated cirrhosis or to HCC. Individuals with decompensated cirrhosis can then progress to HCC or can be considered for liver

transplant (as can individuals with HCC), which, if successful, results in the individual moving to the post liver-transplant stage. HCV disease-related death occurs from the decompensated cirrhosis, HCC, liver transplant and post liver-transplant stages with disease stage-specific death rates.

Treatment of HCV infection is allowed only in the F0–F3 and compensated cirrhosis (F4) stages, as it is unclear whether or not treatment in later disease stages is beneficial.<sup>93</sup> A number of PWID,  $\Phi$ , are assumed to be treated each year and on treatment a proportion,  $\alpha$ , achieve a sustained virological response (SVR) and re-enter the susceptible non-infectious category. Treatment of ex-injecting drug users occurs at per capita rate  $r$ , with the same proportion,  $\alpha$ , achieving SVR. Those who do not attain SVR remain in the infected category and are eligible for retreatment. This simplifying assumption was made based on the influx of new treatment regimes becoming available. On successful treatment, individuals enter the respective susceptible category with the same disease stage (see *Figure 17c*). Disease progression still occurs among these individuals if they have compensated cirrhosis, but at a slower rate. We assume no further disease progression if treatment is successful in the F0–F3 chronically infected non-cirrhotic stages.<sup>94,95</sup> The disease progression of ex-injecting drug users is also tracked to assess the long-term impact that interventions will have on this subpopulation. It is assumed that ex-injecting drug users who are susceptible or who have been successfully treated cannot be reinfected.

### Model parameterisation

The model parameters can be found in *Table 10*. The model was calibrated to the following parameters estimated from survey data: HCV infection prevalence, coverage of OST and NSP, proportion of PWID with high-risk behaviour and injecting duration distribution of PWID over time.

Odds ratio effect estimates for the degree to which the risk of HCV infection transmission is modified when an injecting drug user is on OST or there is  $\geq 100\%$  NSPs in the high-risk category or for different injecting durations were taken from a pooled analysis of UK and Australian data (see *Chapter 2*). The OR combined effect of OST and  $\geq 100\%$  NSP was calculated by multiplying together the effects estimates for OST and  $\geq 100\%$  NSP alone, to reflect the assumption that both interventions together would be more beneficial than alone, giving a range comparable to that from the systematic review (see *Chapter 1*).

Hepatitis C treatment was assumed to occur in all settings since 2009 at context-specific rates based on recent data from those settings, except for Walsall where data from Bristol was used because of a lack of data from that setting. Before 2015, we estimated the SVR rate for pegylated interferon and ribavirin from a recent study of PWID in the UK.<sup>99</sup> After 2015, we assumed that treatment would involve using the new direct-acting antiviral (DAA) drugs, and so assumed a high SVR rate of 90% for all genotypes.<sup>103</sup>

Instantaneous HCV infection disease stage progression rates were calculated from a recent meta-analysis of PWID-specific progression probabilities to compensated cirrhosis<sup>101</sup> and a systematic review of general progression probabilities for other disease stages,<sup>101</sup> and, similarly, the spontaneous clearance probability came from a published meta-analysis.<sup>96</sup> Non-HCV-related death and injecting cessation were combined into one rate for each injecting duration strata, with the death rates being estimated from a cohort study of PWID in Scotland,<sup>91</sup> and the cessation rates being estimated through fitting the model to the observed distribution of PWID by injecting duration.

The leaving rate from the high-risk category, characterised as homelessness or crack cocaine injection, came from two studies among PWID in the UK.<sup>39,97</sup> The leaving rates from NSP and OST came from a Welsh cohort study.<sup>39</sup> Conversely, the recruitment rates to these states were obtained through calibration.

### Model calibration and uncertainty

The model was calibrated to data on PWID population size, historical coverage levels of OST and NSP, prevalence of high-risk behaviours (crack cocaine injection and homelessness), HCV infection prevalence and the distribution of injecting duration. These calibration data were collated from various sources (*Appendix 4*, *Table 29* summarises the data used), including size estimation studies,<sup>104–107</sup> three Bristol community surveys

TABLE 10 Model parameters

Parameter	Symbol	Value/range	Reference
<b>Epidemiological and demographic parameters</b>			
Number of new injectors per year	$\theta$	Fitted to obtain population sizes	See <i>Appendix 4, Table 29</i> and supporting information
Combined death and cessation rates per year	$\mu_i$	Fitted to obtain injecting duration profiles for each setting	See <i>Appendix 4, Table 29</i> and supporting information
Infection rate per year	$\pi$	Fitted to obtain HCV infection prevalence required in each setting	See <i>Appendix 4, Table 29</i> and supporting information
Proportion of new infections that spontaneously clear	$\delta$	Sampled from uniform distribution (0.22–0.29)	Micallef <i>et al.</i> , 2006 <sup>96</sup>
Leaving rate per year from high- to low-risk behaviour	$\zeta$	Sampled range (0.6761–1.617)	Data from cohort study <sup>97</sup> found that 78 out of 145 injectors were no longer homeless after 8 months. Transition probability sampled from beta distribution $\alpha = 78$ and $\beta = 67$ and converted to instantaneous rate
Recruitment rate per year from low- to high-risk behaviour	$\sigma$	Fitted to obtain required high-risk proportions in each setting	See <i>Appendix 4, Table 29</i> and supporting information
<b>Intervention-related parameters</b>			
Leaving rate per year off OST	$\gamma$	1–3	Duration on OST was 8 months (4–12 months) in a cohort of PWID in the UK <sup>98</sup>
Leaving rate per year off high-coverage NSP	$\kappa$	0.37–0.77	Welsh cohort study: 61% of PWID were still > 100% NSP after 1 year <sup>39</sup>
Recruitment rate per year on OST	$\beta$	Fitted to obtain required OST coverage proportions in each setting	See <i>Appendix 4, Table 29</i> and supporting information
Recruitment rate per year on high-coverage NSP	$\eta$	Fitted to obtain required high NSP coverage proportions in each setting	See <i>Appendix 4, Table 29</i> and supporting information
Proportion of treatments achieving SVR prior to 2015	$\alpha$	Sampled from uniform distribution (0.3992–0.6653)	Weighted mean of pooled intention to treat SVR for genotypes 1 and 2/3 taken from treatment data for PWID in the UK <sup>99</sup>
Proportion of treatments achieving SVR post 2015	$\alpha$	Sampled from uniform distribution (0.859–0.915)	Harris <i>et al.</i> , 2014 <sup>100</sup>
Proportion of infected ex-injecting drug users treated in chronic and compensated cirrhosis stages	$r$	0.03	Harris <i>et al.</i> , 2014 <sup>100</sup>
Number of PWID treated per year	$\Phi$	Bristol: 18  Dundee: 34 (2009–15) and 40 (2015 onwards)  Walsall: 2	Number of HCV infection treatments in 2011. Assumed treatment of PWID commenced in 2009. <sup>99</sup> More recent values for Dundee from correspondence with John Dillon (John Dillon, University of Dundee, 2016, personal communication). Walsall value assumed to be same rate per infected PWID as Bristol

continued



TABLE 10 Model parameters (continued)

Parameter	Symbol	Value/range	Reference
<b>Relative transmission risk parameters</b>			
Risk associated with being on OST only	$\Gamma$	0.41 (0.22–0.75) sampled from log-normal distribution	OR and 95% CI from pooled analysis (see Chapter 2)
Risk associated with being on high-coverage NSP only	$\Pi$	0.59 (0.36–0.96) sampled from log-normal distribution	OR and 95% CI from pooled analysis (see Chapter 2)
Risk associated with being on both OST and high-coverage NSP	$\Gamma \times \Pi$	0.26 (0.09–0.64)	Calculated as product of risk associated with being solely on OST or NSP. Compares well with estimate for systematic review 0.29 (0.13–0.65)
Risk associated with being a recent injector compared with being a long-term injector	$\chi_1$	1.53 (0.93–2.52) sampled from log-normal distribution	OR from pooled analysis (Lucy Platt, London School of Hygiene and Tropical Medicine, 2015, personal communication)
Risk associated with being in the high-risk category	$\Xi$	For Dundee: 2.13 (1.40–3.24) For Bristol and Walsall: 2.75 (1.97–4.22) Sampled from log-normal distribution	OR from pooled analysis. For Dundee, the OR is just for homelessness because there is little crack cocaine injection, whereas it is for crack cocaine injection or homelessness for Bristol and Walsall
<b>Disease progression parameters</b>			
Yearly progression rate from F0 to F1	$\rho_1$	0.529–0.2095 sampled from normal distribution	PWID-specific instantaneous rates from Smith <i>et al.</i> , 2015 <sup>101</sup>
Yearly progression rate from F1 to F2	$\rho_2$	0.0216–0.1013 sampled from normal distribution	
Yearly progression rate from F2 to F3	$\rho_3$	0.0450–0.1145 sampled from normal distribution	Instantaneous rates calculated from sampled beta distributions of transition probabilities in Shepherd <i>et al.</i> , 2007 <sup>93</sup>
Yearly progression rate from F3 to compensated cirrhosis	$\rho_4$	0.0513–0.1838 sampled from normal distribution	
Yearly progression rate from compensated cirrhosis to decompensated cirrhosis	$\rho_5$	0.0166–0.0921	
Yearly progression rate from compensated cirrhosis or decompensated cirrhosis to HCC	$\rho_6$	0.0003–0.0684	
Yearly progression rate from decompensated cirrhosis or HCC to liver transplant	$\rho_7$	0.0062–0.0962	
Yearly progression rate from liver transplant to post liver transplant	$\rho_8$	1.0423–2.4412	Sampled from transformed log-normal distribution <sup>102</sup>
Decompensated cirrhosis-related death rate per year	$d_9$	0.1063–0.1842	
HCC-related death rate per year	$d_7$	0.3904–0.7697	Sampled from transformed log-normal distribution <sup>95</sup>
Liver transplant-related death rate per year	$d_8$	0.0911–0.4348	
Post liver transplant-related death rate per year	$d_6$	0.0280–0.1016	Sampled from transformed log-normal distribution <sup>95</sup>
Relative risk for progression rate from compensated to decompensated cirrhosis ( $\rho_5$ ) following SVR	$e_5$	0.07 (95% CI 0.03 to 0.2)	
Relative risk for progression rate from compensated cirrhosis to HCC ( $\rho_6$ ) following SVR	$e_6$	0.23 (95% CI 0.16 to 0.35)	

in 2004, 2006 and 2009,<sup>44,73,88,89</sup> yearly UAMP surveys from 1991 (Bristol) or 2006 (Walsall) to 2014,<sup>70</sup> and four surveys from NESI for Dundee from 2008 to 2014.<sup>70</sup> Data on incidence for Dundee (NESI) and Bristol (community survey 2009) were used for model validation as well as for prevalence data post 2006 for Bristol and Walsall (UAMP).

Model calibration was carried out in three steps with 1000 parameter sets obtained at each step:

1. population size and injecting duration fitting using a PWID demographic submodel without infection
2. NSP and OST coverage fitting using a submodel that includes HCV infection transmission but no disease progression
3. HCV infection prevalence fitting using the full model with disease progression.


## Step 1

In Dundee, survey data<sup>70</sup> suggested that the proportion of the PWID population in each injecting duration category was stable from 2008 to 2014, and so we assumed a constant population size estimated from unpublished data from Scotland. In Bristol and Walsall, size estimation data suggest that the PWID population has decreased by between 10% and 30% between 2009 and 2011.<sup>104–106,108</sup> Concurrently, survey data<sup>44,70,73,88,89</sup> suggest that the proportion of PWID injecting for > 10 years has increased, whereas the proportion injecting for between 3 and 10 years has decreased (*Figure 18*). There has been little change in the proportion injecting for < 3 years. It was assumed that these changes were partly attributable to a decrease in the initiation rate of new injectors and a change in the cessation rates of non-recent and long-term injectors. We allowed for uncertainty around these parameters and estimated them by fitting the model to the population size and injecting duration profile (proportion of PWID in each injecting duration category) at two time points for Walsall and Bristol and one time point for Dundee. This fitting was done with a demographic submodel, which had only three injecting duration categories and no other stratification. We assumed that the PWID population size was at equilibrium initially (before 2004, 2006 and 2008 for Bristol, Walsall and Dundee, respectively). We sampled 1000 values for this 'stable' initial population size and the cessation rate from the recent injector category for each setting. For each of these 1000 parameter sets, the wide prior distributions for the cessation rates from non-recent and long-term injectors (see *Appendix 4, Table 29*) were then sampled, and for each sample the model was fit to the initial population size by calculating a suitable PWID recruitment rate, using the steady state equations for the demographic submodel (for more details, see *Appendix 4*). Parameter sets were retained if the resulting injecting duration profile lay within the ranges suggested from the data, otherwise the cessation rates were resampled. We then sampled 1000 estimates for the later population size in 2011 for Bristol and Walsall, as well as new cessation rates for non-recent and long-term injectors, and the PWID recruitment rate was recalibrated to fit to this new sampled population size for the 2011 data (for Bristol and Walsall only). This refitting of the demographic submodel was done using the Matlab release 2014b (The MathWorks, Inc., Natick, MA, USA) algorithm *fzero* applied to the analytic solution of the model with initial conditions from the first step of fitting. Parameter sets were retained if the resulting injecting duration profile lay within ranges suggested from data for the years 2004 and 2011 for Bristol and 2008 and 2011 for Walsall, otherwise the new cessation rates for this second step were resampled to obtain a fit to each of the first step parameter sets (1000 each for Bristol and Walsall).


## Step 2

Coverage levels for PWID currently on OST have increased over the past 12 years. In Bristol, the proportion of PWID currently on OST increased from 40% in 2004<sup>73</sup> to 81% in 2009.<sup>88</sup> In Walsall, OST coverage increased from 40% in 2006 to 70% in 2009,<sup>70</sup> and in Dundee it increased from 43% in 2008 to 72% in 2014.<sup>87</sup> Conversely, over this same time period, the proportion of PWID with > 100% NSP coverage remained stable in both Bristol (55%)<sup>70,73,88</sup> and Walsall (38%),<sup>70</sup> although it increased over time in Dundee from 41% in 2008 to 60% in 2014.<sup>70</sup> Modelled OST coverage levels for each city were calibrated to this coverage data by varying the recruitment rate onto each intervention. A service provision estimate of NSP coverage was calculated for each setting using data on needles distributed from the costings analysis (2014 data), population size (calculated from the model in 2014) and injecting frequency from survey data. Bootstrap samples of the mean injecting frequency were calculated for each setting using UAMP (Bristol

(a)




(b)



**FIGURE 18** Graphs showing model fitting of the baseline scenarios in each setting. Error bars in black are data points from surveys, error bars in blue are the ranges used for model calibration (for NSP coverage this was the service provision estimate). (a) Bristol; (b) Walsall; and (c) Dundee. (continued)

(c)



**FIGURE 18** Graphs showing model fitting of the baseline scenarios in each setting. Error bars in black are data points from surveys, error bars in blue are the ranges used for model calibration (for NSP coverage this was the service provision estimate). (a) Bristol; (b) Walsall; and (c) Dundee.

and Walsall) and NESI (Dundee) data. In addition, the mean injecting frequency in Dundee has decreased from 717 injections per year in 2008 to 388 injections per year in 2014. Therefore, an estimate of NSP coverage was calculated for each time point. The average service provision estimates of NSP coverage were 56% and 28% in Bristol and Walsall, respectively, in 2014 and 27% and 49% in 2008 and 2014, respectively, for Dundee (see *Appendix 4, Table 29* for more details). The recruitment rates were estimated using an intervention submodel that incorporated no onward disease progression, as these mechanisms have little effect on the coverage levels obtained. Using the Matlab fitting algorithm *lsqnonlin*, recruitment rates were found to fit the submodel to the initial and end-point coverage of each intervention (as shown in *Appendix 4, Table 29*), while assuming that coverage levels were quasi-stable. In the full model, the recruitment rates for the initial coverage level were first used to obtain initial conditions for the first time point for each city, and then the recruitment rate was gradually varied linearly between the two values to obtain the required increase in coverage for that city.

Survey data suggest that the prevalence of crack cocaine injecting and/or homelessness, our markers of high HCV infection transmission risk, have remained stable in Dundee (33% homeless) and Walsall (52% homeless or crack cocaine injection), whereas it has increased in Bristol from 75% in 2004 to 87% in 2014 (homeless or crack cocaine injection). We assumed that a proportion of injectors are high risk when they initiate injecting, which is consistent with available data.<sup>97</sup> The leaving rate from these high-risk categories was estimated from a cohort study on homelessness, which found that approximately two-thirds of homeless PWID are no longer homeless after 1 year.<sup>97</sup> This agrees with unpublished findings from a Welsh cohort study for both crack cocaine injecting and homelessness.<sup>39,86</sup> The leaving rate was sampled 1000 times and used for all three settings. The proportion of PWID that are high risk was also sampled 1000 times for each setting. The recruitment rates were then calculated for each parameter set using the steady-state solution of the high- and low-risk submodel (two variables). In Bristol, where the proportion of high-risk PWID has increased, we calculated a second recruitment rate for the second time point (2014) using the same method. For Bristol, the recruitment rate was gradually varied linearly to obtain the increase in the proportion of PWID that are high risk.

### Step 3

The last step of the model calibration involved fitting the full model to the HCV infection prevalence data from each setting (sampled 1000 times from the ranges given in *Appendix 4, Table 29*). This incorporated the 1000 parameter sets from the previous model calibration steps, and involved calibrating the model's infection rate using the *lsqnonlin* function in Matlab. The model was first fit to the initial prevalence estimate (sampled from the ranges given in *Appendix 4, Table 29*) in 2004, 2006 and 2008 for Bristol, Walsall and Dundee, respectively (see *Figure 18* and *Appendix 4, Table 29*), while assuming that the epidemic was in a stable state at that time. For Walsall and Bristol, this one infection rate well captured the subsequent baseline epidemic dynamics (slightly increasing in Bristol and Walsall) and, therefore, no change in the infection rate was assumed after that point. The baseline transmission rates in Bristol and Walsall were comparable (0.07–0.21 and 0.09–0.22, respectively), whereas Dundee had a slightly higher baseline transmission risk (0.16–0.39). However, for Dundee, we needed to fit a second increased infection rate (0.36–0.94) to capture the increase in HCV infection prevalence from 2008 to 2014 (using the parameters from the first prevalence fitting step as the initial conditions). This suggests either that the epidemic was not stable in 2008 or that there has been a change in the risk profile of PWID in Dundee that is not fully captured by changes in intervention coverage or the prevalence of high-risk behaviours. *Table 29* in *Appendix 4* and *Figure 18* show the model parameters that were fitted in the model.

### Impact analysis

First, the model was used to estimate the impact of current intervention activities over the next 15 years, from 2016 to 2031. This included the impact of current coverage levels of OST, NSP and HCV infection treatment. To estimate the impact of each intervention, the baseline epidemic projections with these interventions incorporated were compared with what would happen if the effect of these interventions were removed from the start of 2016 (i.e. either the efficacy parameter for a specific intervention was set to one from 2016 or no additional PWID were HCV infection treated). Following this, we also assessed the detrimental impact of current levels of high-risk behaviours. This was evaluated in the same way over 15 years. The impact of each scenario was assessed in terms of the relative change in prevalence and incidence, and the relative change in the number of incident infections and the number of disease-related deaths. Specifically, we investigated how the epidemic in each setting would change from 2016 to 2031 if the following interventions or behaviours had no effect on HCV infection transmission rates:

- > 100% NSP
- OST intervention
- > 100% NSP and OST intervention
- HCV infection treatment of PWID
- all high-risk behaviours.

Following this, we then considered the potential impact to 2031 of increasing the coverage of > 100% NSP from 2016 to 80% or 90% over the next 5 years.


### Sensitivity analysis

The model calibration algorithm involved probabilistic sampling over a large number of the model parameters, and we fit the model across the full uncertainty of the calibration data. The different runs from this model calibration exercise were used to assess those parameters that effected the model projections most. We undertook a linear regression analysis of covariance<sup>109</sup> to determine those parameter uncertainties that contribute most to uncertainty in the 15-year impact of current NSP coverage levels on the relative change in the number of infections. The proportion of each model outcome's sum-of-squares contributed by each parameter was calculated to estimate the importance of individual parameters to the overall uncertainty.


## Results

### Baseline epidemic projections and model validation


In agreement with available recent HCV infection prevalence data up to 2014, we projected a slightly increasing HCV infection prevalence in Bristol and Walsall when fitting prevalence to only the first time point (2004 and 2006, respectively), as shown in *Figure 19*. The increasing HCV infection prevalence in Dundee was obtained by fitting the prevalence to two time points. The incidence of HCV infection calculated from the model in 2014 was used to validate the model and varies between the three settings, with the highest incidence in Dundee [16.8, 95% credible interval (CrI) 10.7 to 24.7 per 100 person-years], which agrees with incidence estimates from NESI (14.3, 95% CI 4.9 to 25.9 per 100 person-years). In Bristol, we project a lower



**FIGURE 19** Impact of each intervention scenario on HCV infection prevalence and incidence in each setting. (a) Bristol incidence; (b) Bristol prevalence; (c) Walsall incidence; (d) Walsall prevalence; (e) Dundee incidence; and (f) Dundee prevalence. The solid line is the median of the baseline model scenario, with the shaded region representing the 95% CrIs around those projections. Error bars in black are data points and those in blue are the ranges used for calibration. py, person-years. (*continued*)



**FIGURE 19** Impact of each intervention scenario on HCV infection prevalence and incidence in each setting. (a) Bristol incidence; (b) Bristol prevalence; (c) Walsall incidence; (d) Walsall prevalence; (e) Dundee incidence; and (f) Dundee prevalence. The solid line is the median of the baseline model scenario, with the shaded region representing the 95% CrIs around those projections. Error bars in black are data points and those in blue are the ranges used for calibration. py, person-years. (*continued*)



**FIGURE 19** Impact of each intervention scenario on HCV infection prevalence and incidence in each setting. (a) Bristol incidence; (b) Bristol prevalence; (c) Walsall incidence; (d) Walsall prevalence; (e) Dundee incidence; and (f) Dundee prevalence. The solid line is the median of the baseline model scenario, with the shaded region representing the 95% CrIs around those projections. Error bars in black are data points and those in blue are the ranges used for calibration. py, person-years.

HCV infection incidence of 6.9 (95% CrI 3.9 to 11.5) per 100 person-years, slightly lower than the most recent HCV infection incidence estimate from 2009 (10.0, 95% CI 9.7 to 14.0 per 100 person-years).<sup>88</sup> In Walsall, we project an even lower HCV infection incidence of 3.4 (95% CrI 1.7 to 6.5) per 100 person-years, corresponding to the low and decreasing prevalence in that setting. Unfortunately, no empirical estimates of HCV infection incidence exist for Walsall against which to compare these estimates.

Over the period from 2016 to 2031, the model suggests that HCV infection prevalence will slightly decrease in Bristol and Walsall, and decrease markedly in Dundee from 36.9% (95% CrI 28.7% to 43.5%) to 10.1% (95% CrI 0.0% to 42.3%). The decreases in all settings are attributable to the use of more effective DAA treatment commencing in 2015, with the larger decrease in Dundee being attributable to treatment already



being scaled up as part of a trial intervention. Over each year, the models project that 32 (95% CrI 21 to 43), 6 (95% CrI 1 to 11) and 14 (95% CrI 9 to 20) HCV-related deaths will occur among PWID and ex-injecting drug users in Bristol, Dundee and Walsall, respectively, with most (> 85%) of these deaths occurring among ex-injecting drug users. Baseline prevalence, incidence and disease-related mortality can be found in *Table 11*.

### Impact of existing interventions

Regardless of setting, removing either or both of NSP and OST would have a large detrimental impact on both prevalence and incidence in all three settings by 2031, as shown in *Figure 19*. As expected, removing both interventions has the biggest effect on the epidemics, with the model suggesting at least a 337% (range 337–1525% between settings) relative increase in incidence by 2031 compared with baseline 2031 levels, a 125% (range 125–166%) relative increase in the number of new HCV infections over the period 2016 to 2031 and a 35% (range 65–636%) relative increase in prevalence compared with baseline projections in all settings from 2016 to 2031. Following this, removing OST has the next biggest impact, resulting in at least a 196% (range 196–1034%) relative increase in incidence, an 86% (range 86–125%) increase in the number of HCV infections and a 46% (range 46–562%) relative increase in prevalence in 2031. The next biggest impact is removing NSP, which increases incidence by at least 35% (range 35–372%) and prevalence by at least 17% (range 17–275%). NSP has a smaller impact than OST because it has lower coverage in each setting and lower efficacy (NSP lowers transmission risk by 41% vs. 59% for OST) as suggested by our pooled analysis. Removing NSP still results in a large relative increase in the number of new HCV infections by 2031, with a 30% (95% CrI 7.0% to 67.0%) increase in Bristol, a 22% (95% CrI 6% to 40%) increase in Walsall and 59% (95% CrI 12% to 219%) increase in Dundee, as seen in *Figure 20*.

Across the cities, a greater relative impact on prevalence and incidence is seen by removing NSP and/or OST in Dundee, then Walsall and, finally, Bristol. Removing NSP and/or OST has the greatest impact in Dundee because HCV infection prevalence and incidence were otherwise decreasing to low levels by 2031, whereas removing the interventions causes prevalence to increase, as seen in *Figure 19*.


Removing treatment of PWID in each setting has similar impacts on prevalence and incidence to removing NSP, as seen in *Figure 19*. However, less impact is seen on the number of new infections, as seen in *Figure 20*. This is explained by treatments lowering incidence indirectly through reducing prevalence, as opposed to directly reducing the incidence of new infections, which is the case for NSP and OST.

### The impact of current high-risk behaviours

When the increased transmission risk associated with homelessness and crack cocaine injecting (or homelessness only in Dundee) is removed, a decrease in incidence and prevalence of HCV infection occurs. The biggest relative decrease is seen in Dundee, where incidence decreases by 99% (95% CrI 86% to 100%) and the number of

**TABLE 11** Baseline scenario characteristics for each setting

Setting	Prevalence 2016 (%), median (95% CrI)	Prevalence 2031 (%), median (95% CrI)	Incidence 2016 per 100 person-years, median (95% CrI)	Incidence 2031 per 100 person-years, median (95% CrI)	Disease-related deaths per year 2016, median (95% CrI)
Bristol	49.8 (37.4 to 62.2)	44.5 (21.0 to 65.6)	6.9 (3.9 to 11.5)	6.1 (2.2 to 12.3)	32 (21 to 44)
Walsall	21.7 (13.4 to 34.2)	21.2 (7.5 to 42.2)	3.4 (1.7 to 6.5)	4.8 (0 to 23.1)	14 (9 to 20)
Dundee	36.7 (29.2 to 43.6)	10.2 (0.02 to 42.3)	16.9 (10.7 to 24.7)	3.3 (0.9 to 8.2)	6 (1 to 11)
CrI, credible interval.					




**FIGURE 20** Impact of removing NSP, OST, NSP and OST or treatment of PWID on the number of new infections from 2016 to 2031 for each setting. The box plots signify the uncertainty (the middle line is the median, the limits of the box are 25% and 75% percentiles, and the whiskers 2.5% and 97.5% percentiles).


new infections decreases by 58% (95% CrI 29% to 77%) between 2016 and 2031 (*Figure 21*). Similarly, the number of new infections decreases by 59% (95% CrI 40% to 75%) in Walsall and 64% (95% CrI 45% to 78%) in Bristol. However, despite Bristol having the highest proportion (> 80%) of high-risk PWID, the smallest relative decrease in prevalence (35%, 95% CrI 22% to 53%) occurs here when we remove the elevated risk among high-risk PWID; this is compared with a 99% (95% CrI 69% to 99.7%) decrease in Dundee and a 45% (95% CrI 28% to 64%) decrease in Walsall. This could be due in part to the longer injecting duration predicted by the model in Bristol, with a median of 15 years injecting in Bristol compared with 8 years in Dundee and Walsall.

### Impact of scaling up needle and syringe programmes

Scaling up > 100% NSP coverage to 80% or 90% has a substantial impact on the number of new infections by 2031, as shown in *Figure 22*. For instance, a large impact is seen in Walsall because of the low current coverage of NSP (21–42%), in which the number of new infections is decreased by 25% (95% CrI 7% to 40%) and incidence decreases by 41% (95% CrI 12% to 61%) when NSP is scaled up to 80% coverage.



**FIGURE 21** Impact of removing transmission risk associated with high-risk behaviour on decreasing the number of new infections from 2016 to 2031 for each setting. The box plots signify the uncertainty (the middle line is the median, the limits of the box are the 25% and 75% percentiles, and the whiskers are the 2.5% and 97.5% percentiles).



**FIGURE 22** Impact of increasing NSPs in each setting on the number of new infections from 2016 to 2031. The box plots signify the uncertainty (the middle line is the median, the limits of the box are 25% and 75% percentiles, and the whiskers 2.5% and 97.5% percentiles).


Conversely, increasing NSP coverage in Bristol and Dundee has less impact because of the higher current coverage in both settings (38–82% in Bristol and 34–79% in Dundee), with the number of infections decreasing by 10% (95% CrI 2.0% to 22%) in Bristol and 26% (95% CrI 6.0% to 48%) in Dundee. Less impact is always seen on prevalence, with an absolute drop of approximately 4% in all three settings.

### Sensitivity analysis

The results of the sensitivity analysis are shown in *Figure 23*. In Bristol and Walsall, the model parameter with the largest percentage contribution to the variability in the relative number of infections averted from current coverage levels of NSP is the efficacy estimate for NSP (which accounts for 41%, 20% and 48% of variation in Bristol, Dundee and Walsall, respectively). In Bristol and Walsall, the next most important input was the 2014 coverage of NSP (32% of variation in Bristol and 39% in Walsall). Conversely, for Dundee, HCV infection prevalence in 2014 had the largest contribution (36%) to the variability, followed by NSP effectiveness, OST effectiveness then NSP and OST effectiveness (20%, 10% and 6%, respectively). In Bristol and Dundee, the population size estimate contributed 3% and 5%, respectively, to the variability. All other parameters and inputs contributed < 5% to the variability in the impact of NSPs on the number of infections averted. The different patterns seen between Bristol/Walsall and Dundee could be attributable to the differences in the fitting procedures for each setting. Dundee required an extra fitting step to calibrate the model to the increasing prevalence from 2008 to 2014 and had a constant population size, which would account for the impact of those parameters. The presence of the OST and OST + NSP effectiveness parameters can be explained by the impact of these parameters when NSP is removed, which results in the OST + NSP effectiveness becoming the same value as the OST effectiveness parameter.

### Conclusions

This analysis for three contrasting UK settings suggests that existing coverage levels of > 100% NSP and OST in combination and separately are currently preventing considerable transmission of HCV infection in these cities, with their combined removal resulting in at least a 125% increase in the number of new HCV infections over the next 15 years. Less impact is achieved from NSP on its own, but in combination with OST, synergistic benefits are generally achieved that increase impact further than would be expected from each intervention separately. Despite the large impact already achieved, our analyses suggest that the impact could be increased further, with a relative decrease in new infections by 2031 of 10–26% if NSP coverage is increased to 80% in all settings. Increasing NSP coverage has a larger effect in low prevalence and coverage settings, such as



**FIGURE 23** Sensitivity analysis results: percentage contribution of the uncertainty in different model parameters to the overall variation in the relative increase in number of infections when NSP is removed (only those aspects with > 3% contribution in any of the settings are shown). (a) Bristol; (b) Walsall; and (c) Dundee.

Dundee where local elimination is a feasible possibility, with incidence decreasing by 99% compared with 2016 levels by 2031. In the other settings, these increases in NSP in parallel with DAA treatments being used at current treatment rates are still likely to reduce incidence considerably (by 29% and 42% in Bristol and Walsall, respectively), but more will be needed to approach local elimination. Conversely, less impact is achieved on prevalence by 2031, with a sustained increase in NSP coverage as well as other interventions being needed to result in large decreases in HCV infection prevalence among PWID if the trend in longer-term injecting continues. Finally, current factors linked to high transmission risk, homelessness and crack cocaine injection should also be considered targets for intervention activities because our projections suggest that if the heightened transmission risk associated with these behaviours is removed it could avert about 60% of HCV infections over the next 15 years.

### **Strengths and limitations**

Our detailed modelling of contrasting settings gives a better understanding of how the impact of interventions vary across the UK, with the use of updated empirical efficacy estimates for OST and NSP consistent with the included systematic review, thereby lending added strength to the results. In addition, our model stratified and calibrated PWID by injecting duration, allowing it to incorporate possible important changes in injecting recruitment and cessation over recent years, thus giving more realism to the model projections.

As with all modelling, there are several limitations. The main limitation is the sparsity of data on how injecting cessation and recruitment has changed; we thus had to extrapolate from imperfect data on size estimates and changes in the sample distributions by injecting duration in successive surveys. Importantly, we incorporated the uncertainty in these parameters, and our model projections were informative despite this. However, better data on these hard-to-quantify parameters would improve the accuracy of our model projections. Second, we did not consider any impact of OST on injecting cessation or mortality rates. Long-term OST use has been shown to increase injecting duration and lower mortality rates,<sup>91</sup> while being associated with increased incidences of temporary cessation.<sup>110</sup> It is possible that the increasing proportion of long-term injectors seen in Bristol and Walsall may in part be due to the high current levels of OST in these settings. Future modelling could consider temporary cessation as well as permanent cessation, with current OST use impacting on the rates of cessation.

Third, we assumed that the whole population of PWID would be eligible for OST, but there is a growing proportion (from 3.9% in 2004 to 12% in 2014) of PWID in the UK who inject non-opioid substances, such as amphetamines, as their main drug.<sup>70</sup> This is likely to have diluted the effect estimates from the pooled analysis, meaning that we may have underestimated the impact of current OST levels on HCV infection incidence. Fourth, we did not model incarceration, which can be associated with HCV infection transmission risk in the UK.<sup>111</sup> The role of incarceration in driving HCV infection transmission in the UK is the focus of current research. Finally, we did not consider IPED injectors in this model because the HCV infection prevalence in this subpopulation of PWID is much lower than psychoactive drug injectors (3.6% HCV antibody prevalence compared with 50%).<sup>70</sup> It is likely that their contribution to the overall HCV infection epidemic in the UK is small.

### **Other evidence and implications**

Other models have looked at the impact of NSP or OST on HCV infection transmission, but have generally lacked empirical efficacy estimates for the effect of these interventions on HCV infection acquisition risk,<sup>79,112–114</sup> or have not considered impact in specific cities parameterised with detailed data.<sup>86</sup> Our modelling extends existing analyses by including detailed context-specific modelling of the impact of OST, NSP and HCV infection treatment, as well as the disabling effect of high-risk behaviours and how it varies across UK settings.

## Summary

Our projections are important for showing how the current impact of interventions vary across settings and where the scale-up of interventions should be targeted. They emphasise the crucial need to avoid any scale-back in the coverage of current interventions, which could result in huge increases in HCV infection transmission across these settings. Despite coverage being high in many settings, the projections also suggest that important benefits could still be achieved from scaling up NSP further, especially in settings with current low coverage levels. In addition, as suggested by other recent modelling analyses,<sup>99,114</sup> scaling up other interventions such as HCV infection treatment could also have a large impact on HCV transmission, although treatment will need to scale up considerably to see a large impact on incident infections. Importantly, strategies need to be devised to tackle or reduce the harms associated with homelessness and crack cocaine injection among PWID, which our modelling suggests is doubling the level of transmission in each setting. Reducing the risk of HCV transmission among these vulnerable subpopulations should be a priority for any strategy attempting to reduce HCV transmission or hoping to achieve HCV elimination, as recently set out by WHO.<sup>115</sup> There is now a realistic possibility to reduce HCV to low levels, even in higher-prevalence settings, and mathematical models could be useful for guiding these efforts.



# Chapter 6 Cost-effectiveness analysis

## Methods

The cost data described in *Chapter 3* were used to populate a cost-effectiveness model to estimate the incremental cost-effectiveness of NSPs in each of the three cities described previously.

### Model calibration

The model was calibrated for each city using survey data from each city (see *Chapter 4* for more detail). The model was used to estimate the cost-effectiveness of existing levels of NSP compared with if they were removed from 2016, with the removal of NSP being simulated for 10 years (2016 to end 2025) and then the subsequent transmission effects simulated for a further 40 years (2026 to end 2065). For the baseline intervention scenario, we assumed that OST and > 100% NSP coverage levels remained at current levels and kept other model parameters constant. In the sub-baseline counterfactual scenario, the lower transmission risk associated with > 100% NSP was set to one, and the transmission risk for current OST and > 100% NSP use was set to the transmission risk associated with just current OST use. This was done for 10 years to investigate the detrimental impact of removing current levels of > 100% NSP in each city. No costs of NSP were assumed over this time. After 10 years, the transmission risks associated with > 100% NSP, and current OST and > 100% NSP were set to baseline levels again to simulate the resumption of NSP activities, with the estimated costs of NSP being included for subsequent years. We calculated the costs and quality-adjusted life-years (QALYs) over two time horizons. First, we calculated costs and QALYs for a further 40 years after NSP was reintroduced, giving a total time horizon of 50 years. We also calculated costs and QALYs for a further 90 years after NSP was reintroduced, giving a total time horizon of 100 years. The numbers of individuals in each category of the model were recorded, and QALYs and costs were attached to each category as appropriate. Both time horizons are presented in the results.

Uncertainty in the underlying parameters was accounted for, such that demographic and epidemiological parameters, disease progression rates, costs and health utilities were randomly sampled from appropriate distributions. For each city, we obtained 1000 matched simulations for the costs and QALYs of the baseline intervention scenario and the sub-baseline counterfactual scenario.

Using the sampled simulation sets, we calculate the total costs and the total QALYs gained for the baseline scenario with NSP coverage, and for the scenario removing NSP services for a period of 10 years. These scenarios are presented as 'NSP' and 'no NSP' respectively for clarity. All future costs and QALYs were discounted using a baseline discount rate of 3.5%.

### Cost data

The fixed city-level cost and cost per needle of NSP programmes was estimated over 1000 iterations, simultaneously varying all parameters described in the costing sensitivity analysis, and these 1000 estimates for costs were input into the model. The number of needles distributed each year was calculated by multiplying the total number of PWID with > 100% NSP coverage from the model by the mean injecting frequency per year (see *Chapter 4* for details). The total NSP cost per year is then the total number of needles distributed per year multiplied by the cost per needle, added to the fixed city-level cost. (The sampled values of the cost per needle and the fixed city-level cost are shown in *Appendix 5, Table 30*.)

To enable use of the model for the cost-effectiveness analyses, HCV infection care costs were assigned to different HCV infection stages in the model. These costs were drawn from previously published estimates of the costs of treatment and care for HCV infection in the UK (see *Appendix 5, Tables 31 and 32* for data used). Detailed estimates of total cost for each disease stage were drawn from the literature and inflated to 2014 GBP using the hospital and community health services index (see *Appendix 5, Table 31* for the



cost values used in the cost-effectiveness model). We assumed that 50% of chronic infections (F0–F3 disease stages) in PWID and ex-injecting drug users are diagnosed and incur a cost. We also assumed that treatment costs for active PWID were higher than those for ex-injecting drug users or non-injecting drug users. Costs associated with the supportive care of compensated cirrhosis were applied to all individuals in that disease stage.

### Effectiveness

Health utility values (QALY weights) are sourced from previous economic evaluations of HCV infection treatment interventions (see *Appendix 5, Table 32*). Following previous analyses, we assume that the baseline quality of life for active injectors is lower than that for ex- or non-injectors. As for the model fitting for the impact analyses, the HCV infection disease utility and costs were sampled for each run.

### Sensitivity analysis

Seven different scenarios were tested in the sensitivity analysis: increasing time horizon to 100 years, no chronic HCV infection disease (F0–F3) stage cost (baseline was 50% of those infected incurred cost), no associated disease cost for chronic HCV infection or compensated cirrhosis disease states (F0–F3 and compensated cirrhosis), a discount rate of 0% for costs and QALYs instead of 3.5%, the same treatment cost for PWID as for ex-injecting drug users; and, finally, assuming a reduction of 50% in the drug cost component of the treatment costs from 2016.

## Results

### Model outputs

*Table 12* shows the total deaths and HCV infections averted through NSP compared with no NSP in each city. Bristol has a median anticipated 21 deaths averted over 50 years and Dundee has a median 23 deaths averted; Walsall has a median anticipated 5.8 deaths averted over the same time horizon. The number of infections averted varies by city, from 93 infections in Walsall to 749 infections in Dundee. Walsall has the smallest prevalence of HCV infection within the injecting population and, therefore, saw the smallest number of deaths and infections averted, despite the fact that the proportion of deaths and infections averted through NSP was similar in each city, as shown in *Chapter 4*. There was wide uncertainty in the outputs in all cities.

*Table 13* shows the total health-related costs incurred over the 50-year time horizon for Bristol, Dundee and Walsall, discounted to reflect their current value. Removing NSPs consistently increases health-related costs across all cities, including costs of health care for early-stage HCV infection, costs for HCV infection treatment among PWID and costs for HCV infection treatment among ex-/non-injecting drug users. These increased costs reflect an increase in HCV infection transmission in the 'no NSP' scenario, including to people who then cease injecting. The costs of NSP are higher in the 'NSP' scenario. In Dundee, this additional cost for NSPs increases the total cost marginally compared with the 'no NSP' scenario; however, in Walsall the total median costs for the 'NSP' scenario are lower than those for the 'no NSP' scenario, despite additional NSP costs. In Bristol, total median costs are the same in both scenarios.

**TABLE 12** Total deaths and infections averted through NSPs, by city

Site	Deaths averted			Infections averted		
	Median	2.5% CrI	97.5% CrI	Median	2.5% CrI	97.5% CrI
Bristol	20.5	4.3	51.1	199.5	42.5	505.2
Dundee	23.1	3.8	57.5	749	119.1	1637.6
Walsall	5.8	1.2	14.9	92.7	22.3	200.5

**TABLE 13** Total health-related costs over 50 years (GBP millions), by city

Setting and health-care category	Projected total health-related costs (£) over 50-year time horizon					
	NSPs			No NSPs		
	Mean	2.5% CrI	97.5% CrI	Mean	2.5% CrI	97.5% CrI
<b>Bristol</b>						
Health-care costs	130.4	60.0	289.8	131.6	60.3	292.6
HCV infection treatment cost	39.9	23.5	58.8	41.1	24.3	60.6
HCV infection treatment PWID cost	9.3	6.6	11.2	9.3	6.7	11.2
NSP cost	6.0	3.7	8.3	3.8	2.3	5.3
OST cost	112.3	86.8	142.5	112.2	86.8	142.4
Total cost	297.8			298.0		
<b>Dundee</b>						
Health-care costs	27.1	5.8	66.5	28.9	6.5	70.3
HCV infection treatment cost	15.5	8.1	28.2	18.7	9.5	31.1
HCV infection treatment PWID cost	12.9	5.5	24.2	16.2	7.3	24.5
NSP cost	2.9	1.6	4.4	1.9	0.5	2.8
OST cost	37.1	32.1	44.3	37.1	32.1	42.3
Total cost	95.4			102.9		
<b>Walsall</b>						
Health-care costs	64.1	31.2	131.5	64.5	31.3	132.3
HCV infection treatment cost	23.3	14.4	34.0	23.9	14.8	34.7
HCV infection treatment PWID cost	1.0	0.8	1.2	1.0	0.8	1.2
NSP cost	3.0	1.6	5.3	1.9	1.0	3.5
OST cost	61.7	38.3	96.5	61.7	38.3	96.5
Total cost	153.1			153.0		

### Cost-effectiveness

Table 14 presents the average total costs, QALYs and incremental cost-effectiveness ratios (ICERs) for the 50-year time horizon. In Bristol and Dundee, providing NSP services is cost-saving; keeping NSP services is estimated to save an average of £137,949 in Bristol and nearly £7.5M over the 50-year time horizon in Dundee. NSPs are also anticipated to contribute 502 and 958 incremental QALYs in comparison to the 'no NSP' scenario in Bristol and Dundee, respectively. In Bristol and Dundee, an additional £10M and £26M, respectively, could be spent on NSP without any additional impact, and NSPs would still fall under the commonly cited willingness-to-pay (WTP) threshold of £20,000 per QALY gained.

In Walsall, the mean incremental costs of the NSP scenario compared with the 'no NSP' scenario are estimated at £115,250. NSPs are expected to contribute 192 incremental QALYs compared with the scenario removing NSPs. The mean incremental cost-effectiveness of NSPs in Walsall is estimated at £601 per QALY gained. Our central estimate for the ICER in Walsall is well below the commonly cited NICE WTP threshold of £20,000–30,000 per QALY gained and, therefore, can be regarded as highly cost-effective. In fact, an additional £3.7M could be spent with no impact, and NSPs would still fall under the £20,000 per QALY threshold. It has recently been suggested that a more appropriate WTP threshold in a UK setting would be £13,000, as this is the rate at which the NHS is able to turn costs into QALYs.<sup>116</sup> Our central estimate for Walsall also falls well below this threshold, indicating a high return on investment in the current NHS setting.

**TABLE 14** Cost-effectiveness results: average total costs, QALYs and ICERs for baseline NSPs compared with no NSPs over a 50-year time horizon


Setting	Total cost (£)	Incremental cost (£)	Total QALYs	Incremental QALYs	ICER (£)	Net monetary benefit (£)
Bristol						
No NSP	297,970,375		187,663			
NSP	297,832,426	−137,949	188,165	502	−274.76	10,179,353
Dundee						
No NSP	102,891,384		124,208			
NSP	95,420,292	−7,471,093	125,165	958	−7799.19	26,629,720
Walsall						
No NSP	153,007,364		142,702			
NSP	153,122,615	115,250	142,894	192	600.68	3,722,082

Table 15 presents the average total costs, QALYs and ICERs for the 100-year time horizon. Over the 100-year time horizon, NSPs are cost-saving in all cities, saving £687,351, £8,800,186 and £177,778 in Bristol, Dundee and Walsall, respectively, and contributing 699, 1326, and 278 QALYs, respectively, in that time. Using the lower WTP threshold of £20,000 per QALY gained, this represents a net monetary benefit of > £14.6M in Bristol, £35M in Dundee and £5.7M in Walsall over the 100-year time horizon.


The ICERs for Bristol, Dundee and Walsall over 1000 baseline runs for the 50-year time horizon are shown in Figures 24–26. All cities show some uncertainty in the ICER; however, across all cities there were no estimates in the bottom-left quadrant (indicating that NSPs are dominated). In Dundee, 99% of iterations are located in the bottom-right quadrant, indicating that NSPs are cost-saving. In Bristol, 45% of iterations are cost-saving, and in Walsall, 40% of iterations are cost-saving.

**TABLE 15** Cost-effectiveness results: average total costs, QALYs and ICERs for baseline NSPs compared with no NSPs over a 100-year time horizon


Setting and intervention scenario	Total cost (£)	Incremental cost (£)	Total QALYs	Incremental QALYs	ICER (£)	Net monetary benefit (£)
Bristol						
No NSP	334,009,891		225,720			
NSP	333,322,534	−687,357	226,419	699	−982.81	14,675,014
Dundee						
No NSP	114,678,850		151,461			
NSP	105,878,665	−8,800,186	152,787	1326	−6634.97	35,326,845
Walsall						
No NSP	173,478,543		176,097			
NSP	173,300,765	−177,778	176,375	278	−638.61	5,745,412



**FIGURE 24** Incremental cost-effectiveness: Bristol.




**FIGURE 25** Incremental cost-effectiveness: Dundee.




**FIGURE 26** Incremental cost-effectiveness: Walsall.

### Sensitivity analysis


Figures 27–29 show cost-effectiveness acceptability curves over a range of sensitivity analysis scenarios for Bristol, Dundee and Walsall, respectively. As indicated in the figures, our model was relatively robust to assumptions, and the likelihood of cost-effectiveness was not substantially altered in the sensitivity analysis scenarios. In the base case, 96% of iterations in Bristol, 100% of iterations in Dundee and 95% of iterations in Walsall are located below the WTP threshold of £13,000 per QALY saved. Using the more commonly cited lower-bound threshold of £20,000 per QALY saved, 98% of iterations from Bristol, 100% of iterations from Dundee and 98% of iterations from Walsall are below the threshold.



**FIGURE 27** Cost-effectiveness sensitivity analysis: Bristol.



**FIGURE 28** Cost-effectiveness sensitivity analysis: Dundee.



**FIGURE 29** Cost-effectiveness sensitivity analysis: Walsall.

The sensitivity analysis scenario with the greatest impact on the ICER assumes a discount rate of 0% for both costs and QALYs. Under this scenario, 86% of iterations in Bristol, 100% of iterations in Dundee and 85% of iterations in Walsall are below a WTP threshold of £0. The scenario reducing HCV infection treatment drugs to half of their listed price returns the lowest proportion of iterations below any given WTP threshold overall. However, even under this scenario, the large majority of iterations are below a WTP threshold of £20,000 (98% in Bristol, 100% in Dundee and 97% in Walsall).

## Conclusions

Overall, we found NSPs to be highly likely to be cost-effective at low WTP thresholds and, in fact, to be cost-saving in some settings. In both Bristol and Dundee, the large majority of iterations from the model were cost-saving, and in Walsall the large majority of iterations were considerably below a WTP threshold of £13,000 per QALY gained.

The difference in ICERs between cities is likely to be driven partly by population size and HCV infection prevalence in each study setting. Walsall had the lowest population of people injecting drugs citywide, so NSPs had a lesser impact in the form of a reduction in infections and deaths and, therefore, had less of an overall impact on cost. There was also a larger amount of uncertainty in the NSP costs for this city owing to the fact that the out-of-hours pharmacy had only recently begun providing services at the time of data collection; this generated substantial uncertainty, as we extrapolated observations from the past month to an annual estimate.

The unit costs presented do not reflect the substantial gains from averting other health problems. Most importantly, there is substantial evidence that NSPs are highly effective in averting HIV infection.<sup>13</sup> Incorporating HIV infections averted through NSPs into our model would further increase the number of QALYs averted through NSPs, thereby increasing the cost-effectiveness of our estimates. These estimates also do not reflect the supportive nature of transactions, or any other measures of quality. Quality of transactions will vary substantially across sites and may be reflected in the costs; for example, a service might take more time per visit if practitioners engage the client in discussions about their injecting behaviour and safe practices. Services offering a wider range of injecting equipment may also encounter higher supply costs; however, this wide range of supplies may draw additional clients in or improve the quality of services. For example, a number of fixed sites are looking into offering so-called 'crack packs' as a harm-reduction mechanism to encourage clients to smoke rather than inject drugs. Similarly, two fixed sites offered water for injection in order to enable clients to use clean water when injecting heroin; this will increase the overall supply costs but will possibly reduce the costs related to injection-site infections.

Furthermore, fixed-site NSPs also commonly provide other services such as wound care, vaccination, links to social and welfare services, and psychosocial support. Similarly, the drop-in centre offered other services, including a safe place, psychosocial support, food and bedding for rough sleepers, and a sense of community. Many of these benefits have not been evaluated for their effectiveness, but are likely to contribute to well-being among PWID. A co-financing approach whereby funding is split across the multiple sectors benefiting from an intervention, such as that suggested by Remme *et al.*,<sup>117</sup> would further improve WTP for NSPs, for example across the health-care and social care sectors in the UK.

Finally, this analysis does not investigate the cost-effectiveness of OST in detail, as it does for NSP. Costs for OST were not collected in detail as they were for NSP and were instead drawn from published unit cost estimates from the Personal Social Services Research Unit in the UK. Other benefits of OST, such as reducing drug-related mortality or incarceration and social costs, have also not been included in the model. More expansive analyses have shown OST to be cost-saving when these other outcomes are included. Further research to evaluate the combined impact and cost-effectiveness of both NSP and OST across both social care and health-care sectors would fill a major gap in current understanding.

This report presents model projections rather than empirical evidence, and caution is advised in interpretation of our findings. Key limitations relate to the simplifying assumptions of the model and uncertainty around several parameters. There was some uncertainty in our estimates of the cost of NSP programmes and in the anticipated impact for all cities. This was partly due to uncertainty in the primary data collection in terms of costs and outputs. This was especially true for pharmacies, where detailed records of needle exchanges are not usually kept. There was also substantial uncertainty in NSP coverage estimates in the UK. The pooled analysis (see *Chapter 2*) suggested that estimates of coverage varied widely, with a median coverage of 2.5 needles distributed per injection (interquartile range 1.4–4.7) reported in community-recruited surveys of PWID in Leeds but a median of 1 (interquartile range 0.48–2.5) from the UAMP survey, which primarily recruits from NSPs and low-threshold treatment settings. Coverage estimates per site were presented at the National Needle Exchange Forum annual meeting in November 2014, and responses from practitioners suggested that coverage estimated through community surveys was far higher than reported by services.

Nonetheless, this modelling exercise indicates that NSP services are highly likely to be cost-effective at almost any WTP threshold and, in some settings, are cost-saving. Policies to ensure that NSPs can be accessed widely alongside the provision of OST are needed, and obstacles preventing the concurrent use of both NSP and OST could be removed to maximise the reduction in HCV infection transmission. Further research is also needed to improve our understanding of the mechanisms through which NSPs and OST achieve their effect and of the optimum contexts to support their implementation.





## Chapter 7 Conclusions and recommendations

**A**lthough there is good evidence that NSPs and OST in combination reduce injecting risk behaviours and some evidence to show their impact on HIV incidence, there is little evidence for their impact on HCV infection incidence among PWID. There have been no economic evaluations of NSPs undertaken in Western Europe and few have considered the costs saved as a result of care and treatment being averted. All existing studies have relied on weak measures of NSP effectiveness, with most using changes in self-reported risk behaviour, which can be biased. This project filled a gap in the evidence by attempting to provide more robust estimates of the efficacy of NSP and OST on reducing the risk of HCV infection transmission, and an assessment of the probable impact of existing coverage levels of NSPs and changes in the extent of provision. It also provided the first assessment of the costs and cost-effectiveness of needle and syringe provision in UK, and ICERs associated with increasing coverage on HCV infection transmission among PWID.

### Opioid substitution therapy and needle and syringe programme efficacy estimates

Primary meta-analysis of 12 observational studies adjusting for key confounders enrolling 5910 anti-HCV negative participants showed that the current use of OST compared with no intervention reduced the risk of HCV infection acquisition by 50% (RR 0.50, 95% CI 0.40 to 0.63). The intervention effect is strong, but the evidence is considered to be of low quality because it was derived from observational studies with serious risk of bias. Nonetheless, the findings were robust to sensitivity analyses excluding studies judged to be at critical risk of bias, studies drawing on unpublished data, case-control and cross-sectional studies reporting only baseline data, and studies reporting only unadjusted estimates. There also was no evidence of publication bias. All of these sensitivity analyses showed a statistically significant benefit of OST.

A few studies reported other types of exposure to OST. Three studies reported past exposure to OST and three reported interrupted OST use [one study measuring OST use for detoxification and two studies measuring high dosage ( $\geq 60$  mg) or low dosage (1–59 mg) of methadone for daily use]. Among these exposures, only high dosage of OST was associated with a reduction in risk of HCV infection acquisition.

Primary meta-analysis of seven observational studies pooling unadjusted estimates and enrolling 5669 anti-HCV negative participants showed weak and low-quality evidence that NSP exposure did not reduce the risk of HCV infection acquisition. This effect remained consistent in sensitivity analyses. After removing studies from North America, high NSP coverage in Europe was associated with a 61% reduction in HCV infection acquisition risk (RR 0.39, 95% CI 0.24 to 0.64) with less heterogeneity ( $I^2 = 0\%$ ;  $p = 0.428$ ).

There was moderate-quality evidence for the impact of combined high coverage of NSP and OST from studies comprising 3356 anti-HCV negative participants, which suggested a 71% reduction in the risk of HCV infection acquisition (RR 0.29, 95% CI 0.13 to 0.65). There were insufficient data to conduct a sensitivity analysis with this intervention group. A summary of key findings and quality of evidence is presented in *Table 3*.

Findings from a pooled analysis of full harm reduction compared with minimal exposure reduced the risk of injecting with a used needle/syringes by 50% (AOR 0.5, 95% CI 0.38 to 0.62), as well as reuse of the same needle/syringe for injecting by 40% (AOR 0.59, 95% CI 0.40 to 0.88) and frequency of injecting. There was weaker evidence for an association with injecting-site infections or shared used of filters and spoons for drug preparation. Full harm reduction was associated with twice the odds of testing for both HCV and HIV (AOR 1.9, 95% CI 1.56 to 2.23 and AOR 1.9 95% CI 1.6 to 2.20, respectively). Combining estimates of NSP coverage from the systematic review with two data sets<sup>69,70</sup> not already represented in the review strengthened the evidence for the effect of high NSP coverage on reducing the risk of HCV infection acquisition to 39% (RR 0.61, 95% CI 0.43 to 0.87) with moderate heterogeneity ( $I^2 = 30\%$ ;  $p = 0.189$ ).

## Costs of needle and syringe programme provision through different modalities

Evidence showed a degree of variation in costs across the three different commissioning areas evaluated; variation in cost and outputs was observed across fixed sites and pharmacies. The primary cost driver in most settings was the cost of supplies, which accounted for an average of 60% of total costs across sites (range 28–78%). This was followed in most cases by administrative and overhead costs, which accounted for 9–28% of total costs. There was some considerable uncertainty in our estimates owing to the fact that cost and output data on NSP distribution are not routinely collected for some distribution modalities within the UK.

The difference in costs is likely to be driven partly by the type of needle distribution and the ease of access to needles for PWID. We observed a large variation in the number of visits per user across cities and in the number of needles distributed at each visit. A higher number of visits per person in the injecting population citywide did appear to increase the costs of distribution, suggesting that distributing a greater number of needles in fewer visits may be more efficient than restricting the number of needles distributed at each visit, assuming that there is demand for greater quantities of needles within a visit.

## Cost-effectiveness of needle and syringe programme provision

Overall, we found that needle and syringe exchange services are highly likely to be cost-effective at almost any WTP threshold and, in fact, are cost-saving in some settings, despite some uncertainty in total outputs. Under the 50-year time horizon, in Dundee the large majority of iterations from the model were cost-saving, and in Bristol and Walsall the large majority of iterations were below a WTP threshold of £13,000 per QALY gained. Under the 100-year time horizon, NSP services in all three cities were cost-saving.

The difference in cost-effectiveness between cities is also likely to be driven partly by population size and HCV infection prevalence in each study setting. Walsall had the lowest population of people injecting drugs citywide, so a reduction in infections and deaths had less of an overall impact on cost-effectiveness. There was also greater uncertainty in the NSP costs for this city.

These cost-effectiveness estimates do not reflect the substantial gains from averting other health problems associated with injecting drug use, including HIV and other infections. Previous research has indicated that NSPs are highly effective in averting HIV infection; incorporating these health gains would substantially improve cost-effectiveness.

## Impact modelling of needle and syringes programmes and opioid substitution therapy

Regardless of setting, removing either or both of NSP and OST would have a large detrimental impact on both prevalence and incidence of HCV infection in all three settings by 2031. As expected, removing both interventions has the biggest effect on the epidemics, with the model suggesting at least a 109% relative increase in incidence, a 51% relative increase in the number of new HCV infections and a 23% relative increase in prevalence being projected in all settings from 2016 to 2031. Following this, removing OST has the next biggest impact, resulting in at least a 59% relative increase in incidence, a 31% increase in the number of HCV infections and a 14% relative increase in prevalence by 2031. This is followed by removing NSPs, which increases relative incidence by at least 8% and prevalence by at least 3%. NSP has a smaller impact than OST because it has lower coverage in each setting, and lower efficacy (NSP lowers transmission risk by 41% vs. 59% for OST), as suggested by our pooled analysis. However, removing NSPs still generally results in a large relative increase in the number of new HCV infections, with a median increase of 32% (95% CrI 7% to 71%) in Bristol, 23% (95% CrI 6% to 43%) in Walsall and 61% (95% CrI 12% to 219%) in Dundee.

Scaling up > 100% NSP coverage to 80% or 90% has a substantial impact on the number of new infections by 2031. The largest relative impact is seen in Walsall, where the number of new infections is decreased by 27% (95% CrI 7% to 43%) and incidence decreases by 40% (95% CrI 11% to 59%) when NSP is scaled up to 80% coverage. This is due to the low current coverage of NSP (21–42%) and the low prevalence of HCV infections in Walsall. Increasing NSP coverage from the current level of between 38% and 80% in Bristol up to 80% coverage from 2021 onwards, results in a decrease in actual prevalence of 3% (95% CrI 0.7% to 6.9%) by 2031, corresponding to a relative decrease of 6% (95% CrI 1% to 14%); however, the number of infections is reduced by 11% (95% CrI 2% to 24%).

## Limitations

We have discussed individual limitations of the methods separately in each of the results chapters. Here, we discuss some overarching limitations that cross all the methods and that stem from the complex nature of NSPs and OST that do not lend themselves to evaluation through traditional evaluation study designs. This produced the following limitations.

First, the evidence synthesised in the systematic review was drawn from observational studies. The ACROBAT-NRSI tool that we applied to assess the risk of bias<sup>28</sup> assesses studies according to seven domains [(1) confounding, (2) selection bias, (3) measurement of interventions, (4) departures from intervention, (5) missing data, (6) measurement of outcomes and (7) selection of reported results] to give an overall risk of bias, which can be classified into four categories (ranging from low to critical). A study categorised as being at low risk of bias would be comparable to a well-performed randomised trial, whereas one that is at critical risk is defined as being too problematic to provide any useful evidence and should be excluded from the synthesis. It is worth noting that observational studies are unlikely to be rated as being at 'low' risk of bias because they will always score poorly on the confounding domain, as it is impossible to ensure that an observational study has adjusted for all possible residual confounding. Assessing quality of study designs alongside RCTs as a gold standard reduces the strength of the assertions that we can make about observational evidence. The use of the GRADE system to assess the overall quality draws heavily on the risk-of-bias assessment, further reducing confidence in the strength of the evidence. Many of the studies included in the systematic review were assessed as being at severe risk of bias and only two were judged as being at moderate overall risk of bias. It is questionable how appropriate it is to apply this quality assessment system to complex interventions such as NSP and OST, which rely on observational study designs to measure effect. Individual random allocation to the intervention would be unethical, as there is sufficient evidence of their effectiveness in relation to other adverse health outcomes. Other reviews conducted outside Cochrane that do not assess quality against a RCT as a gold standard conclude that there is much stronger evidence of effect, although they present comparable results and are drawn from comparable study designs.<sup>17</sup>

Second, it is clear from both the systematic review and the pooled analysis that there are difficulties in accurately measuring the use of NSPs. We used a simple definition of NSP use, encompassing coverage that requires correct recall of frequency of injecting and the numbers of needles/syringe obtained in the same time period. It is clear that the use of NSPs purely for obtaining clean needles/syringes oversimplifies its benefits for PWID. This definition does not consider any of the other engagement programmes delivered by the fixed-site NSP services, such as one-to-one support, sexual health services, help with housing, welfare benefits, legal advocacy or other social welfare issues. These linked support services are key to bringing people into the NSP and providing the necessary enabling environment for both participants and providers to reduce behaviours that lead to HCV infection. The oversimplification of the use of NSPs may further explain the weaker efficacy estimates that we found in the pooled analysis and systematic review. This has subsequent implications for the mathematical modelling that estimated the impact of NSPs on HCV infection transmission, because the modelling estimates are only as strong as the parameters on which the model draws. These additional services were not evaluated in the cost-effectiveness analysis but are likely to contribute to well-being among PWID and to further improve WTP.

Finally, another limitation of the project was that we set out to consider strategies for achieving improved coverage of the interventions, including different methods of delivery, and to consider this as part of the cost-effectiveness analysis. However, we were unable to source any estimate on the potential effect of strategies to improve coverage in order to parameterise the model and, thus, we were unable to do this.

## Patient and public involvement

People who inject drugs and NSP/OST service providers were consulted on the research at several stages of the project. We convened an advisory group consisting of members of the National Needle Exchange Forum, Addaction and the Hepatitis C Trust, who we met to consult on the study design and emerging findings. Through close consultation with them, we selected the NSP sites across the UK in which to conduct the costing analysis. These sites were selected to represent a range of NSP delivery modalities, different types of injecting drug use and epidemiology of HCV infection, as well as being driven by pragmatic reasons and the availability of data. Preliminary findings of the pooled analysis and the costing analysis were also presented at the annual meeting of the National Needle Exchange Forum, attended by NSP employees and service users. They provided some feedback on the initial findings and commented on the plausibility of our NSP coverage estimates derived from the pooled analysis and for use in the impact modelling. Further consultation on the findings of the costing analysis and results of the systematic review were elicited from each of the collaborating sites (Bristol, Dundee and Walsall) through sites visits. As well as receiving feedback on the findings, we sought opinion on appropriate strategies for scale-up from staff and service users. However, further input from PWID would have been beneficial and its absence should be recognised as a limitation of the project.

## Implications for service and local decision-makers

Findings emphasise the crucial need to avoid any scale-back in the coverage of current interventions, which, if it occurred, could result in huge increases in HCV infection transmission across these settings. Despite NSP and OST coverage being high in many settings, model projections also suggest that important benefits could still be achieved from scaling up NSP further, especially in settings with current low coverage levels. NSPs are neglected in most countries by government officials and funders, and are often underprioritised by drug treatment organisations.<sup>23</sup> This can be seen clearly in the UK, where priorities have shifted to treatment and recovery interventions, and these policies need to be addressed to prioritise harm reduction and the provision of NSPs and OST.<sup>118,119</sup> Policies to ensure that NSPs can be accessed widely alongside provision of OST are needed. Policies that insist on the cessation of injection to qualify for OST prescriptions could be stopped to encourage ongoing use of NSPs alongside OST. Evidence shows that the co-location of NSPs with OST provision services can act as a disincentive to the use of NSPs. Preventing the concurrent use of both NSP and OST needs to be removed to maximise reduction in HCV infection transmission.

Strategies are needed to reduce the harms associated with homelessness and crack cocaine injection among PWID, which our modelling suggests is doubling the level of transmission in each setting. Reducing the risk of HCV infection transmission among these vulnerable subpopulations should be a priority for any strategy attempting to reduce HCV infection transmission or hoping to achieve HCV infection elimination as recently set out by WHO.<sup>115</sup>

## Research priorities

Given the body of evidence demonstrating the effectiveness of OST and NSPs in reducing the transmission of HCV and HIV shown here and elsewhere,<sup>16,17</sup> research needs to turn to understanding how NSPs and OST can be most effective and efficient in responding to HIV/HCV and the other health needs that PWID have. Improving our understanding of the mechanisms through which NSPs and OST achieve their effect

and the optimum contexts in which to support their implementation is integral to reducing the health inequalities experienced by PWID in the UK and internationally.

We know that the effectiveness of NSP varies by geographical location, and without the provision of counselling, education and drug treatment services including OST, NSPs are not sufficient to reduce epidemics of HIV and HCV infection among PWID, even when sufficient clean needles are distributed to cover each injection.<sup>120</sup> There is a need to understand the pathways between contextual factors and mechanisms of service delivery, and the extent to which these influence effectiveness across different outcomes. This is particularly relevant in the UK in the current austerity climate and ongoing financial pressure on health and social care services. Further research on what happens to distributed needles/syringes, how much wastage there is and whether it is better to distribute single needle/syringes or packs is needed. Better information on this would facilitate decision-making around service provision and improve efficiency. There is also a need to improve the understanding of the ways in which the coverage of NSPs might be expanded and the potential impact of these various methods of expanding coverage.

Finally, routine data collection on costs associated with NSP provision is needed to reduce uncertainty in NSP costings and to facilitate cost-effective analyses incorporating costs associated with other health gains that NSPs bring. Particularly in pharmacies, there is currently little tracking of the numbers and types of patients accessing needle exchange.



# Acknowledgements

We would like to thank Craig Moss from Addaction; Rachel Ayres, Jane Neale, Joseph Fisher and Tracy Chamberlain from the BDP; Ingrid Hainey and Mike Burns from CAIR Scotland, Dundee, who were our key collaborators in Bristol, Dundee and Walsall for facilitating data collection for the costing analysis and who provided ongoing feedback on the study design and findings. We would also like to thank Jamie Bridge from the National Needle Exchange Forum, and Charles Gore and Grace Everest from the Hepatitis C Trust who advised on the selection of NSP sites and provided critical insights into the analyses. They are currently reviewing the policy brief and advising on future dissemination strategies.

## Contributions of authors

**Lucy Platt, Matthew Hickman and Peter Vickerman** devised the overall study design.

**Lucy Platt**, with help from **Matthew Hickman, Vivian Hope, Lisa Maher and Peter Vickerman**, conducted the pooled analysis.

**Jenny Iversen and Alison Munro** cleaned data sets for inclusion in the pooled analysis, and with **Avril Taylor** commented on findings and helped with the interpretation of the results.

**Vivian Hope and John Parry** were responsible for the reanalysis of the DBSs to provide measures of new HCV infection cases.

**Lucy Platt**, with help from **Matthew Hickman, Sharon Hutchinson, Lisa Maher and Peter Vickerman**, conducted the systematic review.

**Sedona Sweeney and Lorna Guinness** were responsible for the collection of NSP costing data as well as for the write up and interpretation of the cost-effectiveness analysis.

**Noel Craine and Josie Smith** advised on the collation of costing data.

**Zoe Ward and Peter Vickerman** developed and parameterised the mathematical model for use in the impact modelling and cost-effectiveness analysis.

**Lucy Platt** led the write up of the report with individuals leading on specific chapters including the systematic review and pooled analysis (**Lucy Platt**), the costing analysis and cost-effectiveness (**Sedona Sweeney**), and the impact modelling (**Zoe Ward and Peter Vickerman**). All authors commented on a draft of the report.

## Publications

Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, *et al.* Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. *Cochrane Database Syst Rev* 2016;**1**:CD012021.

Platt L, Minozzi S, Reed J, Vickerman P, Hogan H, French C, *et al.* Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis [published online ahead of print 11 September 2017]. *Addiction* 2017.



Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, *et al.* Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs [published online ahead of print 18 September 2017]. *Cochrane Database Syst Rev* 2017.

### Planned publications

Platt L, Vickerman P, Hope V, Ingle SN, Craine J, Iversen A, *et al.* The effect of needle/syringe provision and opiate substitution therapy on HCV incidence: update on a pooled analysis from the UK and Australia. *Addiction* 2016.

Sweeney S, Ward Z, Platt L, Guinness L, Hickman Smith JM, Ayres R, *et al.* Cost-effectiveness of needle and syringe provision to prevent transmission of HCV.

Ward Z, Platt L, Sweeney S, Hutchinson S, Hickman M, Smith J, *et al.* Impact of current and scaled up levels of needle and syringe programmes and Opiate substitution therapy in three UK settings.

### Policy brief

Preventing Hepatitis C: the role of needle syringe programmes and opiate substitution therapy.

### Conference dissemination

Sweeney S, Ward Z, Platt L, Hope V, Maher L, Hutchinson S, *et al.* *The Cost-Effectiveness of Needle and Syringe Provision in Preventing Transmission of Hepatitis C Virus in People who Inject Drugs*. Public Health England Research and Applied Epidemiology Conference, Warwick, UK, March 2017.

Ward Z, Platt L, Sweeney S, Hope V, Maher L, Hutchinson S, *et al.* *Impact of Current and Scaled Up Levels of Needle and Syringe Programmes and Opiate Substitution Therapy in Three UK Settings*. Fifth International Symposium on Hepatitis Care in Substance Users, Oslo, Norway, September 2016.

Platt L, Reed J, Minozzi S, Hickman M, French C, Hope V, *et al.* *Effectiveness of Needle/Syringe Programmes and Opiate Substitution Therapy in Preventing HCV Transmission Among People who Inject Drugs*. International Harm Reduction Conference, Kuala Lumpur, Malaysia, 2015.

Platt L, Reed J, Minozzi S, Hickman M, French C, Hope V, *et al.* *Effectiveness of Needle/Syringe Programmes and Opiate Substitution Therapy in Preventing HCV Transmission Among People who Inject Drugs*. Fourth International Symposium on Hepatitis Care in Substance Users, Sydney, NSW, Australia, October 2015.

Platt L. *Effectiveness of NSPs and OST on HCV Incidence*. National Needle Exchange Forum, High Wycombe, UK, December 2014.

### Data sharing statement

All data will be made available following publication in peer-reviewed journals on request to the corresponding author (lucy.platt@lshtm.ac.uk).

All data requests should be submitted to the corresponding author (lucy.platt@lshtm.ac.uk) for consideration. Access to anonymised data may be granted following review.

# References

1. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. *Addiction* 2012;**107**:1057–65. <http://dx.doi.org/10.1111/j.1360-0443.2011.03765.x>
2. Strathee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, Hankins CA. HIV and risk environment for injecting drug users: the past, present, and future. *Lancet* 2010;**376**:268–84. [http://dx.doi.org/10.1016/S0140-6736\(10\)60743-X](http://dx.doi.org/10.1016/S0140-6736(10)60743-X)
3. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. *Addiction* 2010;**105**:844–59. <http://dx.doi.org/10.1111/j.1360-0443.2009.02888.x>
4. NICE. *Needle and Syringe Programmes (2009)*. London: NICE; 2014.
5. Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. *Drug Alcohol Depend* 2007;**89**:214–22. <https://doi.org/10.1016/j.drugalcdep.2006.12.035>
6. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. *J Acquir Immune Defic Syndr* 1992;**5**:1116–18.
7. Tilson H, Aramrattana A, Bozzette SA. *Preventing HIV Infection Among Injecting Drug Users in High-risk Countries: An Assessment of the Evidence*. Washington, DC: Institute of Medicine; 2007.
8. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. *Cochrane Database Syst Rev* 2011;**8**:CD004145. <http://dx.doi.org/10.1002/14651858.CD004145.pub4>
9. Vormo H, Sokero P, Aaltonen M, Turtiainen S, Hughes LA, Savolainen J. Participation in opioid substitution treatment reduces the rate of criminal convictions: evidence from a community study. *Addict Behav* 2013;**38**:2313–16. <http://dx.doi.org/10.1016/j.addbeh.2013.03.009>
10. Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. *Cochrane Database Syst Rev* 2013;**2**:CD003409. <http://dx.doi.org/10.1002/14651858.CD003409.pub4>
11. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. *Cochrane Database Syst Rev* 2003;**3**:CD002208. <http://dx.doi.org/10.1002/14651858.CD002208>
12. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. *AIDS* 1999;**13**:1807–18. <https://doi.org/10.1097/00002030-199910010-00002>
13. Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. *A Review of the Effectiveness and Cost-effectiveness of Needle and Syringe Programmes for Injecting Drug Users*. Liverpool: Centre for Public Health, Liverpool John Moores University; 2008.
14. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M, Amsterdam Cohort. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. *Addiction* 2007;**102**:1454–62. <https://doi.org/10.1111/j.1360-0443.2007.01912.x>

15. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. *AIDS* 2001;**15**:1329–41. <https://doi.org/10.1097/00002030-200107270-00002>
16. Aspinall E, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, *et al.* Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. *Int J Epidemiol* 2014;**43**:235–48. <https://doi.org/10.1093/ije/dyt243>
17. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, *et al.* Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. *BMJ* 2012;**345**:e5945. <http://dx.doi.org/10.1136/bmj.e5945>
18. Wodak A, Cooney A. *Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV/AIDS Among Injecting Drug Users*. Geneva: WHO; 2004.
19. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. *J Infect Dis* 2011;**204**:74–83. <http://dx.doi.org/10.1093/infdis/jir196>
20. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, *et al.* The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. *Addiction* 2011;**106**:1978–88. <http://dx.doi.org/10.1111/j.1360-0443.2011.03515.x>
21. Vickerman P, Miners A, Williams J, editors. *Assessing the Cost-effectiveness of Interventions Linked to Needle and Syringe Programmes for Injecting Drug Users: An Economic Modelling Report*. NICE; 2008. URL: [www.nice.org.uk/nicemedia/pdf/NSPEconomicmodellingFullreportJune08.pdf](http://www.nice.org.uk/nicemedia/pdf/NSPEconomicmodellingFullreportJune08.pdf) (accessed 1 March 2016).
22. Committee on the Prevention of HIV infection among Injecting Drug Users in High-Risk Countries. *Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence*. Washington, DC: Institute of Medicine; 2007.
23. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, *et al.* HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. *Lancet* 2010;**375**:1014–28. [http://dx.doi.org/10.1016/S0140-6736\(10\)60232-2](http://dx.doi.org/10.1016/S0140-6736(10)60232-2)
24. Lurie P. Invited commentary: le mystère de Montréal. *Am J Epidemiol* 1997;**146**:1003–6. <https://doi.org/10.1093/oxfordjournals.aje.a009227>
25. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. *Lancet* 2010;**376**:285–301. [http://dx.doi.org/10.1016/S0140-6736\(10\)60742-8](http://dx.doi.org/10.1016/S0140-6736(10)60742-8)
26. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, *et al.* Needle syringe programmes and opiate substitution therapy for preventing hepatitis C transmission in people who inject drugs [published online ahead of print 18 September 2017]. *Cochrane Database Syst Rev* 2017. <http://dx.doi.org/10.1002/14651858.CD012021>
27. Platt L, Minozzi S, Reed J, Vickerman P, Hogan H, French C, *et al.* Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis [published online ahead of print 11 September 2017]. *Addiction* 2017.
28. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;**343**:d5928. <http://dx.doi.org/10.1136/bmj.d5928>

29. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, *et al.* GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;**64**:383–94. <http://dx.doi.org/10.1016/j.jclinepi.2010.04.026>
30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;**336**:924–6. <http://dx.doi.org/10.1136/bmj.39489.470347.AD>
31. Schünemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, *et al.* An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. *Am J Respir Crit Care Med* 2006;**174**:605–14. <https://doi.org/10.1164/rccm.200602-197ST>
32. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, *et al.* Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**:1490–4. <https://doi.org/10.1136/bmj.328.7454.1490>
33. Bruneau J. *Analyses Received from Julie Bruneau and her Study Team*. Unpublished data set; 2015.
34. Mehta S. *Analyses Received from Shruti Mehta and her Study Team*. Unpublished data set; 2015.
35. Page K. *Analyses Received from Kim Page and her Study Team*. Unpublished data set; 2015.
36. Judd A. *Data Set Obtained from Ali Judd and Analyses Conducted by the Review Team*. Unpublished data set; 2015.
37. Aitken CK, Agius PA, Higgs PG, Stoové MA, Bowden DS, Dietze PM. The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs. *Epidemiol Infect* 2017;**145**:796–801. <https://doi.org/10.1017/S0950268816002892>
38. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. *Addiction* 2006;**101**:1499–508. <https://doi.org/10.1111/j.1360-0443.2006.01543.x>
39. Craine N, Hickman M, Parry JV, Smith J, Walker AM, Russell D, *et al.* Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. *Epidemiol Infect* 2009;**137**:1255–65. <http://dx.doi.org/10.1017/S0950268809000212X>
40. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. *Addiction* 1997;**92**:999–1005. <https://doi.org/10.1111/j.1360-0443.1997.tb02979.x>
41. Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. *Am J Public Health* 1995;**85**:1531–7. <https://doi.org/10.2105/AJPH.85.11.1531>
42. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. *Am J Epidemiol* 1999;**149**:203–13. <https://doi.org/10.1093/oxfordjournals.aje.a009792>
43. Holtzman D, Barry V, Ouellet LJ, Des Jarlais DC, Vlahov D, Golub ET, *et al.* The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994–2004. *Prev Med* 2009;**49**:68–73. <http://dx.doi.org/10.1016/j.ypmed.2009.04.014>
44. Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, *et al.* Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. *J Viral Hepat* 2011;**18**:262–70. <http://dx.doi.org/10.1111/j.1365-2893.2010.01297.x>

45. Lucidarme D, Bruandet A, Ille D, Harbonnier J, Jacob C, Decoster A, *et al.* Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. *Epidemiol Infect* 2004;**132**:699–708. <https://doi.org/10.1017/S095026880400247X>
46. Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, Wood E. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. *Addiction* 2014;**109**:2053–9. <http://dx.doi.org/10.1111/add.12682>
47. Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, Taylor A. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. *J Viral Hepat* 2014;**21**:25–32. <http://dx.doi.org/10.1111/jvh.12117>
48. Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, *et al.* Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. *CMAJ* 2001;**165**:889–95.
49. Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. *Scand J Infect Dis* 1996;**28**:27–9. <https://doi.org/10.3109/00365549609027145>
50. Roy E, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, *et al.* High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. *Int J STD AIDS* 2007;**18**:23–7. <http://dx.doi.org/10.1258/095646207779949880>
51. Ruan Y, Qin G, Yin L, Chen K, Qian HZ, Hao C, *et al.* Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. *AIDS* 2007;**21**(Suppl. 8):39–46. <http://dx.doi.org/10.1097/01.aids.0000304695.54884.4f>
52. Spittal PM, Pearce ME, Chavoshi N, Christian WM, Moniruzzaman A, Teegee M, Schechter MT. The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities. *BMC Public Health* 2012;**12**:632. <http://dx.doi.org/10.1186/1471-2458-12-632>
53. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. *J Urban Health* 2000;**77**:331–45. <https://doi.org/10.1007/BF02386744>
54. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, *et al.* Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. *Am J Epidemiol* 2002;**155**:645–53. <https://doi.org/10.1093/aje/155.7.645>
55. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. *JAMA Intern Med* 2014;**174**:1974–81. <http://dx.doi.org/10.1001/jamainternmed.2014.5416>
56. Vallejo F, Barrio G, Brugal MT, Pulido J, Toro C, Sordo L, *et al.* High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. *J Epidemiol Community Health* 2015;**69**:599–603. <https://doi.org/10.1136/jech-2014-205070>
57. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. *BMJ* 1998;**317**:433–7. <https://doi.org/10.1136/bmj.317.7156.433>
58. White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. *Med J Aust* 2014;**201**:326–9. <https://doi.org/10.5694/mja13.00153>



59. Hope V. Unpublished data set. Data set obtained from Vivian Hope and analyses conducted by the review team; 2015.
60. Maher L. Unpublished data set. Data set obtained from the International Collaborative of prospective studies of HIV and Hepatitis in IDU and analyses conducted by Meghan Morris; 2015.
61. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014;**61**(Suppl. 1):45–57. <http://dx.doi.org/10.1016/j.jhep.2014.07.027>
62. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, *et al.* Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet* 2008;**372**:1733–45. [http://dx.doi.org/10.1016/S0140-6736\(08\)61311-2](http://dx.doi.org/10.1016/S0140-6736(08)61311-2)
63. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, *et al.* Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis* 2016;**16**:797–808. [http://dx.doi.org/10.1016/S1473-3099\(15\)00485-5](http://dx.doi.org/10.1016/S1473-3099(15)00485-5)
64. Wood E, Lloyd-Smith E, Li K, Strathdee SA, Small W, Tyndall MW, *et al.* Frequent needle exchange use and HIV incidence in Vancouver, Canada. *Am J Med* 2007;**120**:172–9. <https://doi.org/10.1016/j.amjmed.2006.02.030>
65. Hagan H, McGough JP, Thiede H, Hopkins SG, Weiss NS, Alexander ER. Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs. *J Urban Health* 2000;**77**:103–12. <http://dx.doi.org/10.1007/BF02350966>
66. Vickerman P, Platt L, Jolley E, Rhodes T, Kazatchkine MD, Latypov A. Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modeling. *Int J Drug Policy* 2014;**25**:1163–73. <https://doi.org/10.1016/j.drugpo.2014.09.013>
67. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, Hall AJ. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. *BMJ* 2005;**330**:24–5. <https://doi.org/10.1136/bmj.38286.841227.7C>
68. Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, *et al.* Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. *PLOS ONE* 2014;**9**:e104515. <http://dx.doi.org/10.1371/journal.pone.0104515>
69. Iversen J, Maher L. *NSP Survey National Data Report 1995–2014. Prevalence of HIV, HCV and Injecting and Sexual Behaviour Among Needle and Syringe Program Attendees*. Sydney, NSW: Kirby Institute, University of New South Wales; 2015.
70. Public Health England. *Shooting Up: Infections Among People who Inject Drugs in the UK*. London: Public Health England; 2015.
71. Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, *et al.* Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. *J Med Virol* 2003;**71**:49–55. <http://dx.doi.org/10.1002/jmv.10463>
72. Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. *J Gen Virol* 1995;**76**:2493–507. <http://dx.doi.org/10.1099/0022-1317-76-10-2493>
73. Aceijas C, Hickman M, Donoghoe MC, Burrows D, Stuijke R. Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. *Addiction* 2007;**102**:1244–50. <https://doi.org/10.1111/j.1360-0443.2007.01848.x>

74. Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;**18**(Suppl. 1):37–44. <https://doi.org/10.1097/00042560-199802001-00008>
75. Lewis JR, Sauro J. When 100% really isn't 100%: improving the accuracy of small-sample estimates of completion rates. *J Usability Stud* 2010;**1**:136–50.
76. Wilson EB. Probable inference, the law of succession, and statistical inference. *J Am Stat Assoc* 1927;**22**:209–12. <https://doi.org/10.1080/01621459.1927.10502953>
77. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;**21**:1539–58. <http://dx.doi.org/10.1002/sim.1186>
78. Guinness L, Vickerman P, Quayyum Z, Foss A, Watts C, Rodericks A, et al. The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. *Addiction* 2010;**105**:319–28. <http://dx.doi.org/10.1111/j.1360-0443.2009.02755.x>
79. Kwon JA, Anderson J, Kerr CC, Thein HH, Zhang L, Iversen J, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. *AIDS* 2012;**26**:2201–10. <http://dx.doi.org/10.1097/QAD.0b013e3283578b5d>
80. Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. *Int J Drug Policy* 2015;**26**(Suppl. 1):22–6. <http://dx.doi.org/10.1016/j.drugpo.2014.08.014>
81. NICE. *Needle and Syringe Programmes*. London: NICE; 2014.
82. Drummond M, Health Outcomes International. *Return on Investment in Needle and Syringe Programs in Australia: Report*. Canberra, ACT: Commonwealth Department of Health and Ageing; 2002.
83. WHO. *Guide to Starting and Managing Needle and Syringe Programmes*. Geneva: WHO; 2007.
84. Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. *BMJ Open* 2013;**3**:e003207. <http://dx.doi.org/10.1136/bmjopen-2013-003207>
85. Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. *Drug Alcohol Depend* 2002;**65**:303–8. [https://doi.org/10.1016/S0376-8716\(01\)00174-0](https://doi.org/10.1016/S0376-8716(01)00174-0)
86. Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. *J Infect Dis* 2012;**205**:1342–50. <http://dx.doi.org/10.1093/infdis/jis213>
87. Information Services Division Scotland. *Injecting Equipment Provision in Scotland Survey 2013/14*. 2015. URL: [www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2015-06-23/2015-06-23-IEP-Report.pdf](http://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2015-06-23/2015-06-23-IEP-Report.pdf) (accessed 1 March 2016).
88. Mills HL, Colijn C, Vickerman P, Leslie D, Hope V, Hickman M. Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK. *Drug Alcohol Depend* 2012;**126**:324–32. <http://dx.doi.org/10.1016/j.drugalcdep.2012.05.036>
89. Mills HL, Johnson S, Hickman M, Jones NS, Colijn C. Errors in reported degrees and respondent driven sampling: implications for bias. *Drug Alcohol Depend* 2014;**142**:120–6. <http://dx.doi.org/10.1016/j.drugalcdep.2014.06.015>

90. Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. *Epidemiol Infect* 2015;**143**:1398–407. <http://dx.doi.org/10.1017/S0950268814002040>
91. Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, Robertson JR. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. *BMJ* 2010;**341**:c3172. <http://dx.doi.org/10.1136/bmj.c3172>
92. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. *BMC Infect Dis* 2006;**6**:93. <https://doi.org/10.1186/1471-2334-6-93>
93. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. *Health Technol Assess* 2007;**11**(11). <https://doi.org/10.3310/hta11110>
94. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. *Am J Gastroenterol* 2009;**104**:1147–58. <http://dx.doi.org/10.1038/ajg.2009.31>
95. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med* 2013;**158**:329–37. <http://dx.doi.org/10.7326/0003-4819-158-5-201303050-00005>
96. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. *J Viral Hepat* 2006;**13**:34–41. <https://doi.org/10.1111/j.1365-2893.2005.00651.x>
97. Kemp PA, Neale J, Robertson M. Homelessness among problem drug users: prevalence, risk factors and trigger events. *Health Soc Care Community* 2006;**14**:319–28. <https://doi.org/10.1111/j.1365-2524.2006.00624.x>
98. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *BMJ* 2010;**341**:c5475. <http://dx.doi.org/10.1136/bmj.c5475>
99. Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. *J Viral Hepat* 2015;**22**:399–408. <http://dx.doi.org/10.1111/jvh.12338>
100. Harris RJ, Thomas B, Griffiths J, Costella A, Chapman R, Ramsay M, et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. *J Hepatol* 2014;**61**:530–7. <http://dx.doi.org/10.1016/j.jhep.2014.05.008>
101. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis. *Int J Drug Policy* 2015;**26**:911–21. <http://dx.doi.org/10.1016/j.drugpo.2015.07.004>
102. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* 2012;**308**:2584–93. <http://dx.doi.org/10.1001/jama.2012.144878>
103. Kohli A, Shaffer A, Sherman A, Kottitil S. Treatment of hepatitis C: a systematic review. *JAMA* 2014;**312**:631–40. <http://dx.doi.org/10.1001/jama.2014.7085>



104. Jones HE, Welton NJ, Ades AE, Pierce M, Davies W, Coleman B, *et al.* Problem drug use prevalence estimation revisited: heterogeneity in capture–recapture and the role of external evidence. *Addiction* 2016;**111**:438–47. <https://doi.org/10.1111/add.13222>
105. Hay G, Gannon M, MacDougall J, Millar T, Eastwood C, McKeganey N. *National and Regional Estimates of the Prevalence of Opiate Use and/or Crack Cocaine Use 2006/07: A Summary of Key Findings*. Home Office Research Report 9. London: Home Office; 2008.
106. Hay G, Rael dos Santos A, Millar T. *Estimates of the Prevalence of Opiate Use and/or Crack Cocaine Use, 2010/11: Sweep 7 Report*. London: Centre for Public Health, Liverpool John Moores University; 2013.
107. King R, Bird SM, Overstall A, Hay G, Hutchinson SJ. Injecting drug users in Scotland, 2006: listing, number, demography, and opiate-related death-rates. *Addict Res Theory* 2013;**21**:235–46. <http://dx.doi.org/10.3109/16066359.2012.706344>
108. Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, *et al.* Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. *J Public Health* 2009;**31**:374–82. <http://dx.doi.org/10.1093/pubmed/fdp067>
109. Briggs A, Claxton K, Sculpher MJ. *Decision Modelling for Health Economic Evaluation*. Oxford: Oxford University Press; 2006.
110. Xia Y, Seaman S, Hickman M, Macleod J, Robertson R, Copeland L, *et al.* Factors affecting repeated cessations of injecting drug use and relapses during the entire injecting career among the Edinburgh Addiction Cohort. *Drug Alcohol Depend* 2015;**151**:76–83. <http://dx.doi.org/10.1016/j.drugalcdep.2015.03.005>
111. Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. *Int J Drug Policy* 2012;**23**:346–52. <http://dx.doi.org/10.1016/j.drugpo.2012.07.006>
112. Vickerman P, Hickman M, Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. *Int J Epidemiol* 2007;**36**:396–405. <https://doi.org/10.1093/ije/dyl276>
113. Vickerman P, Platt L, Hawkes S. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. *Sex Transm Infect* 2009;**85**(Suppl. 2):23–30. <http://dx.doi.org/10.1136/sti.2008.034660>
114. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, *et al.* Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology* 2013;**58**:1598–609. <http://dx.doi.org/10.1002/hep.26431>
115. WHO. *Draft Global Health Sector Strategy on Viral Hepatitis, 2016–2021 – The First of its Kind*. Geneva: WHO; 2015.
116. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, *et al.* Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. *Health Technol Assess* 2015;**19**(14). <http://dx.doi.org/10.3310/hta19140>
117. Remme M, Vassall A, Lutz B, Luna J, Watts C. Financing structural interventions: going beyond HIV-only value for money assessments. *AIDS* 2014;**28**:425–34. <http://dx.doi.org/10.1097/QAD.000000000000076>
118. Public Health England. *Drug Treatment in England 2013–2014*. London: Public Health England; 2014.

119. Welsh Government. *Substance Misuse Treatment Framework (SMTF) Recovery Oriented Integrated Systems of Care*. Cardiff: Welsh Government; 2013.
120. Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. *AIDS* 1997;**11**:F59–65. <https://doi.org/10.1097/00002030-199708000-00001>
121. Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. *J Viral Hepat* 2007;**14**:645–52. <https://doi.org/10.1111/j.1365-2893.2007.00855.x>
122. Personal Social Services and Research Unit (PSSRU). *Unit Costs of Health and Social Care 2013*. Canterbury: PSSRU, University of Kent; 2013.
123. Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. *J Viral Hepat* 2005;**12**:58–66. <https://doi.org/10.1111/j.1365-2893.2005.00575.x>
124. Martin NK, Vickerman P, Dore GJ, Hickman M. How should HCV treatment be prioritized in the direct-acting antiviral era? An economic evaluation including population prevention benefits. *J Hepatol* 2016;**65**(Suppl. 1):17–25.



# Appendix 1 Supplementary material for Chapter 2

**TABLE 16** Univariable metaregression analysis for adjusted studies measuring impact of current OST use on HCV infection incidence

Variable	Number of studies	Univariable RR (95% CI)	Ratio of RRs (95% CI)	p-value	$\tau^2$
Geographic region					
Europe	8	0.51 (0.37 to 0.70)	1.0 (reference)		
Australia	5	0.55 (0.28 to 1.11)	1.12 (0.52 to 2.41)		
North America	6	0.69 (0.44 to 1.08)	1.42 (0.73 to 2.78)	0.53	0.103
Site of recruitment					
Service attenders	12	0.67 (0.49 to 0.92)	1.0 (reference)		
Community	7	0.49 (0.33 to 0.73)	0.73 (0.42 to 1.27)	0.256	0.06
Females	9		1.59 (1.13 to 2.29)	0.01	0.04
Prison	7		1.06 (0.61 to 1.79)	0.821	0.4303
Homelessness	6		1.08 (0.83 to 1.40)	0.521	0.2327
Injection of stimulants	7		0.89 (0.65 to 1.22)	0.405	0.15
Daily injection	4		0.88 (0.64 to 1.22)	0.373	0.17

Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

**TABLE 17** Univariable metaregression analysis for studies measuring impact of high NSP coverage on HCV infection incidence

Variable	Number of studies	Univariable RR (95% CI)	Ratio of RRs (95% CI)	p-value	$\tau^2$
Geographic region					
Europe	5	0.44 (0.24 to 0.80)	1.0 (reference)		
North America	3	1.58 (0.57 to 4.42)	3.73 (0.95 to 14.7)	0.057	0.41
Site of recruitment					
Service attenders	3	0.67 (0.28 to 1.59)	1.0 (reference)		
Community	5	0.82 (0.29 to 2.32)	0.76 (0.12 to 4.88)	0.74	0.89
Females	7		2.97 (0.38 to 23.1)	0.24	0.87
Prison	3		NA		
Homelessness	6		1.01 (0.38 to 2.67)	0.976	1.53
Injection of stimulants	7		1.08 (0.47 to 2.51)	0.827	1.15
Daily injection	5		3.66 (0.22 to 61.3)	0.239	1.15

NA, not applicable.

Reproduced from Platt *et al.*,<sup>26,27</sup> which are published open access under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.



## Appendix 2 Supplementary material for Chapter 3

**TABLE 18** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and injecting with a used needle/syringe

Explanatory factors	<i>n</i>	Total	%	OR	95% CI	<i>p</i> -value	AOR	95% CI	<i>p</i> -value
< 100 NSP, no OST	181	911	20	1.0			1.0		
> 100 NSP, no OST	196	1462	13	0.6	0.50 to 0.78	< 0.001	0.5	0.38 to 0.62	< 0.001
< 100 NSP, OST	219	1301	17	0.8	0.66 to 1.02	0.0682	0.7	0.57 to 0.94	0.0155
> 100 NSP, OST	313	2126	15	0.7	0.57 to 0.85	0.0004	0.5	0.41 to 0.65	< 0.001
Female				1.2	1.00 to 1.37	0.0431	1.1	0.95 to 1.37	0.1644
History of prison				1.2	1.00 to 1.35	0.0516	1.4	1.19 to 1.73	0.0002
Injection of crack cocaine				0.8	0.67 to 0.89	0.0004	1.2	1.00 to 1.42	0.0501
Duration of injection (years)									
0–3				1.0			1.0		
3.1–5				1.1	0.82 to 1.58	0.4498	1.0	0.67 to 1.47	0.953
6–10				1.1	0.85 to 1.44	0.4456	1.1	0.78 to 1.45	0.6853
11+				1.2	0.96 to 1.49	0.1014	1.1	0.86 to 1.49	0.3613
Study									
Bristol 1				1.0			1.0		
Leeds				0.2	0.11 to 0.31	< 0.001	0.2	0.11 to 0.32	< 0.001
Birmingham				0.1	0.04 to 0.17	< 0.001	0.1	0.05 to 0.18	< 0.001
Wales				0.2	0.16 to 0.38	< 0.001	0.3	0.17 to 0.48	< 0.001
Bristol 2				0.2	0.15 to 0.38	< 0.001	0.2	0.12 to 0.34	< 0.001
NESI				5.7	4.03 to 8.13	< 0.001	7.7	5.24 to 11.37	< 0.001
UAMP				0.3	0.23 to 0.41	< 0.001	0.3	0.22 to 0.40	< 0.001
ANSPS				0.5	0.39 to 0.68	< 0.001	0.7	0.50 to 0.92	0.0121
On OST				1.0	0.87 to 1.16	0.929	0.9	0.76 to 1.07	0.2319
High NSP coverage				0.8	0.65 to 0.86	< 0.001	0.6	0.50 to 0.69	< 0.001

**TABLE 19** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and reuse of the same needle/syringe for injecting

Explanatory factors	<i>n</i>	Total	%	OR	95% CI	<i>p</i> -value	AOR	95% CI	<i>p</i> -value
< 100 NSP, no OST	62	181	34	1.0			1.0		
> 100 NSP, no OST	62	224	28	0.73	0.48 to 1.12	0.154	0.71	0.45 to 1.09	0.1187
< 100 NSP, OST	125	318	39	1.24	0.85 to 1.82	0.2625	1.11	0.74 to 1.66	0.6196
> 100 NSP, OST	116	472	25	0.63	0.43 to 0.91	0.0133	0.59	0.40 to 0.88	0.0088
Female				0.79	0.58 to 1.07	0.1287	0.8	0.56 to 1.13	0.1997
History of prison				1.21	0.88 to 1.65	0.2484	1.06	0.74 to 1.52	0.7349
Injection of crack cocaine				1.48	1.14 to 1.91	0.0032	1.5	1.13 to 2.00	0.0055
Duration of injection (years)									
0–3				1.0			1.0		
3.1–5				1.41	0.81 to 2.46	0.2201	1.24	0.68 to 2.26	0.4791
6–10				1.8	1.19 to 2.73	0.0054	1.72	1.10 to 2.70	0.0178
11+				1.54	1.05 to 2.27	0.0275	1.37	0.89 to 2.10	0.1511
Study									
Bristol 1				1.0			1.0		
Leeds				0.38	0.27 to 0.54	< 0.001	0.39	0.27 to 0.56	< 0.001
Birmingham				0.33	0.23 to 0.47	< 0.001	0.35	0.24 to 0.51	< 0.001
Bristol 2				0.59	0.42 to 0.81	0.0012	0.57	0.40 to 0.81	0.0018
On OST				0.98	0.76 to 1.27	0.8821	0.93	0.70 to 1.22	0.5873
> 100 NSP				0.58	0.45 to 0.73	< 0.001	0.59	0.46 to 0.76	< 0.001
High NSP coverage				0.58	0.45 to 0.73	< 0.001	0.59	0.46 to 0.76	< 0.001

**TABLE 20** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and frequency of injecting

Explanatory factors	Mean ( <i>n</i> )	OR	95% CI	<i>p</i> -value	OR	95% CI	<i>p</i> -value
< 100 NSP, no OST	72.4 (1156)	Reference			Reference		Reference
> 100 NSP, no OST	48.6 (2184)	–23.8	–28.3 to –19.3	< 0.001	–21.6	–26.2 to –17.0	< 0.001
< 100 NSP, OST	56.1 (2083)	–16.2	–20.8 to –11.7	< 0.001	–18.4	–23.1 to –13.8	< 0.001
> 100 NSP, OST	30.3 (5091)	–42	–46.1 to –37.9	< 0.001	–41.2	–45.5 to –37.0	< 0.001
Female		0.2	–2.4 to 2.85	0.882	–0.14	–10.0 to 9.71	0.2
History of prison		7.9	5.5 to 10.3	< 0.001	6.3	3.58 to 9.07	< 0.001
Injection of crack cocaine		15.7	13.1 to 18.2	< 0.001	11.7	8.59 to 14.8	< 0.001
Duration of injection (years)							
0–3		Reference			Reference		
3.1–5		1.6	–3.06 to 6.18	0.508	2.3	–2.8 to 7.38	0.384
6–10		3.2	–0.63 to 7.03	0.101	3.82	–0.44 to 8.09	0.079
11+		2.6	–0.78 to 5.92	0.132	4.35	0.44 to 8.27	0.029

**TABLE 20** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and frequency of injecting (*continued*)

Explanatory factors	Mean (n)	OR	95% CI	p-value	OR	95% CI	p-value
Study							
Bristol 1		Reference			Reference		
Leeds		-3.08	-13.3 to 7.12	0.554	-0.14	-9.98 to 9.71	0.978
Birmingham		-10.63	-20.7 to -0.51	0.04	-5.32	-15.1 to 4.45	0.286
Bristol 2		-1.85	-10.5 to 6.80	0.674	4.21	-6.15 to 14.6	0.426
On OST		7.29	-2.64 to 17.22	0.150	7.98	-1.94 to 17.90	0.115
High NSP coverage		-13.3	-20.7 to -5.87	< 0.001	1.82	-5.62 to 9.26	0.632

**TABLE 21** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and use of shared spoons and filters

Explanatory factors	n	Total	%	OR	95% CI	p-value	AOR	95% CI	p-value
< 100 NSP, no OST	442	1027	43	1.0			1.0		
> 100 NSP, no OST	572	1684	34	0.68	0.58 to 0.80	< 0.001	0.77	0.63 to 0.93	0.0063
< 100 NSP, OST	644	1606	40	0.89	0.76 to 1.04	0.1353	0.8	0.66 to 0.97	0.0252
> 100 NSP, OST	1021	2906	35	0.72	0.62 to 0.83	< 0.001	0.78	0.66 to 0.93	0.0066
Female				0.93	0.84 to 1.03	0.1855	1.08	0.95 to 1.24	0.2457
History of prison				1.46	1.32 to 1.61	< 0.001	1.15	1.01 to 1.31	0.0417
Injection of crack cocaine				1.72	1.56 to 1.88	< 0.001	1.11	0.98 to 1.27	0.1099
Duration of injection (years)									
0-3				1.0			1.0		
3.1-5				1.09	0.90 to 1.32	0.3731	1.01	0.79 to 1.29	0.9344
6-10				1.27	1.09 to 1.49	0.0021	0.95	0.78 to 1.16	0.6396
11 +				0.93	0.81 to 1.06	0.2796	0.87	0.73 to 1.04	0.127
Study									
Bristol 1				1.0			1.0		
Leeds				0.78	0.29 to 2.12	0.6227	0.78	0.29 to 2.12	0.624
Birmingham				0.04	0.02 to 0.08	< 0.001	0.04	0.02 to 0.08	< 0.001
Wales				0.03	0.01 to 0.06	< 0.001	0.03	0.01 to 0.06	< 0.001
Bristol 2				0.18	0.08 to 0.41	< 0.001	0.19	0.08 to 0.45	0.0001
NESI				0.01	0.00 to 0.01	< 0.001	0.01	0.00 to 0.02	< 0.001
UAMP				0.01	0.00 to 0.02	< 0.001	0.01	0.00 to 0.02	< 0.001
ANSPS				0.01	0.00 to 0.02	< 0.001	0.01	0.00 to 0.02	< 0.001
On OST				1.01	0.91 to 1.11	0.8797	0.94	0.83 to 1.06	0.3343
High NSP coverage				0.69	0.63 to 0.76	< 0.001	0.88	0.78 to 0.98	0.0244



**TABLE 22** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and injecting-site infection

Explanatory factors	<i>n</i>	Total	%	OR	95% CI	<i>p</i> -value	AOR	95% CI	<i>p</i> -value
< 100 NSP, no OST	213	621	34	1.0			1.0		
> 100 NSP, no OST	254	596	43	1.42	1.13 to 1.79	0.0029	1.2	0.90 to 1.51	0.2524
< 100 NSP, OST	450	1082	42	1.36	1.11 to 1.67	0.003	1.4	1.14 to 1.81	0.002
> 100 NSP, OST	698	1960	36	1.06	0.88 to 1.28	0.5509	1.2	0.99 to 1.52	0.0603
Female				1.29	1.13 to 1.48	0.0002	1.3	1.12 to 1.58	0.0011
History of prison				1.02	0.90 to 1.16	0.7517	0.9	0.77 to 1.08	0.2929
Injection of crack cocaine				0.94	0.84 to 1.05	0.2946	1.4	1.18 to 1.58	< 0.001
Duration of injection (years)									
0–3				1.0			1.0		
3.1–5				1.15	0.91 to 1.46	0.2518	0.99	0.74 to 1.33	0.9442
6–10				1.01	0.84 to 1.22	0.9081	0.94	0.74 to 1.18	0.5745
11+				0.93	0.79 to 1.09	0.3797	1.22	0.99 to 1.50	0.0637
Study									
Bristol 1				1.0			1.0		
Leeds				0.56	0.41 to 0.78	0.0005	0.58	0.42 to 0.80	0.001
Birmingham				0.68	0.49 to 0.94	0.0188	0.72	0.52 to 1.00	0.0509
Wales				1.81	1.36 to 2.40	< 0.001	2.76	1.89 to 4.03	< 0.001
Bristol 2				0.6	0.44 to 0.82	0.0014	0.55	0.39 to 0.76	0.0004
ANSPS				0.27	0.21 to 0.35	< 0.001	0.26	0.20 to 0.33	< 0.001
On OST				1.12	0.98 to 1.28	0.0843	1.29	1.11 to 1.50	0.0007
High NSP coverage				0.87	0.77 to 0.98	0.0262	1.03	0.89 to 1.18	0.7318

**TABLE 23** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and HCV infection testing

Explanatory factors	<i>n</i>	Total	%	OR	95% CI	<i>p</i> -value	AOR	95% CI	<i>p</i> -value
< 100 NSP, no OST	858	1126	76	Reference			1.0		
> 100 NSP, no OST	1748	2101	83	1.6	1.29 to 1.85	< 0.001	1.4	1.13 to 1.69	0.0015
< 100 NSP, OST	1727	2028	85	1.8	1.49 to 2.15	< 0.001	1.7	1.41 to 2.12	< 0.001
> 100 NSP, OST	5833	6781	86	1.9	1.65 to 2.24	< 0.001	1.9	1.56 to 2.23	< 0.001
Female				1.2	1.08 to 1.32	0.0004	1.4	1.22 to 1.57	< 0.001
History of prison				1.9	1.77 to 2.11	< 0.001	1.6	1.45 to 1.83	< 0.001
Injection of crack cocaine				1.6	1.42 to 1.76	< 0.001	1.4	1.20 to 1.62	< 0.001
Duration of injection (years)									
0–3				1.0			1.0		
3.1–5				1.9	1.63 to 2.21	< 0.001	1.7	1.41 to 2.06	< 0.001
6–10				2.8	2.43 to 3.15	< 0.001	2.2	1.83 to 2.52	< 0.001
11+				5.5	4.86 to 6.15	< 0.001	3.3	2.82 to 3.80	< 0.001

**TABLE 23** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and HCV infection testing (*continued*)

Explanatory factors	<i>n</i>	Total	%	OR	95% CI	<i>p</i> -value	AOR	95% CI	<i>p</i> -value
Study									
Bristol 1				1.0			1.0		
Leeds				1.2	0.77 to 1.78	0.4674	1.1	0.72 to 1.73	0.6138
Birmingham				0.8	0.52 to 1.13	0.1813	0.8	0.55 to 1.26	0.3816
Wales				0.2	0.15 to 0.30	< 0.001	0.3	0.21 to 0.46	< 0.001
Bristol 2				2.5	1.54 to 4.02	0.0002	2.6	1.47 to 4.45	0.0009
NESI				1.0	0.71 to 1.29	0.7937	1.3	0.93 to 1.78	0.1267
UAMP				1.2	0.90 to 1.67	0.1888	1.3	0.94 to 1.80	0.1136
ANSPS				2.8	1.98 to 3.81	< 0.001	3.6	2.52 to 5.20	< 0.001
On OST				1.5	1.36 to 1.65	< 0.001	1.5	1.36 to 1.71	< 0.001
High NSP coverage				1.4	1.27 to 1.54	< 0.001	1.2	1.04 to 1.31	0.0098

**TABLE 24** Association between intervention coverage defined as a combination of harm-reduction interventions and NSP coverage, and OST alone and HIV testing

Explanatory factors	<i>n</i>	Total	%	OR	95% CI	<i>p</i> -value	AOR	95% CI	<i>p</i> -value
< 100 NSP, no OST	765	1092	70	1.0			1.0		
> 100 NSP, no OST	1586	2037	78	1.5	1.27 to 1.78	< 0.001	1.3	1.10 to 1.58	0.0028
< 100 NSP, OST	1582	1975	80	1.7	1.45 to 2.04	< 0.001	1.7	1.40 to 2.02	< 0.001
> 100 NSP, OST	5452	6732	81	1.8	1.58 to 2.10	< 0.001	1.9	1.60 to 2.20	< 0.001
Female				1.2	1.12 to 1.36	< 0.001	1.4	1.22 to 1.53	< 0.001
History of prison				1.6	1.51 to 1.78	< 0.001	1.4	1.25 to 1.54	< 0.001
Injection of crack cocaine				1.3	1.20 to 1.46	< 0.001	1.2	1.04 to 1.34	0.0121
Duration of injection (years)									
0–3									
3.1–5				1.7	1.48 to 2.01	< 0.001	1.6	1.31 to 1.88	< 0.001
6–10				2.2	1.92 to 2.48	< 0.001	1.8	1.52 to 2.05	< 0.001
11+				3.8	3.41 to 4.29	< 0.001	2.7	2.33 to 3.07	< 0.001
Study									
Bristol 1				1.0			1.0		
Leeds				0.8	0.56 to 1.18	0.2786	0.8	0.52 to 1.12	0.1644
Birmingham				0.7	0.51 to 1.05	0.0903	0.8	0.53 to 1.13	0.1824
Bristol 2				1.5	1.01 to 2.22	0.0463	1.3	0.83 to 1.94	0.2724
NESI				0.9	0.64 to 1.11	0.2365	1.0	0.70 to 1.27	0.7086
UAMP				1.1	0.84 to 1.48	0.4395	1.1	0.83 to 1.50	0.4803
ANSPS				2.0	1.49 to 2.69	< 0.001	2.2	1.61 to 3.04	< 0.001
On OST				1.4	1.27 to 1.53	< 0.001	1.5	1.36 to 1.68	< 0.001
High NSP coverage				1.2	1.04 to 1.27	0.0044	1.2	1.05 to 1.30	0.0037



## Appendix 3 Supplementary material for Chapter 4

**TABLE 25** Parameters for costing uncertainty analysis

Parameter	Base case	Minimum	Maximum
Discount rate (%)	4	1	6
Salaries multiplier (%)	100	50	200
Equipment wastage (%)	100	50	200
Opportunity cost of volunteer time (annual)	18,992.87	–	18,992.87
Opportunity cost of volunteer time (hourly)	0	0	12.5
<b>Per cent of visits for non-IPED users</b>			
Fixed sites	92	75	90
Pharmacies	100	100	100
Walk-in centres	100	100	100
<b>Per cent of needles to non-IPED users</b>			
Fixed sites	81	75	90
Pharmacies	100	100	100
Walk-in centres	100	100	100
<b>Visits per client</b>			
Pharmacies	8	6	10
Walk-in centres	8	6	10
Needle distribution			
Needle pack size	10	10	10
Needle packs per transaction	1.06	1.00	1.12
'One hit kit' packs per transaction	4	1	10

**TABLE 26** Outputs: fixed sites

Site and output type	Total outputs			Opioids and other		IPEDs	
	Total, <i>N</i>	Male, <i>n</i> (%)	Female, <i>n</i> (%)	Total	Male, <i>n</i> (%)	Total	Male, <i>n</i> (%)
BDP							
Total clients	1134	991 (87)	143 (13)	755 (67)	618 (82)	379 (33)	373 (98)
Total visits	10,796	9353 (87)	1443 (13)	9937 (92)	8502 (86)	859 (8)	851 (99)
Total needles	286,698			252,039 (88)		34,659 (12)	
CAIR Scotland							
Total clients	817	504 (62)	201 (25)	697 (85)		121 (15)	
Total visits	6251			5692 (91)		559 (9)	
Total needles	50,186			36,455 (73)		13,731 (27)	

continued

**TABLE 26** Outputs: fixed sites (*continued*)

Site and output type	Total outputs			Opioids and other		IPEDs	
	Total, <i>N</i>	Male, <i>n</i> (%)	Female, <i>n</i> (%)	Total	Male, <i>n</i> (%)	Total	Male, <i>n</i> (%)
Addaction Walsall							
Total clients	569	520 (91)	44 (8)	190 (33)		379 (67)	
Total visits	1756			1609 (92)		147 (8)	
Total needles	78,914			63,644 (81) <sup>a</sup>		15,270 (19) <sup>a</sup>	

<sup>a</sup> Value was estimated using assumptions described in *Chapter 3, Methods*.

**TABLE 27** Outputs: pharmacies in cost study

Site	Distribution style	Total clients (all opiate users)			Total visits	Total needles distributed
		Total, <i>N</i>	Male, <i>n</i> (%)	Female, <i>n</i> (%)		
Pharmacy 1 (Bristol)	Packs	176 <sup>a</sup>	132 (75) <sup>a</sup>	44 (25) <sup>a</sup>	1405	28,100 <sup>a</sup>
Pharmacy 2 (Bristol)	Packs	213 <sup>a</sup>	160 (75) <sup>a</sup>	53 (25) <sup>a</sup>	1705	36,100 <sup>a</sup>
Pharmacy 3 (Dundee)	Pick and mix	287	224 (78)	62 (22)	1940	21,982
Pharmacy 5 (Dundee)	Pick and mix	210	149 (71)	61 (29)	1914	18,518
Pharmacy 4 (Walsall)	Packs	290 <sup>a</sup>	217 (75) <sup>a</sup>	72 (25) <sup>a</sup>	2316 <sup>a</sup>	24,520
Pharmacy 6 (Walsall)	Packs	207 <sup>a</sup>	155 (75) <sup>a</sup>	52 (25) <sup>a</sup>	1656 <sup>a</sup>	17,530

<sup>a</sup> Value was estimated using assumptions described in *Chapter 3, Methods*.

**TABLE 28** Outputs: other needle distribution modes

Site and output type	Total			Opioids and other		IPEDs	
	Total, <i>N</i>	Male, <i>n</i> (%)	Female, <i>n</i> (%)	Total, <i>n</i> (%)	Male, <i>n</i> (%)	Total, <i>n</i> (%)	Male, <i>n</i> (%)
Out-of-hours pharmacy (Walsall)							
Total clients	213	160 (75) <sup>a</sup>	53 (25) <sup>a</sup>	213 (100)		0	
Total visits	1704			1704 (100)		0	
Total needles	6816			6816 (100)		0	
Drop-in centre (Walsall)							
Total clients	113	84 (75) <sup>a</sup>	28 (25) <sup>a</sup>	113 (100)		0	
Total visits	900			900 (100)		0	
Total needles	7812			7812 (100)		0	
Outreach service (Bristol)							
Total clients	396	348 (88)	48 (12)	286 (72)	240 (84)	110 (28)	108 (98)
Total visits	1778	1438 (81)	340 (19)	1207 (68)	1248 (79)	192 (11)	190 (99)
Total needles	101,326			92,171 (91)		9155 (9)	

<sup>a</sup> Value was estimated using assumptions described in *Chapter 3, Methods*.

## Appendix 4 Supplementary material for Chapter 5

### Model equations

$S_{i,j,k}^{n,m}$  and  $C_{i,j,k}^{n,m}$  are the number of susceptible and chronically infected individuals in the model, in which  $i = 0, 1$  for off OST and on OST respectively,  $j = 0, 1$  for < 100% NSP and > 100% NSP, respectively,  $n = 1, 2, 3, 4$  for recent and non-recent or long-term injectors and ex-injecting drug users,  $m = l, h$  for low and high risk, respectively, and  $k = 1, 2 \dots 6$  for the disease progression states chronic infected, compensated cirrhosis, decompensated cirrhosis, HCC, liver transplant and post liver transplant, respectively.

The ordinary differential equation model is made up of 300 equations, which are described below for different aspects of the model.

### Inflow of injectors

There are only two variables in the model that allow an inflow of new injectors. These are low- and high-risk susceptible individuals in the first disease progression category with no intervention: the number of new low-risk individual per year is  $\theta(1 - \phi)$  and the number of new high-risk individuals per year is  $\theta\phi$ .

### Injecting duration progression

These terms in the equations are concerned with movement from one injecting duration category to another as well as PWID-related and background mortality.  $ID_{i,j,k}^{n,m}$  denotes the terms in an ordinary differential equation of injecting duration category  $n$ . It occurs for all values of  $m, i, j, k$ .  $Y_{i,j,k}^{n,m}$  is used to describe one of the variables in the model, in which  $Y = S$  or  $C$  and the subscripts and superscripts are as described previously.

$$\begin{pmatrix} ID_{i,j,k}^{1,m} \\ ID_{i,j,k}^{2,m} \\ ID_{i,j,k}^{3,m} \end{pmatrix} = \begin{pmatrix} -\tau_1 - \mu_1 & 0 & 0 \\ \tau_1 & -\tau_2 - \mu_2 & 0 \\ 0 & \tau_2 & -\tau_3 \end{pmatrix} \begin{pmatrix} Y_{i,j,k}^{1,m} \\ Y_{i,j,k}^{2,m} \\ Y_{i,j,k}^{3,m} \end{pmatrix} \quad (1)$$

When  $n = 4$  (ex-injecting), the terms have a different form:

$$ID_k^4 = \sum_{i,j,m} \omega_1 Y_{ijk}^{1,m} + \sum_{i,j,k,m} \omega_2 Y_{ijk}^{2,m} + \sum_{i,j,k,m} \omega_3 Y_{ijk}^{3,m} - v_4 Y_k^4. \quad (2)$$

### Interventions: opioid substitution therapy and needle and syringe programmes

These terms in the equations are concerned with the movement of injectors from one intervention category to another.  $IT_{i,j,k}^{n,m}$  denotes the terms in the ordinary differential equation of OST intervention category  $i$  and NSP intervention category  $j$ . These terms can be found for all values of  $m, k$  and current injector categories but not for the ex-injecting drug user category ( $n = 4$ ):

$$\begin{pmatrix} IT_{0,0,k}^{n,m} \\ IT_{1,0,k}^{n,m} \\ IT_{0,1,k}^{n,m} \\ IT_{1,1,k}^{n,m} \end{pmatrix} = \begin{pmatrix} -\eta - \beta & \gamma & \kappa & 0 \\ \beta & -\gamma - \eta & 0 & \kappa \\ \eta & 0 & -\kappa - \beta & \gamma \\ 0 & \eta & \beta & -\gamma - \kappa \end{pmatrix} \begin{pmatrix} Y_{0,0,k}^{n,m} \\ Y_{1,0,k}^{n,m} \\ Y_{0,1,k}^{n,m} \\ Y_{1,1,k}^{n,m} \end{pmatrix}. \quad (3)$$

### High and low risk

These terms in the equations are concerned with movement of current injectors between low and high risk.  $HR_{i,j,k}^{n,m}$  denotes the terms in the ordinary differential equation of risk category  $m$ . These terms can be found in the equations for all values of  $i, j, k$  and  $n = 1, 2, 3$ .

$$\begin{pmatrix} HR_{i,j,k}^{n,l} \\ HR_{i,j,k}^{n,h} \end{pmatrix} = \begin{pmatrix} -\sigma & \zeta \\ \sigma & -\zeta \end{pmatrix} \begin{pmatrix} Y_{i,j,k}^{n,l} \\ Y_{i,j,k}^{n,h} \end{pmatrix} \quad (4)$$

### Disease progression

These terms in the equations are concerned with movement through the disease states. Infection and treatment are described separately.  $DS_{i,j,k}^{n,m}$  denotes the terms in the ordinary differential equation of disease category  $k$  for susceptible individuals and  $DC_{i,j,k}^{n,m}$  for infected individuals. These terms can be found in the equations for all values of  $i, j, n, m$ .

$$\begin{pmatrix} DS_{i,j,1}^{n,m} \\ DS_{i,j,2}^{n,m} \\ DS_{i,j,3}^{n,m} \\ DS_{i,j,4}^{n,m} \\ DS_{i,j,5}^{n,m} \\ DS_{i,j,6}^{n,m} \end{pmatrix} = \begin{pmatrix} 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -e_3\rho_3 - e_4\rho_4 & 0 & 0 & 0 & 0 \\ 0 & e_3\rho_3 & -\rho_5 - \rho_4 - d_3 & 0 & 0 & 0 \\ 0 & e_4\rho_4 & \rho_4 & -d_4 & 0 & 0 \\ 0 & 0 & \rho_5 & 0 & -\rho_6 - d_5 & 0 \\ 0 & 0 & 0 & 0 & \rho_6 & -d_6 \end{pmatrix} \begin{pmatrix} S_{i,j,1}^{n,m} \\ S_{i,j,2}^{n,m} \\ S_{i,j,3}^{n,m} \\ S_{i,j,4}^{n,m} \\ S_{i,j,5}^{n,m} \\ S_{i,j,6}^{n,m} \end{pmatrix} \quad (5)$$

$$\begin{pmatrix} DC_{i,j,1}^{n,m} \\ DC_{i,j,2}^{n,m} \\ DC_{i,j,3}^{n,m} \\ DC_{i,j,4}^{n,m} \\ DC_{i,j,5}^{n,m} \\ DC_{i,j,6}^{n,m} \end{pmatrix} = \begin{pmatrix} -\rho_2 & 0 & 0 & 0 & 0 & 0 \\ \rho_2 & -\rho_4 - \rho_3 & 0 & 0 & 0 & 0 \\ 0 & \rho_3 & -\rho_5 - \rho_4 - d_3 & 0 & 0 & 0 \\ 0 & \rho_4 & \rho_4 & -d_4 & 0 & 0 \\ 0 & 0 & \rho_5 & 0 & -\rho_6 - d_5 & 0 \\ 0 & 0 & 0 & 0 & \rho_6 & -d_6 \end{pmatrix} \begin{pmatrix} C_{i,j,1}^{n,m} \\ C_{i,j,2}^{n,m} \\ C_{i,j,3}^{n,m} \\ C_{i,j,4}^{n,m} \\ C_{i,j,5}^{n,m} \\ C_{i,j,6}^{n,m} \end{pmatrix} \quad (6)$$

### Infection terms

The forces of infection below are concerned with acquiring infection. The terms are of the form:

$$FOI_{i,j,k}^{n,m} = \lambda_{i,j,k}^{n,m} S_{i,j,k}^{n,m}. \quad (7)$$

When the ordinary differential equation is for susceptible, the force of infection term is subtracted and the same term is added to the matching infectious category.

$$\begin{aligned} \lambda_{0,0,k}^{1,l} &= \pi X_1 (1-\delta) \Upsilon \\ \lambda_{0,0,k}^{2,l} &= \pi X_2 (1-\delta) \Upsilon \\ \lambda_{0,0,k}^{3,l} &= \pi (1-\delta) \Upsilon \\ \lambda_{0,0,k}^{1,h} &= \pi X_1 \Xi (1-\delta) \Upsilon \\ \lambda_{0,0,k}^{2,h} &= \pi X_2 \Xi (1-\delta) \Upsilon \\ \lambda_{0,0,k}^{3,h} &= \pi \Xi (1-\delta) \Upsilon \\ \lambda_{0,1,k}^{n,m} &= \Gamma \lambda_{0,0,k}^{n,m} \\ \lambda_{1,0,k}^{n,m} &= \Pi \lambda_{0,0,k}^{n,m} \\ \lambda_{1,1,k}^{n,m} &= B \lambda_{0,0,k}^{n,m} \end{aligned} \quad (8)$$

Define:

$$\begin{aligned}
 C^{n,m} &= \sum_{k=1}^6 (C_{0,0,k}^{n,m} \quad C_{0,1,k}^{n,m} \quad C_{1,0,k}^{n,m} \quad C_{1,1,k}^{n,m}), \\
 S^{n,m} &= \sum_{k=1}^6 (S_{0,0,k}^{n,m} \quad S_{0,1,k}^{n,m} \quad S_{1,0,k}^{n,m} \quad S_{1,1,k}^{n,m}), \\
 I &= \begin{pmatrix} 1 \\ \Gamma \\ \Pi \\ B \end{pmatrix},
 \end{aligned} \tag{9}$$

to give

$$Y = \frac{[X_1(C^{1,l} + \Xi C^{1,h}) + X_2(C^{2,l} + \Xi C^{2,h}) + (C^{3,l} + \Xi C^{3,h})]I}{\{X_1[C^{1,l} + S^{1,l} + \Xi(C^{1,h} + S^{1,h})] + X_2[C^{2,l} + S^{2,l} + \Xi(C^{2,h} + S^{2,h})] + [C^{3,l} + S^{3,l} + \Xi(C^{3,h} + S^{3,h})]\}I}. \tag{10}$$

### Treatments

There are a fixed number of treatments per year, given by  $\Phi$ . When the total number of infected individuals in the model is greater than this number, the treatments are allocated proportionately. When the total number of infected individuals is less than the number of possible treatments per year, all are treated. Only the first two disease progression categories are eligible for treatment and will have treatment terms. If the ordinary differential equation is for an infected category, the treatment term will be subtracted and for a susceptible category, the term will be added. If:

$$\Phi < \sum_{k=1}^2 \sum_n \sum_{m,l,j} C_{i,j,k}^{n,m} = C^{treat}, \tag{11}$$

$$T_{i,j,k}^{n,m}(C_{i,j,k}^{n,m}) = \frac{\alpha \Phi C_{i,j,k}^{n,m}}{C^{treat}},$$

for  $k = 1, 2$ , then  $n = 1, 2, 3$ .

Otherwise:

$$T_{i,j,k}^{n,m}(C_{i,j,k}^{n,m}) = \alpha C_{i,j,k}^{n,m}, \tag{12}$$

for  $k = 1, 2$ ,  $n = 1, 2, 3$ .

For ex-injecting drug users, treatment is more straightforward, with a proportion,  $r$ , of the chronically infected and compensated cirrhosis individuals being treated each year.

$$T_k^4(C_k^4) = \alpha r C_k^4, \tag{13}$$

for  $k = 1, 2$ .

As an example, below is the ordinary differential equation for the susceptible category for the first disease progression category, with no interventions, a recent injector (< 3 years) and at low risk. On the right-hand



side in order from left to right there is an inflow term, injecting duration terms, intervention terms, high- and low-risk terms, disease progression terms, infection term and treatment term.

$$\frac{dS_{0,0,1}^{1,i}}{dt} = \theta(1-\phi) + ID_{0,0,1}^{1,i} + IT_{0,0,1}^{1,i} + HR_{0,0,1}^{1,i} + DS_{0,0,1}^{1,i} - \lambda_{0,0,1}^{1,i} S_{0,0,1}^{1,i} + T_{0,0,1}^{1,i} \quad (14)$$

## Submodels used in the fitting procedure

### Injecting duration model

A model with three injecting duration categories was used to fit the population data and the injecting duration profiles from survey data. Here,  $S^i$  is the number of susceptible injectors in the  $i$  category. The categories are:  $r$ , recent injector;  $n$ , non-recent injector; and  $l$ , long-term injector. The  $\mu_i$  and  $\tau_i$  are as described above.

$$\begin{aligned} \frac{dS^r}{dt} &= \theta - (\mu_1 + \tau_1)S^r \\ \frac{dS^n}{dt} &= \mu_1 S^r - (\mu_2 + \tau_2)S^n \\ \frac{dS^l}{dt} &= \mu_2 S^n - \mu_3 S^l \end{aligned} \quad (15)$$

The steady state solution of this model is given below:

$$S^r = \frac{\theta}{\mu_1 + \tau_1}, S^n = \frac{\theta \tau_1}{(\mu_1 + \tau_1)(\mu_2 + \tau_2)}, S^l = \frac{\theta \tau_1 \tau_2}{(\mu_3(\mu_1 + \tau_1)(\mu_2 + \tau_2))}. \quad (16)$$

With total population  $N = S^r + S^n + S^l$ , the analytical solution of this system is:

$$\begin{aligned} S^r(t) &= S^r(0)e^{-(\mu_1 + \tau_1)t} + \frac{\theta}{\mu_1 + \tau_1}(1 - e^{-(\mu_1 + \tau_1)t}), \\ S^n(t) &= \frac{\tau_1 \theta}{(\mu_1 + \tau_1)(\mu_2 + \tau_2)} + S^n(0)e^{-(\mu_2 + \tau_2)t} + \frac{\tau_1}{\mu_1 + \tau_1 - \mu_2 - \tau_2} S^r(0)(e^{-(\mu_2 + \tau_2)t} - e^{-(\mu_1 + \tau_1)t}) \\ &\quad + \frac{\tau_1 \theta}{\mu_1 + \tau_1 - \mu_2 - \tau_2} * (e^{-(\mu_1 + \tau_1)t} / (\mu_1 + \tau_1) - e^{-(\mu_2 + \tau_2)t} / (\mu_2 + \tau_2)), \\ S^l(t) &= e^{-\mu_3 t} \left( S^l(0) + \frac{\tau_2}{\mu_2 + \tau_2 - \mu_3} \left( \frac{\tau_1 S^r(0)}{\mu_1 + \tau_1 - \mu_3} - \frac{\tau_1 \theta}{\mu_3(\mu_1 + \tau_1 - \mu_3)} + S^n(0) \right) \right) \\ &\quad + \frac{e^{-(\mu_2 + \tau_2)t} \tau_2}{\mu_2 + \tau_2 - \mu_3} \left( \frac{\tau_1 S^r(0)}{\mu_2 - \tau_2 + \mu_1 + \tau_1} + \frac{\tau_1 \theta}{(\mu_2 + \tau_2)(-\mu_2 - \tau_2 + \mu_1 + \tau_1)} - S^n(0) \right) \\ &\quad + \frac{e^{-(\mu_1 + \tau_1)t} \tau_1 \tau_2 \theta}{(\mu_1 + \tau_1)(\mu_1 + \tau_1 - \mu_3)(\mu_1 + \tau_1 - \mu_2 - \tau_2)} + \frac{\tau_1 \tau_2 \theta}{\mu_3(\mu_1 + \tau_1)(\mu_2 + \tau_2)} \end{aligned}$$

### High-risk model

A model with a high and low risk only was used to calculate parameter values in the calibration process. The variable  $S^h$  denotes high risk and  $S^l$  denotes low risk:

$$\begin{aligned} \frac{dS^h}{dt} &= -\zeta S^h + \sigma S^l \\ \frac{dS^l}{dt} &= \zeta S^h - \sigma S^l \end{aligned} \quad (17)$$

As this is a closed system, we can use  $N - S^h = S^l$ , which gives:

$$\frac{dS^h}{dt} = -\zeta S^h + \sigma(N - S^h). \quad (18)$$

Setting the left-hand side to zero and rearranging gives the proportion of the total population that are high risk ( $\Phi$ ):

$$\Phi = \frac{\sigma}{\sigma + \zeta}. \quad (19)$$

This expression was used to calculate the required value of the recruitment rate  $\sigma$  from the sampled values of the proportion of high-risk individuals and the leaving rate  $\sigma$ .

**TABLE 29** Summary of data collated for each setting for model calibration

Parameter	Bristol	Walsall	Dundee	Relevant parameter
Current PWID population size	2004: sampled 111–125% <sup>106</sup> of 2011 value <sup>104</sup>  2011: 2025–2564 adjusted from Jones <i>et al.</i> (2016) <sup>104</sup> to include only 60% of people on OST not in contact with other services. <sup>104</sup> Sampled uniformly	2006: 125% <sup>106</sup> of 2011 value  2011: 1296–1623 estimated from local number on OST and unpublished PWID prevalence estimates for West Midlands. Sampled uniformly	Constant level: 675–825 local estimate adjusted from King <i>et al.</i> (2013) <sup>107</sup>  Sampled uniformly	$\theta$ , number of new injectors per year. Value of $\theta$ found using steady-state equations of population submodel for the first time point in all three settings. In Bristol and Walsall, a second value of $\theta$ is found using Matlab <i>fzero</i> and analytical solution to population submodel that gives population size required with sampled cessation rates
Injecting duration profile: proportion of PWID that are R, NR or LT	2004: R, 0.04–0.2; NR, 0.25–0.45; LT, 0.4–0.65 <sup>73</sup>  2014: R, 0.075–0.2; NR, 0.05–0.22; LT, 0.55–0.85 (UAMP)	2006: R, 0.1–0.3; NR, 0.45–0.65; LT, 0.2–0.3  2014: R, 0.1–0.3; NR, 0.15–0.4; LT, 0.4–0.6 (UAMP)	Constant level: R, 0.15–0.35; NR, 0.36–0.65; LT, 0.12–0.35 (NESI)	Death and cessation rates ( $\mu_i$ ) (per year). Prior distribution for $\mu_1$ (0.0351–0.1702) calculated from assumption that between 10% and 40% of recent initiates cease injecting within 3 years. <sup>91</sup> A large upper bound of 0.4 was assumed for the prior distributions of $\mu_2$ and $\mu_3$ owing to a lack of information. Lower bounds of 0.004 and 0.008 were chosen to ensure that the leaving rate was greater than the likely death rate. <sup>98</sup> Parameter sets were accepted if PWID demographic submodel fits were within the ranges for each injecting duration

continued

TABLE 29 Summary of data collated for each setting for model calibration (*continued*)

Parameter	Bristol	Walsall	Dundee	Relevant parameter
Chronic HCV infection prevalence (75% of HCV antibody prevalence)	Constant level 40–50% (community surveys, UAMP); sampled from truncated beta (305.25,364.75)	2006: 11–26% (UAMP); sampled from truncated beta (30.75,132.25)  2014: 15–39% (no fitting required)	2008: 15–30% (NESI); sampled from truncated beta (18.75,64.25)  2014: 31–44% adjusted from (NESI); sampled from truncated beta (54.6,90.4)	$\pi$ , infection rate used to fit the HCV infection prevalence estimates
Proportion high risk	2004: 70–80% (2004, 2006 community surveys and UAMP). Sampled uniformly  2014: 80–95% (UAMP); sampled uniformly	Constant level of 40–65% (UAMP); sampled uniformly	Constant level of 26–42% (NESI); sampled from beta (156,315)	$\phi$ , proportion of injectors initially high risk assumed to be the same as sampled proportion high risk  $\sigma$ , recruitment rate per year from low- to high-risk behaviour, calculated from sampled leaving rate, $\zeta$ , and proportion high risk, $\phi$
Proportion on OST	2004: 33.3–46.7% <sup>121</sup> sampled from truncated beta (81,121)  2009: 76.5–86.3% (community survey, 2009) sampled from truncated beta (241,55)	2006: 30–50% (UAMP); sampled from truncated beta (32,48)  2009: 61–82% (UAMP); sampled from truncated beta (47,18)	2008: 433–53% (NESI) sampled from beta (36,47)  2014: 65–79% (NESI) sampled from beta (106,40)	$\beta$ , recruitment rate per year on to OST
Proportion > 100% NSP [needles distributed/ (population size x injecting frequency)]	Needles distributed in 2014 (786,542–844,646), population size in 2014 and injecting frequency (470–859 per year from UAMP) sampled. Mean calculated coverage 56%	Needles distributed in 2014 (225,275–237,111), population size in 2014 and injecting frequency (435–716 per year from UAMP) sampled. Mean calculated coverage 28%	Needles distributed in 2014 (assumed to be the same as in 2008), population size in 2008 and injecting frequency (517–999 per year from NESI) sampled. Mean calculated coverage 27%. Needles distributed in 2014 (138,246–145,768), population size in 2014 and injecting frequency (251–533 per year from NESI) sampled. Mean calculated coverage 49%	$\eta$ , recruitment rate per year onto high-coverage NSP

LT, long-term injectors; NR, non-recent injectors; R, recent injectors.

## Appendix 5 Supplementary material for Chapter 6

**TABLE 30** Cost associated with NSP for cost-effectiveness model

Setting	Fixed citywide cost (£)			Cost per needle distributed (£)		
	Median	Minimum	Maximum	Median	Minimum	Maximum
Bristol	44,142	36,758	49,890	0.26	0.14	0.42
Dundee	10,159	8672	11,807	0.78	0.37	1.19
Walsall	21,068	16,320	26,318	0.45	0.20	1.03

**TABLE 31** Cost associated with different stages of disease progression for cost-effectiveness model

Disease stage	Annual costs (2014 GBP)	Distribution	Source
OST (specialist prescribing)	2839.28	Gamma	PSSRU <sup>122</sup>
Uninfected	0.00	Gamma	Wright <i>et al.</i> , 2005 <sup>123</sup>
F0 and F1 mild HCV infection	187.59	Gamma	Wright <i>et al.</i> , 2005 <sup>123</sup>
F2 and F3 moderate HCV infection	974.68	Gamma	Wright <i>et al.</i> , 2005 <sup>123</sup>
Compensated cirrhosis	1546.98	Gamma	Wright <i>et al.</i> , 2005 <sup>123</sup>
Decompensated cirrhosis	12,397.57	Gamma	Wright <i>et al.</i> , 2005 <sup>123</sup>
HCC	11,170.04	Gamma	Wright <i>et al.</i> , 2005 <sup>123</sup>
Liver transplant	40,273.00	Gamma	Martin <i>et al.</i> , 2016 <sup>124</sup>
Post transplant	2041.00	Gamma	Martin <i>et al.</i> , 2016 <sup>124</sup>
Hospital costs year of transplant	13,937.00	Gamma	Martin <i>et al.</i> , 2016 <sup>124</sup>
Treatment		Gamma	
Sofosbuvir + Ledipasvir (Harvoni®, Gilead) – PWID	48,816.00	Gamma	Martin <i>et al.</i> , 2016 <sup>124</sup>
Sofosbuvir + Ledipasvir – ex- or non-injecting drug user	40,680.00	Gamma	Martin <i>et al.</i> , 2016 <sup>124</sup>
Liver-related death	0.00	Gamma	Assumption

**TABLE 32** Quality-of-life values used in cost-effectiveness analysis

Disease stage	QALYs	Distribution	Source
Uninfected			
Ex- or non-injecting drug user	0.94	Constant	Martin <i>et al.</i> , 2016 <sup>124</sup>
Injecting drug user	0.85	Uniform(0.8, 0.9)	Martin <i>et al.</i> , 2016 <sup>124</sup>
Mild HCV infection			
Without treatment (F0 and F1)	0.77	Beta(521.2375, 155.6943)	
SVR (F1 only)	0.82	Beta(65.8678, 14.4588)	
Moderate HCV (F2 and F3)			Martin <i>et al.</i> , 2016 <sup>124</sup>
Without treatment	0.66	Beta(168.2461, 86.6723)	Martin <i>et al.</i> , 2016 <sup>124</sup>
SVR	0.72	Beta(58.0608, 22.592)	
Compensated cirrhosis			
Without treatment	0.55	Beta(47.1021, 38.5381)	Martin <i>et al.</i> , 2016 <sup>124</sup>
SVR	0.61	Beta(58.0608, 37.1124)	Martin <i>et al.</i> , 2016 <sup>124</sup>
Decompensated cirrhosis	0.45	Beta(123.75, 151.25)	Martin <i>et al.</i> , 2016 <sup>124</sup>
HCC	0.45	Beta(123.75, 151.25)	Martin <i>et al.</i> , 2016 <sup>124</sup>
Liver transplant	0.45	Beta(123.75, 151.25)	Martin <i>et al.</i> , 2016 <sup>124</sup>
Post transplant	0.67	Beta(59.2548, 29.1852)	Martin <i>et al.</i> , 2016 <sup>124</sup>
Liver-related death	0		Martin <i>et al.</i> , 2016 <sup>124</sup>



A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and flow.

EME  
HS&DR  
HTA  
PGfAR  
**PHR**

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health*

***Published by the NIHR Journals Library***